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ABSTRACT 
 
EARLY POSTZYGOTIC MUTATIONS CONTRIBUTE TO DE NOVO 
VARIATION IN A HEALTHY MONOZYGOTIC TWIN PAIR 
 
GülĢah Merve Dal 
Ph.D. in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Tayfun Özçelik 
September, 2014 
 
 
Characterizing the patterns and rate of de novo mutations is crucial for our perception 
of evolution and genetic basis of human disease. Direct observation of de novo single 
nucleotide variation (SNV) rate in healthy individuals revealed a rate in a range of 
0.82 – 1.70 ×10-8 base pair per generation. However, the developmental timing of the 
de novo mutations is unknown and thus, contribution of the early post-zygotic 
mutations to the human de novo SNV rate remained unknown. In an attempt to 
estimate the rate of de novo mutations regarding the developmental timing of 
mutagenesis, we sequenced the whole genomes of a healthy monozygotic twin pair 
and their parents with a total of 170 fold coverage. We identified the de novo SNVs 
through examination of the genotypes of each individual for each of the variants in a 
synchronous manner. Subsequent to the Sanger sequencing based validation, we 
conservatively characterized a total of 32 de novo SNVs. Of these 23 were shared by 
the twin pair, 8 were specific to twin I, and 1 was specific to twin II. We estimated 
the overall de novo SNV rate of 1.31 × 10-8 for twin I and 1.01 × 10-8 for twin II. The 
rate of the early post-zygotic de novo SNVs was calculated to be 0.34 × 10-8 and 0.04 
× 10-8 for twin I and twin II, respectively. These data indicate the growing 
importance of genome mosaicism which might be resulted from de novo mutations 
of early post-zygotic origin in disease pathogenesis. 
 
 
 
 
 
 
Keywords: Mutation rate, de novo SNV, monozygotic twins, somatic mosaicism, 
early post-zygotic, next generation sequencing. 
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ÖZET 
 
SAĞLIKLI BĠR TEK YUMURTA ĠKĠZ ÇĠFTĠNDE ERKEN 
POSTZĠGOTĠK MUTASYONLARIN DE NOVO MUTASTON 
ORANINA KATKISI 
 
GülĢah Merve Dal 
Moleküler Biyoloji ve Genetik, Doktora 
Tez Yöneticisi: Prof. Dr. Tayfun Özçelik 
Eylül, 2014 
 
 
De novo mutasyonların özellikleri ve oranının bilinmesi hastalıkların ve evrimsel 
süreçlerin anlaĢılabilmesi için büyük önem taĢımaktadır. De novo tek nükleotid 
değiĢikliklerinin (SNV) doğrudan incelenmesi ile insanda bir nesilde ortaya çıkan 
yeni tek nükleotid değiĢikliği oranı 0.82 – 1.70 ×10-8 baz çifti olarak belirlenmiĢtir. 
Ancak, bu tek nükleotid değiĢikliklerinin geliĢimin hangi evresinde ortaya çıktığı ve 
dolayısıyla erken post-zigotik mutasyonların toplam de novo mutasyon oranına olan 
katkısı bilinmemektedir. Bu noktada, insanda bir nesilde ortaya çıkan yeni mutasyon 
oranını ortaya çıkma zamanına göre belirlemek amacıyla; anne, baba ve sağlıklı bir 
erkek ikiz çiftinden oluĢan ailede toplam 170 X kapsamalı tüm genom dizilemesi 
yaptık. Bulunan her bir mutasyon için her bir bireyin genotiplerini karĢılaĢtırmalı ve 
eĢ zamanlı olarak analiz ederek de novo tek nükleotid değiĢikliklerinin belirledik. 
Sanger dizilemesi ile yapılan doğrulamanın ardından toplam 32 de novo tek 
nükleotid değiĢikliğini karakterize ettik. Bu mutasyonlardan 23 tanesi ikizlerin her 
ikisinin genomunda, 8 tanesi ikizlerden birinde 1 tanesi ise diğerinde bulunmaktadır. 
Toplam de novo mutasyon oranını ikizlerden biri için 1.31 × 10-8, diğeri için 1.01 × 
10
-8
 olarak hesapladık. Toplam mutasyon oranı içinde, erken post-zigotik 
mutasyonların oranını ise ikizlerden biri için 0.34 × 10-8 ve diğeri için 0.04 × 10-8 
olarak belirledik. Bulgularımız erken post-zigotik mutasyonların sebep olduğu 
genom mozaisizminin hastalıkların anlaĢılması için önem taĢıdığını göstermiĢtir. 
 
 
 
 
 
 
Anahtar Sözcükler: Mutasyon oranı, de novo SNV, tek yumurta ikizleri, somatik 
mozaisizm, erken post-zigotik, yeni nesil dizileme. 
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Chapter 1 
Introduction 
1.1 Genetic Variation in the Human Genome 
Cells store the genetic information in the form of nucleotide sequences. Duplication 
of the hereditary information before each cell division is an essential process. This 
process is carried out precisely by each cell‘s DNA replication and repair 
machinery.[1] Still, nucleotide sequences are frequently subjected to mutations 
because of the environmental factors, stochastic events inside the cell, and failure of 
the replication and repair processes.[2]  
 
Indeed, mutations are the raw materials of the genetic diversity in nature. 
Some of them are deleterious. Thus, they might cause diseases. Some might be 
neutral or advantageous. In that case, they become fixed in a population and provide 
substrates for evolution.[3] 
 
Mutations can be classified into two broad categories with respect to their 
inheritance patterns and occurrence time: Inherited mutations and de novo mutations.  
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1.1.1 Inherited Mutations 
Inherited mutations are the nucleotide changes that are already present in all cells of 
the parents. These mutations are transmitted through parental germ cells during the 
course of fertilization and thus present in all cells of the offspring (Figure 1.1).[4] 
 
 
Figure 1.1: Demonstration of the inherited mutations and their transmission. The 
figure is taken from [A. Poduri, G. D. Evrony, X. Cai, C. A. Walsh, ―Somatic 
mutation, genomic variation, and neurological disease,‖ Science, vol. 341, pp. 
1237758-1-8, 2013]. Reprinted with permission from AAAS. 
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1.1.2 De novo Mutations 
De novo mutations are the new mutations. They are present in the genome of an 
individual yet not present and be detectable in the constitutive DNA of the 
parents.[5]  
 
According to the traditional view, they newly occur either in the parental 
germ cells during the gametogenesis or in the differentiated somatic cells of an 
individual during the postnatal development. Indeed, de novo mutations might occur 
at any time throughout the life cycle of an individual: They might appear during the 
early or late development of the embryo, fetal development, and postnatal growth 
(Figure 1.2).[4, 5, 6]  
 
 
 
 
Figure 1.2: Demonstration of the timing of de novo mutations. Reproduced and 
modified with permission from (L. Vadlamudi, L. M. Dibbens, K. M. Lawrence, X. 
Iona, J. M. McMahon, W. Murrell, et al., ―Timing of De Novo Mutagenesis — A 
Twin Study of Sodium-Channel Mutations,‖ N Engl J Med, vol. 30, pp. 1335-40, 
2010.), Copyright Massachusetts Medical Society. 
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De novo mutations are one of the most severe form of the rare genetic 
variation. They are more deleterious comparing to the mutations of ancient origin 
(Figure 1.3).[7, 8, 9] Their contribution to diseases might be larger than we 
anticipated before. Therefore, knowledge about their patterns and rates is important 
for our perception of the evolutionary processes as well as the genetic basis of 
diseases.  
 
 
 
 
Figure 1.3: Heat map and extended pedigree showing the effect of the mutations. 
Copyright © 2014 Copyright Clearance Center, Inc. Reproduced from (J. R. Lupski, 
J. W. Belmont, E. Boerwinkle, R. A. Gibbs, ―Clan genomics and the complex 
architecture of human disease,‖ Cell, vol. 147, pp. 32-43, 2010) with permission. 
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1.2 Patterns of the De Novo Mutations 
1.2.1 Origins of the de novo mutations 
A de novo mutation might occur during the gametogenesis in parents (A pre-zygotic 
de novo mutation). In that case, the mutation which is introduced during the 
spermatogenesis or oogenesis is not present in the parental constitutive genome yet it 
is transmitted and present in all cells of the offspring (Figure 1.4).[4] 
 
 
 
Figure 1.4: Demonstration of a pre-zygotic de novo mutation. The figure is taken 
from [A. Poduri, G. D. Evrony, X. Cai, C. A. Walsh, ―Somatic mutation, genomic 
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variation, and neurological disease,‖ Science, vol. 341, pp. 1237758-1-8, 2013]. 
Reprinted with permission from AAAS. 
 
 
A new mutational event can also occur in the genome of an individual after 
the fertilization. Herein, if the mutation occurs during the very early mitotic divisions 
of the zygote, only a small proportion of cells in different tissues carries the mutation 
(An early post-zygotic mutation) (Figure 1.5). When it occurs during the late mitotic 
divisions of the embryo (A late post-zygotic mutation), the mutation is present in a 
tissue-specific and mosaic fashion. In that case, only a small subset of cells in the 
tissue carries the variant (Figure 1.6).[4] 
 
 
 
Figure 1.5: Demonstration of an early post-zygotic de novo mutation. The figure is 
taken from [A. Poduri, G. D. Evrony, X. Cai, C. A. Walsh, ―Somatic mutation, 
genomic variation, and neurological disease,‖ Science, vol. 341, pp. 1237758-1-8, 
2013]. Reprinted with permission from AAAS. 
7 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: Demonstration of a late post-zygotic de novo mutation. The figure is 
taken from [A. Poduri, G. D. Evrony, X. Cai, C. A. Walsh, ―Somatic mutation, 
genomic variation, and neurological disease,‖ Science, vol. 341, pp. 1237758-1-8, 
2013]. Reprinted with permission from AAAS. 
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1.2.2 Genome-wide distribution patterns of the de novo mutations  
Mutation occurs as a continuous and stochastic event. However, distribution of the 
new mutations throughout the genome is not random. The biases in the distribution 
of de novo mutations result from the intrinsic properties of the genome as well as the 
extrinsic factors.[8, 10] 
 
De novo mutations tend to occur in the CpG dinucleotides 10 to 18 fold 
higher than in the non-CpG sites. The reason is that cytosine in CpG dinucleotides is 
subjected to methylation selectively. Frequent deamination of the 5-methylcytosine 
spontaneously in these sites results with the 5-methylcytosine to thymine mutation. 
Therefore de novo mutation rate in these sites increases.[11, 12, 13] 
 
In addition to the GC content, various other patterns of the genome affect the 
distribution of the new mutations. For example, single base substitution density 
increases 53% during the replication of the DNA.[14] Transcription is another factor 
that induces the mutations. Herein, mutation density is high on the non-transcribed 
strand of the DNA. This is due to the transcription-coupled repair (TCR) machinery 
which corrects the mutations that occur in the transcribed strand.[15] 
 
Moreover, it has been documented that emergence of a new mutation triggers 
several other nucleotide changes at the same time and these new mutations tend to 
cluster together both in coding and non-coding parts of the genome.[16] 
 
Similar to the SNVs, de novo copy number variations (CNVs) are also 
distributed in a nonrandom fashion throughout the genome. There are repeats and 
segmental duplications in the human genome as a result of the mammalian genome 
evolution.[17] Herein, the frequency of large CNVs (>50 kbp) is high in the regions 
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where the directly oriented segmental duplications present and trigger nonallelic 
homologous recombination (NAHR).[18] 
 
Non-random distribution of the new mutations results with the increased or 
decreased rates for different forms of mutations on the different sites of the genome. 
1.2.3 Sex and age specific patterns of the de novo mutations 
Sex and age specific patterns and thus effect of the parental origin of de novo 
mutations have been examined comprehensively. Effect of the parental origin means 
the tendency of de novo mutations to arise in the paternal or maternal germline 
preferentially.[19] 
 
There is a discrepancy between males and females regarding the 
gametogenesis. Oogenesis is almost complete before birth. It has been calculated that 
twenty two cell divisions with twenty three replications are completed in the female 
germline. This process does not extend to the postnatal growth. Indeed, 
spermatogenesis is an ongoing process. During the reproductive life of man, sperm 
production occurs continuously, thus the number of mutations that occur during 
DNA replication in the male germline increases. Correspondingly, paternal bias for 
the de novo SNVs appears [20]; as fathers age increases, number of de novo 
mutations increases. This has been discovered by early genetic studies [21] and 
confirmed by various recent studies based on the whole genome and exome 
sequencing.[12,13] 
 
Similar to the SNVs, paternal bias has also been observed for the mutations at 
microsatellites. Father to mother ratio was discovered to be 3.3:1.[22] Additionally, 
increased rate of de novo large chromosomal abnormalities and large CNVs that are 
greater than 150 kbp in the paternal germline has been documented.[23] On the other 
hand, trisomy of the chromosome 21 is an exception and risk for the majority of such 
aneuploidies increases with advanced maternal age.[24] 
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1.2.4 Role of the de novo mutations in diseases 
Classical approach to understand the genetic basis of diseases has been the study of 
inherited mutations. However, an important proportion of the diseases including 
those that are common or rare as well as those that arise sporadically remained 
unsolved.[25]  
 
In recent years, it has been anticipated that de novo mutations might 
contribute to pathogenesis of all diseases more significantly than we thought before. 
There are three rationales underlying this prospect: (a) There is an exponential 
human population growth and weak purifying selection [26, 27, 28], (b) De novo 
mutations are individually rare mutational events but have larger effect collectively, 
and (c) Selective pressures do not act on de novo mutations strictly, leading them to 
become more deleterious.[3, 25] 
 
Involvement of the various forms of de novo mutations extending from the 
single base substitutions to the chromosomal abnormalities in both rare and common 
diseases has been documented. Herein, due to the feasibility of observing 
microscopically visible changes such as aneuploidies comparing to the other types of 
the mutations, roles of this class of de novo mutations have been determined 
relatively earlier. Most famous example is the de novo trisomy of the chromosome 
21 which causes the Down syndrome.[29] 
 
Advent of the microarray and sequencing technologies led to the examination 
of CNVs and SNVs in addition to the large chromosomal abnormalities. Recurrent 
CNVs have been involved in the pathogenesis of the malformation syndromes.[30, 
31] In 2004, Vissers et al. identified a de novo CNV at chromosome 8q12 as a causal 
mutation for CHARGE syndrome.[32] This discovery was followed by the 
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identification of several other CNVs involved in the pathogenesis of several 
monogenic diseases.  
 
Role of the de novo CNVs has also been established for the common diseases, 
especially for the neurodevelopmental disorders.[33] Large-scale de novo CNVs, 
those that are greater than 100 kbp in size, are present in 10% of the individuals 
affected with the sporadic neurodevelopmental diseases. Moreover, number of 
causative de novo CNVs is increased in individuals affected with mental retardation, 
intellectual disability, schizophrenia, and autism spectrum disorders.[34, 35, 36, 37] 
 
In addition to the CNVs, de novo SNVs also account for an important fraction 
of the rare genetic diseases. Initial application of the exome sequencing to discover 
de novo mutations led to the discovery of de novo SNVs in SETBP1 gene in patients 
affected with Schinzel-Giedion syndrome.[38] This was the first demonstration of 
the identification of a de novo mutation in a rare syndrome through exome 
sequencing. Subsequently, de novo SNVs involved in other clinical syndromes, 
including Kabuki syndrome, Bohring-Opitz syndrome, and KBG syndrome were 
identified.[39, 40, 41] Importantly, number of gene disrupting de novo SNVs in 
individuals affected with autism spectrum disorders discovered to be high comparing 
to the healthy controls.[42, 43, 44] These findings indicate the significant 
contribution of de novo SNVs to the disease pathogenesis in human. 
1.3 Rates of the De Novo mutations 
Human de novo mutation rate reflects the rate at which a new observable change in 
the DNA sequence occurs in each generation.[1] The studies concerned with the 
human mutation rate estimation trace their origin back to the 1930s.[21, 45] Since 
that time, several technological improvements were achieved and our knowledge 
about the rates for different classes of de novo genetic variation in human has 
increased.  
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1.3.1 Methods for estimating de novo mutation rate 
1.3.1.1 Indirect method 
Indirect estimation of the de novo mutation rate is the most previous approach which 
was pioneered by Haldane in 1935.[45] He developed a theory on the basis of the 
mutation-selection balance shaping the observed allele frequencies in a population. 
Haldane proposed that the observed allele frequencies in a population is due to the 
presence of a mutational pressure that balances the continuous selection acting on the 
deleterious alleles.[46] Based on this theory, the rate at which a new mutation arises 
can be estimated indirectly.  
 
In addition to the Haldane‘s approach, human mutation rate might be 
estimated through counting the number of affected offspring whose parents are 
unaffected.[47] However, this kind of indirect approach may result with an 
underestimation, because disease gene mutations are not always result with disease 
phenotype. 
 
Mutation rate per generation can also be estimated indirectly through the 
comparison of the nucleotide sequences between different species. This approach 
requires the knowledge of the divergence time and generation length per species.[48] 
To note that, the divergence-based measurement is based on the Kimura‘s neutral 
theory. The neutral theory implies that most of the polymorphisms and substitutions 
are neutral and for the neutral mutations the mutation rate is equal to the rate of 
evolution.[49] On the basis of this theory, rate of the new mutations can be estimated 
through counting the fixed differences between two closely related species. Herein, 
the estimated rate is not interfered with the false positives and somatic mutations. 
However, uncertainties about the size of the populations and divergence times might 
reduce the effectiveness and thus might result with an underestimation.[3]  
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1.3.1.2 Direct method 
Direct estimation of the mutation rate is based on the examination of the nucleotide 
changes present in an individual‘s genome using whole genome and exome 
sequencing. It is achieved through the analysis of the sequencing data for the father-
mother-offspring trios. Once the de novo mutations (those mutations that are present 
in the offspring and absent in the parents) were identified, the rate of the new 
mutations per generation can be calculated regarding the number of de novo 
variations and the target nucleotide size that is covered by sequencing.[3] 
1.3.2 De novo mutation rates 
1.3.2.1 De novo mutation rate based on the indirect approach 
The most previous studies concerned with the estimation of human per generation 
mutation rate have relied on the homologous sequence comparisons as well as the 
screens of disease phenotypes, as explained above. These indirect estimations were 
restricted with the disease genes, pseudogenes or only specific classes of mutations 
(e.g. deleterious mutations) and did not survey the whole genome.  
 
Initially, Haldane reported an indirect estimate of the human per locus 
mutation rate in his book, ―The causes of evolution‖, in 1932.[50]. He proposed that 
in each generation at a rate of approximately 10 
-5
, new hemophilia mutations occur. 
Subsequent to this approximation, he addressed the mutation rate issue in a more 
comprehensive manner on the basis of his mutation-selection balance theory. In 
1935, through considering the known frequency of the men affected with hemophilia 
in London (neglected in his 1932 study), he corrected his estimate of per locus 
mutation rate for the hemophilia gene as 2 x 10
-5
.[45] These studies have been 
accepted as the first indirect estimates of the human per locus per generation 
mutation rate. 
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There is another approach which is based on the counting the children 
affected with dominant disorders when the parents are unaffected.[48, 51] This 
approach yielded rates ranging between 10
-6
 and 10
-4
 per locus per generation.[52] 
 
The most reliable indirect estimates emerged from the comparison of the 
DNA sequences between human and a closely related species. This approach has its 
roots on the neutral theory. Mutation rate was estimated to be 1-2.5 x 10
-8
 per locus 
per generation through comparing the pseudogenes and synonymous sites between 
human and chimpanzee.[48, 52, 53] 
1.3.2.2 De novo mutation rate based on the direct approach 
Recent improvements in the next generation sequencing technologies led to the 
investigation of the human genome comprehensively. Therefore, the rate at which 
new mutations occur has been investigated through whole genome and exome 
sequencing of the families. Accordingly, mutation rate per generation was 
documented in a large number of studies. 
1.3.2.2.1 De novo germline mutation rate 
Direct estimation of the human germline mutation rate has been achieved through 
sequencing the genomes of mother-father-offspring trios. Although these studies 
yielded the human de novo mutation rate per base per generation, the early post-
zygotic mutations could not be distinguished from those that have a pre-zygotic 
origin. Therefore the reported mutation rates that are presumably accepted as 
germline mutation rate might reflect an overestimation.  
1.3.2.2.1.1 De novo SNV rate 
First direct estimation of the human de novo SNV rate is based on the analysis of Y 
chromosome sequences of two men separated by thirteen generations. Accordingly, 
Xue Y et al. reported a de novo SNV rate of 3 × 10−8 per base per generation.[54] In 
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2010, analysis of the whole genome sequence data of a quad family consisting of a 
sib-pair and their parents resulted with the estimation of the de novo SNV rate of 
approximately 1.10 x 10
-8
 per base per haploid genome.[55] Conrad and his 
colleagues sequenced the whole genomes of two parent-offspring trios and reported 
the de novo SNV rate as 0.97 x 10
-8
 and 1.17 x 10
-8
 for each trio. This study has great 
importance in terms of being the first direct report of the variation in mutation rates 
between families.[56] These initial attempts that are based on the calculation of de 
novo mutation rate per base per generation through whole genome sequencing of the 
nuclear families provided de novo SNV rates that are similar to the indirect 
estimations. Still, they are restricted in the scope of sequencing a single family or a 
specific chromosome. 
 
In 2012, Kong A et al conducted a study to treat the de novo mutation rate 
issue in a more comprehensive manner through increasing the sample size. They 
performed deep whole genome sequencing of 78 Icelandic parent-offspring. They 
identified de novo SNVs and calculated the de novo SNV rate of 1.20 x 10
-8
 per base 
per generation.[12] 
 
Rate of the de novo SNVs was also estimated using the advantage of the 
autozygous segments. Autozygous regions are homozygous regions that are inherited 
from a recent ancestor. Campbell CD et al. used autozygosity in the genomes of five 
parent-offspring Hutterite trios selected from a thirteen generation pedigree. Through 
deep whole genome sequencing of the genomes of fifteen individuals, they provided 
a de novo mutation rate estimate of 1.20 x 10
-8
.[13] 
1.3.2.2.1.2 De novo indel and CNV rate 
Investigation of the genetic variations different than SNVs through whole genome 
sequencing is a relatively challenging process. The reason is the difficulty of 
mapping the short sequencing reads to the low complexity and repetitive regions 
where the insertions and deletions (indels) and CNVs are enriched.[3] Despite the 
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difficulties about the analysis of the CNVs and small indels, there are some studies 
that reports the mutation rate for these forms of genetic variation. 
 
It has been reported that indels account for approximately 4% of the human 
spontaneous mutation.[57] Deletions are 2.3 - 4.1 times more common than the 
insertions. The rate of the deletions and insertions is 0.58 x 10
-9
 and 0.20 x 10
-9
 per 
site per generation, respectively.[58, 59] Despite the fact that indels seem to arise in 
lower frequencies comparing to the SNVs in the human genome, the estimated rates 
for both insertions and deletions may be under- or overestimation due to the 
difficulties in the analysis of these variants.   
 
Initial studies concerned with the estimation of de novo CNV rate were 
restricted to the small number of loci. Based on the autosomal dominant genomic 
disorder data, rate of the CNVs was estimated to range between 2 x 10
-5
 and 1.25 x 
10
-4
 per locus.[60] Itsara A et al. analyzed the de novo CNVs that are larger than 100 
kbp in trios. They estimated the rate for large de novo CNVs as 1.2 x 10
-2 
per 
genome.[61] For the CNVs that span less than 100 kbp, the rate could not be 
calculated reliably. 
1.3.2.2.2 Somatic mutation rate 
Patterns and rates of somatic mutations have been investigated largely in the scope of 
cancer studies together with the in vitro cell models. The preliminary studies about 
the somatic mutation rate were restricted to the specific genes. For example, Iwama 
T indirectly estimated the rate of somatic mutations for adenomatous polyposis coli 
(APC) gene as ranging between 2 x 10
-6
 and 3 x 10
-6
 per stem cell per year.[62] 
Another study which was conducted later resulted with the estimation of the rate of 
APC somatic mutations as 10
-5
 per allele per year.[63] Advent of the sequencing 
technologies have led to the more comprehensive examination of the somatic 
mutations. In 2012, examination of the various tumor tissues from different cancer 
types through next generation sequencing resulted with the documentation of diverse 
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somatic mutation rates for different cancer types. Indeed, somatic mutation rate for 
the tumors was discovered to be average of 1.8 mutations per Mb.[64]  
 
In previous studies, average rate of the somatic mutations in healthy 
individuals was estimated to be 7.7 x 10
-10
 per base per cell division.[59] More 
recently, in 2011, a study based on the whole genome sequencing of mother-father-
offspring trios resulted with the estimation of non-germline de novo SNV rate of 2.52 
x 10
-7
.[56] However, this estimate is influenced by the cell-line derived mutations 
and did not reflect the true de novo somatic mutation rate. Another study reported the 
somatic de novo mutation rate for common SNPs in the genomes of healthy 
individuals as 1.2 x 10
-7
 per nucleotide through analysis of the monozygotic twins 
.[65] Despite the initial contributions of these studies to our knowledge about 
patterns and rates of somatic mutations, there is still a need for more comprehensive 
studies which will thoroughly assess the rate of somatic mutations including both 
early and late post-zygotic mutations in healthy individuals‘ genomes. 
1.4 Mosaicism in the Human Genome 
Mosaicism is the presence of more than one population of cells that have different 
genotypes in an individual.[66] Genome mosaicism can be classified into two broad 
categories: (a) germline mosaicism and (b) somatic mosaicism.[67] Germline 
mosaicism is the presence of the gonad in a heterogeneous state, comprised of germ 
cells with or without mutation. Somatic mosaicism is the presence of the 
heterogeneous populations of the non-germline cells in an individual. 
 
Genome mosaicism plays an important role in the biological functions 
required for the normal development as well as in the pathogenesis of diseases. 
Hence, enlightening the mutational processes that lead to the both somatic and 
germline mosaicism has several biological and clinical implications. 
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Germline mosaicism has been found to contribute to the diseases that are 
inherited with an autosomal dominant inheritance pattern. In these diseases, the 
parents are phenotypically unaffected, leading to the wrong-anticipation of the 
autosomal recessive inheritance. Germline mosaic diseases are resulted from the 
mutations that occur during the gametogenesis in the parents and passed to the 
offspring.[67] 
 
Somatic mosaicism arises via the new mutations that occur in the non-
germline cells of an individual.[68] Initially, mutations occur sporadically in a 
precursor cell which gives rise to the different tissues. At this point, number of 
precursor cells that are mutated and thus the degree of mosaicism differs between 
different individuals. This variation is explained by the Luria-Delbruck probability 
distribution.[69] 
 
Somatic mutations contribute to the pathogenesis of several diseases 
including Mendelian disorders, cancer and neurological diseases.[70] Moreover, 
there is a great evidence for the somatic mosaicism in several diseases such as Rett 
syndrome, Duchenne muscular dystrophy, hemophilia A, and Neurofibromatosis.[70, 
71] It is important to note that, timing of the somatic mutations determines their 
tissue specific distribution patterns and the level of mosaicism represented in the 
individual‘s genome.[72] Hence, dissecting the origins of the new mutations that 
arise in the human genome is important to answer the question of ―what time during 
the life cycle of an individual the new mutations mostly emerge?‖ . This will lead to 
the documentation of the somatic mosaicism and its level in both disease and health 
states.  
1.5 Dissecting the Origins of New Mutations 
Tracing the origins of de novo mutations is important. It provides insights into the 
timing of mutagenesis. Moreover, distinguishing the de novo mutations that arise 
mitotically from those that appear meiotically in the human genome might enable the 
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estimation of the real germline vs. somatic mutation rate as well as the degree of 
mosaicism. 
 
It has been reported that there are two possible approaches to delineate the 
embryonic origins of the new mutations and thus timing of the mutagenesis.[3] First 
approach is based on the comparison of the genomes of monozygotic twins. 
Monozygotic twins are developed from a single zygote. Although monozygotic twins 
are expected to carry the same genetic material, genetic differences between them 
have been documented.[68] Herein, a de novo mutation which is shared by a 
monozygotic twin pair is anticipated as occurred during the parental gametogenesis 
meiotically or in the pre-twinning zygote. Otherwise, a de novo mutation which is 
present in the genome of one of the monozygotic twins is expected to arise post-
zygotically during the early mitotic divisions of the embryo.[69] Presence of a post-
zygotic mutation in all cells of one of the twins is interpreted as the mutation 
occurred most likely at the two-cell stage. If the post-zygotic mutation is present in a 
subset of tissues resulting with the somatic mosaicism, timing of the mutagenesis is 
accepted as at the four-cell stage or later.[6] 
 
Second approach to trace the origins and timing of the new mutations is 
assessment of the genetic differences between the different tissues of the same 
individual.[72] This approach resulted with the documentation of genetic variation in 
different somatic tissues obtained from the post-mortem donors.[73, 74] However, 
these studies did not provide the rate of early post-zygotic mutations in healthy 
individuals, and their possible contribution to the overall mutation burden. 
1.6 Importance of the Incidental Findings in the Next Generation 
Sequencing Data 
Advent of the next generation sequencing has revolutionized the research in the field 
of medical genetics. During the past decades, both whole genome and exome 
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sequencing-based studies have identified the genes underlying several common and 
rare disease phenotypes and provided important clinical implications.[75, 76] 
 
Massively parallel sequencing produces a tremendous amount of data in a 
cost- and time- effective manner, leading to the documentation of the genetic 
variation in human disease and health states. Besides the targeted and expected 
results, unintended results that are unrelated to the investigated problem yet have 
clinical importance are also present in the sequencing data [77, 78] For example, it is 
possible to identify all potentially pathogenic and damaging mutations in a study 
which is concerned with the discovery of a causal mutation for a specific disease 
through massively parallel sequencing. Herein, this kind of off-target (secondary) 
results that have clinical significance are defined as ―incidental findings‖.[79] 
 
Examination of the incidental findings in the sequencing data is important for 
the assessment of potentially harmful mutations present in an individual‘s genome. 
Therefore, it might enable the pre-symptomatic testing and preventive care. 
Additionally, these findings are important for the evaluation of the carrier status for 
recessive disorders as well as for the prediction of the late-onset diseases.[80] 
Despite the ethical issues, disclosure of the incidental findings that include the 
known and potential pathogenic variants derived from the sequencing studies that 
survey the whole genomes might have important implications for the human 
health.[81] 
1.7 Aim and Strategy 
Previous studies provided the rates of the de novo mutations in both healthy 
individuals and those that are affected with different disorders. Even in the mutation 
rate estimation studies that are based on the direct observation of the genetic 
variation in the genomes of healthy individuals through whole genome sequencing, 
contribution of the early post-zygotic mutations to the overall mutation burden could 
not be assessed comprehensively. The underlying reason is the study design which is 
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based on the observation of the genetic variation in parent-offspring trios. This kind 
of study design did not allow distinguishing the early post-zygotic mutations from 
those that arise during parental gametogenesis.  
 
Despite the attempts to estimate the developmental timing of mutagenesis for 
some disease conditions, knowledge about the occurrence time and origin of the new 
mutations in the genomes of healthy individuals remained unknown. Hence, our aim 
is to estimate the de novo mutation rate in healthy individuals regarding the 
developmental timing of mutagenesis. At this point, we sought to determine how 
much of the de novo mutations occur meiotically during the parental gametogenesis 
(pre-zygotic) and how much of them arise mitotically during the initial divisions of 
the zygote (early post-zygotic) in the genome of a healthy individual.  
 
To elucidate the origins of de novo mutations, we performed whole genome 
sequencing of a quad family consisting of a healthy male monozygotic twin pair and 
their parents. We restricted our de novo mutation analysis with the SNVs. Our 
strategy is based on the comparison of the genotypes of the twin pair and their 
parents for each of the SNVs concurrently to discover the de novo mutational events. 
We hypothesized that de novo mutations shared by the monozygotic twin pair have 
had parental or pre-twinning zygotic origin whereas those specific for only one of the 
twins have occurred in the post-twinning embryo post-zygotically. On the basis of 
this hypothesis, we characterized de novo SNVs and calculated the mutation rate 
regarding the timing of the new mutations. 
 
In addition to our main target (de novo mutation rate estimation), we also 
intended to evaluate the incidental results present in the genomes of the twin pair and 
their parents. Herein, we performed additional analysis concerned with the 
examination of the genomes of the four individuals to document the disease 
predisposing and the potentially pathogenic variants.  
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Chapter 2 
Materials and Methods  
2.1 Subjects of the Study 
A four-individual family consisting of a healthy 25-year-old male monozygotic twin 
pair, their 59-year-old father and 49-year-old mother participated in this study. We 
coded the samples as 12-020 (Twin I), 12-022 (Mother), 12-023 (Father), and 12-024 
(Twin II). We evaluated the zygosity of the twin pair by comparing the SNVs of each 
twin using ―vcf-compare‖ module of the vcf-tools (99% similar).[82] None of the 
four individuals participated in this study have a Mendelian disorder. They had no 
exposure to chemotherapeutics. The subjects were recruited to the control group of a 
movement disorder study which is approved by the institutional review boards (IRB) 
at Bilkent, Hacettepe, BaĢkent, and Çukurova Universities (decisions: BEK02, 
28.08.2008; TBK08/4, 22.04.2008; KA07/47, 02.04.2007; and 21/3, 08.11.2005, 
respectively). The participants signed the written informed consent prepared 
according to the guidelines of the Ministry of Health in Turkiye before the study.  
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2.2 DNA Isolation  
2.2.1 DNA isolation from the peripheral blood  
We collected the peripheral blood samples from all participants in K3-EDTA 
containing BD Vacutainer® Blood Collection tubes (Becton Drive, NJ, USA) using 
venipuncture technique. We stored the blood samples in 1.5 ml microcentrifuge tubes 
at -80 Cº.  
 
We isolated the genomic DNA from 200 µl peripheral blood samples of each 
individual using the NucleoSpin® Blood (Macherey-Nagel) kit, following the 
manufacturer-provided protocols. To obtain the pure DNA with high concentration 
for whole genome sequencing, we repeated the washing steps two times and eluted 
the DNA using double-distilled water instead of the elution buffer included in the kit.  
2.2.2 DNA isolation from the buccal wash specimen  
We obtained the buccal wash specimen from the parents (12-022 and 12-023). Prior 
to the collection of the mouthwash, we asked the subjects to rinse their mouth with a 
5 ml regular tap water for 30 seconds and collected the samples in the 50 ml falcon 
tubes. 
 
We isolated the DNA from the mouthwash samples using DNeasy Tissue Kit 
(QIAGEN). We first centrifuged the mouthwash samples at 3000 rpm for 5 minutes 
and removed the supernatant to obtain the buccal cell pellet. The proceeding steps of 
the DNA isolation including the incubation, washing and elution steps were 
performed according to the manufacturer‘s protocol. 
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2.2.3 DNA isolation from the urine specimen 
We collected the urine samples of the parents (12-022 and 12-023) in the sterile 
containers and isolated the DNA using the DNeasy Tissue Kit (QIAGEN) according 
to the manufacturer-recommended protocol. 
2.2.4 Assessment of the quality and the quantity of the DNA samples 
We measured the quality of the DNA samples by densitometry analysis through 
horizontal 1% agarose gel electrophoresis. We used Mass Ruler DNA Ladder 
(Sigma, MO, USA) as DNA marker (Figure 2.1). We evaluated the quantity and the 
purity of the DNA samples, by spectrophotometric analysis using NanoDrop
TM
 ND-
1000 Spectrophotometer (NanoDrop Technologies, Inc, DE, USA).  
 
 
 
 
Figure 2.2: DNA marker used in the study.MassRuler DNA Ladder: 10 µL per lane, 
1% agarose gel, 1X TAE 7 V/cm, 45minutes (Sigma , MO, USA) 
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2.3 Whole Genome Sequencing 
Over the past few decades, there has been a remarkable revolution in sequencing 
technologies, leading to the capability of investigating genomes at a single nucleotide 
resolution level in a high throughput and cost-effective manner.[83] Following the 
emergence of the chain-termination method (Sanger sequencing) in 1977, and the 
completion of the first human genome draft sequence in 2001 [84, 85], new 
technologies have been developed and classified as the next generation sequencing. 
Through these technologies, sequencing the whole genome and exomes and 
generating a tremendous amount of data in an acceptable time frame has been 
possible. 
 
There are several widely used platforms commercially available for next 
generation sequencing, including the 454 GS20 instrument (Roche Applied Science), 
Hiseq 2000 instrument (Illumina, Inc.), SOLiD instrument (Applied Biosystems), 
and Heliscope (Helicos, Inc.).[83] In this study, we used the Illumina Hiseq2000 
platform to generate the whole genome sequencing data. 
 
Illumina‘s sequencing technology is based on the ―sequencing by synthesis‖ 
strategy. This strategy relies on the solid-phase bridge amplification of single-
molecule DNA templates. In brief, single-stranded DNA fragments are attached to a 
flow cell through an adaptor. Subsequently, these fragments form a template for 
complementary strand synthesis by forming a bridge through hybridization to the 
complementary adaptors. Following the amplification, a large number of clusters are 
produced on the flow cell. The templates are sequenced in a massively parallel 
fashion by using reversible terminators labeled with the fluorescent colors and DNA 
polymerase. After the sequencing is complete, the generated sequence is determined 
through imaging.[86] 
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2.3.1 Sample preparation 
For the paired-end whole genome sequencing, genomic DNA isolated from the 
whole blood samples of the four individuals was prepared using Illumina TruSeq
TM
 
DNA sample preparation kit according to the manufacturer‘s protocol. 
2.3.2 Paired-end library construction 
One library for each of the parents and two libraries for each of the twins were 
constructed from the whole blood derived DNA samples according to the Illumina-
recommended protocols. For library construction, 1-3 µg of genomic DNA was 
fragmented by sonication. The resulting DNA fragments were end-repaired and 
adenosine overhangs were added. Adaptors were ligated to the end-repaired and 
adenosine overhang-added DNA fragments. For size selection, the resulting DNA 
fragments were run on 2% agarose gel and libraries of 400 bp in size were extracted 
from the gel using QIAGEN MinElute Gel Extraction Kit. The size selected libraries 
were enriched by quantitative PCR. The resulting libraries were purified for paired-
end whole genome sequencing and their quality was assessed according to the 
Illumina‘s recommendations. 
2.3.3 Paired-end whole genome sequencing  
We performed deep whole genome sequencing using Illumina Hiseq 2000 
instrument. Following the sequencing of the paired-end libraries, we performed 
imaging using Illumina SBS kits TruSeq V.3. We used Illumina‘s Real Time 
Analysis software V.1.13 with standard parameters for image analysis and base 
calling.  
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2.4 Analysis of the Whole Genome Sequencing Data 
The common practice to analyze the whole genome sequencing data produced by the 
Illumina platform includes (a) conversion of the base calling data (.bcl files) into 
FASTQ files, (b) mapping of the FASTQ files to the reference genome, (c) 
formatting of the sequencing alignment mapping files for variants calling, (d) 
performing local indel realignment, (e) identifying the genomic variants (SNVs and 
indels), and (f) filtering the variants.[87] 
2.4.1 Mapping of the sequencing reads 
Prior to the mapping of the sequencing reads to the human reference genome, we 
converted the base calling data stored in the format of ―.bcl files‖ into the FASTQ 
files using Illumina CASAVA V.1.8.2 software package. We mapped the paired-end 
sequencing reads to the NCBI Build 37 reference of the human genome using 
Burrows-Wheeler Aligner (BWA, version 0.6.1) with default parameters.[88] We 
converted the resulting Sequence Alignment/Map (SAM) files into the binary version 
(BAM) using SAMtools (version 0.1.18).[89] For each individual, we merged the 
BAM files in a single BAM file. We finally used SAMtools to mark and remove the 
PCR duplicates. 
2.4.2 Discovery of the genomic variants and genotypes 
We discovered the genomic variants including the SNVs and indels using Genome 
Analysis Toolkit software (GATK, version 1.6-13) with standard filtering 
parameters.[90] We used the RealignerTargetCreator and IndelRealigner modules of 
the GATK for indel realignment. This step is required to minimize the false calls due 
to the misalignment of the bases around indels. We identified the initial set of raw 
variants using multisample calling options of the GATK‘s UnifiedGenotyper 
module. We applied the variant quality score recalibration to generate the final list of 
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variants of the four individuals. Finally, we performed the GATK-recommended 
hard filtering with ―AB < 0.2 || MQ0 > 50 || SB > -0.10 || QUAL <10‖ parameters for 
low quality call-sets and generated the analysis-ready variants of the four individuals 
stored in a single variant call format (VCF) file. 
2.4.3 Functional annotation of the variants 
We performed the functional and positional annotation of the variants against human 
database GRCh37.68 using SnpEff.[91] SnpEff is a tool which is used for variant 
annotation and effect prediction. We used VCF files as input for the SnpEff and 
classified the variants according to their genomic context. 
2.4.4 File formats 
Whole genome sequencing using Illumina platform generates the data in the form of 
―.bcl‖ files. These files are converted to the FASTQ files using Illumina‘s CASAVA 
software. FASTQ is a common file format which stores the sequencing data and the 
corresponding per base Phred quality scores. For each of the sequencing reads stored 
in the FASTQ file, there are four lines including the sequence identifier, sequence, 
quality score identifier and quality score. Alignment of the FASTQ files to the 
reference genome produces the SAM files. These files store the nucleotide alignment 
information and are converted to the corresponding binary version (BAM file) using 
SAMtools. BAM files are used as input for variants calling using GATK. The data 
produced by GATK is stored in VCF files. Each line in the tab-delimited VCF file 
contains the information for a single variant. 
2.5 Identification of the Putative De Novo SNVs 
We selected the SNVs (novel and dbSNP137 database-reported) from the 
multisample VCF file that includes all genomic variation (SNVs and indels) for the 
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four individuals (the twin pair and their parents) using ‗SelectVariants‘ module of the 
GATK. We performed the downstream de novo mutation identification analysis 
using this SNV-only VCF file as an input. 
2.5.1 Identification of the de novo SNV candidates shared by the twin pair 
We classified the SNVs that are shared by the twin pair and not observed in the 
parental genomes as ―group I‖ de novo SNVs. We estimated the timing of 
mutagenesis for this class of de novo SNVs as parental or post-zygotic yet prior to 
twinning. To identify the group I putative de novo SNVs, we compared the 
genotypes of the twin pair and their parents for each of the SNVs synchronously 
using SnpSift (version 1.1.3).[92] Herein, all possible genotype combinations, 
including those that could be assorted as genotyping errors (such as those SNVs for 
which one of the twins is homozygous although the variant is present in only one of 
the parents) were evaluated.  
2.5.2 Identification of the twin specific de novo SNV candidates 
We classified the SNVs present in one of the twins yet not present in the other twin 
and the parents as ―group II‖ de novo SNVs. Timing of the mutagenesis for the group 
II de novo SNVs was considered as early post-zygotic in the post-twinning 
developmental period. To discover the group II putative de novo SNVs, we 
compared the genotypes of the twin pair and the parents for each of the SNVs 
concurrently using SnpSift (version 1.1.3).[92] The same strategy described for the 
group I de novo SNV candidates including the evaluation of the all genotype 
combinations was followed for the group II de novo SNVs to generate the initial list 
of variants. 
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2.5.3 Filtering the de novo SNV candidates 
Subsequent to the identification of the group I and group II de novo SNV candidates, 
we applied a set of filters to the initial call-set progressively to distinguish the true de 
novo SNVs from the sequencing and variants calling artifacts. First, we filtered the 
putative de novo SNVs that are reported in the single nucleotide polymorphism 
(SNP) database dbSNP137 using BEDtools.[93] Following the selection of the novel 
putative de novo SNVs, we filtered the variants for which the genotype is missing or 
the read depth is smaller than three in at least one individual using a bash script. We 
filtered the remaining putative de novo SNVs regarding the genomic context using 
the IntersectBed tool included in the BEDtools suite. At this point, the variants 
intersecting the segmental duplications and simple repeats were removed. After the 
final filtering of de novo SNV candidates that are classified as genotyping errors, we 
selected the remaining variants that pass all filtering criteria for further analysis. 
2.6 Evaluation of the Putative De Novo SNVs 
Prior to the design of the validation experiments, we further assessed the validity of 
the putative de novo SNVs that pass the above-described filtering criteria based on 
the (a) visual examination of the sequence alignment data, and (b) reference allele 
frequency. 
2.6.1 Visual inspection of the sequencing data 
We visually analyzed the BAM files of the twin pair and their parents in a 
synchronous manner using Integrative Genomics Viewer (IGV).[94] The putative de 
novo SNVs included in the initial call-set were classified as (a) inherited, (b) no 
variant, (c) located on a low quality read and (d) de novo based on the visual analysis 
of the sequence alignment data. The first three groups were filtered and the variants 
classified as true de novo SNVs were included in the final call-set. Herein, the 
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putative de novo SNVs supported by at least three sequencing reads in one or both 
parents were classified as ―inherited‖. If a putative de novo SNV is not supported by 
three or more sequencing reads in the twins or is located on the ―low-quality reads‖, 
we classified it as ―no variant‖. We filtered the putative de novo SNVs as ―located on 
a low quality read‖ in the presence of the high SNP and indel density on the variant 
supporting reads around the 40 bp flanking region. Remaining variants that pass the 
filtering process and thus classified as de novo were selected for validation by 
capillary sequencing. 
2.6.2 Calculation of the reference allele frequency  
Reference allele frequency (RAF) is the number of reference allele-supporting reads 
as a fraction of the total number of reads.[65] We determined the RAF threshold for 
the heterozygous SNVs as 0.5-0.7 in the twins and 0.95-1.0 in the parents. 
2.7 Validation of the De Novo SNVs 
2.7.1 Primer design 
We designed the primer pairs (see Appendix A for the full list of primers) to test the 
high-confidence putative de novo SNVs using web-based Primer3 tool 
(http://bioinfo.ut.ee/primer3-0.4.0/).[95]  
 
We evaluated the primer self-complementarity, GC content and the internal 
hairpin structures using PerlPrimer software.[96] We assessed the specificity of the 
primer pairs for the genomic region of interest using In Silico PCR 
(http://genome.ucsc.edu/cgi-bin/hgPcr) and BLAT (http://genome.ucsc.edu/cgi-
bin/hgBlat) tools of the UCSC Genome Browser. We purchased the primers from 
Genmar Laboratories (Izmir, Turkiye) and Macrogen (Seoul Rep. of Korea). 
32 
 
2.7.2 PCR amplification 
We amplified the targeted regions by conventional PCR using Techne TC512 
thermal cycler (Bibby Scientific). PCR was performed in a total volume of 25 µl, 
using 25 ng genomic DNA, One Taq DNA Polymerase (New England Biolabs), 5X 
One Taq standard reaction buffer, 25 mM dNTPs (Fermentas), and 10 pmol of each 
forward and reverse primers We applied the following manufacturer-recommended 
thermal cycling conditions for the amplification: Initial denaturation at 94 
o
C for 30 
seconds, 30-35 cycles of denaturation at 94 
o
C for 30 seconds, annealing at 58-62 
o
C 
for 40 seconds and elongation at 68 
o
C for 40 seconds and final elongation at 68 
o
C 
for 5 minutes. 
 
For the regions that are difficult to amplify due to the complexity of the 
corresponding genomic region (presence of the repeats and the high GC content 
around the region flanking the variant of interest), we used Phusion High-Fidelity 2X 
Master Mix (Finnzymes, Finland) according to the manufacturer‘s protocol and 
thermal cycling conditions. 
2.7.3 Visualization of the PCR products 
We analyzed the PCR products through 0.8 % agarose gel electrophoresis. The 
agarose gel was prepared by dissolving the agarose (Basica LE, EU) in the 1X TAE 
buffer through heating. We added 30 ng/ml ethidium bromide (EtBr) to the gel as a 
fluorescence tag for visualization. We loaded the PCR products onto the agarose gel 
after the addition of 6X loading dye (MBI Fermentas, NY, USA).  
 
The PCR products were run on the gel horizontally at 100-120 Volts for 20-
40 minutes. We used pUCMix Marker 8 (MBI Fermentas, NY, USA) to infer the 
length of the amplicons (Figure 2.2). We visualized the PCR products using GelDoc 
imaging system (Bio-Rad,CA, USA) and captured the images by MultiAnalyst 
software version 1.1 (Bio-Rad, CA, USA). 
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Figure 2.2: DNA marker used for the PCR product visualization. pUC Mix Marker 8: 
0.5 µg per lane, 1.7% agarose gel, 1X TvBE, 5 V/cm, 90 minutes (MBI Fermentas, 
NY, USA). 
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2.7.4 Sanger sequencing 
PCR products were purified using MinElute
TM
 96 UF PCR Purification Kit (Qiagen, 
MD, USA) prior to the Sanger based capillary sequencing. Sanger sequencing of the 
PCR products was performed using forward primer, reverse primer or both on ABI 
3130 XL instrument (Applied Biosystems, Inc, CA, USA) by Refgen, Inc, (Ankara, 
Turkiye). 
2.7.5 Analysis of the sequencing data 
Sanger sequencing produced the data in the form of AB1 sequence trace format file. 
To analyze the data, we used CLC Main Workbench software package (CLCBio 
Inc). We aligned the Sanger sequencing data to the corresponding reference 
sequence. To download the reference sequence UCSC Table Browser 
(https://genome.ucsc.edu/cgi-bin/hgTables?command=start) was used.  
2.8 Calculation of the De Novo SNV Rate 
2.8.1 Formula 
We estimated the de novo SNV rate for each of the twins based on the number of 
validated de novo SNVs, number of the callable bases and the false negative rate. 
The formula below was used to estimate the mutation rate:[13] 
 
µ = (N x (1+FNR)) /L 
 
In this formula, (a) µ represents the mutation rate, (b) N is the number of de 
novo SNVs validated by Sanger sequencing, (c) FNR is the false negative rate and 
(d) L is the number of callable bases. 
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2.8.2 Calculation of the number of callable bases 
The number of the callable bases is represented with the ―L‖ in the mutation rate 
calculation formula. We considered the bases with a minimum read depth of three 
and do not intersect the segmental duplications in the human genome as callable. The 
formula below was used to calculate the number of callable bases:  
 
L = [NDP>3] – [NSEGDUP_DP>3] 
 
[NDP>3] = Total number of the bases with read depth of minimum 3 
 
[NSEGDUP_DP>3] = Total number of the segmental duplication intersecting bases with 
read depth of minimum 3  
 
[NDP>3] = samtools view -b individual.PCRDuplicateRemoved.bam | 
genomeCoverageBed -ibam stdin -g b37.genome | grep genome | awk '{if($2 >= 3) 
sum += $3} END {print sum}' 
 
[NSEGDUP_DP>3] = coverageBed -hist -abam individual.PCRDuplicateRemoved.bam -b 
~/segmental_duplications_WGAC_b37_nochr.bed | grep all | awk '{if($2 >= 3) sum 
+= $3} END {print sum}‘ 
 
Segmental duplications file (segmental_duplications_WGAC_b37_nochr.bed) and 
the chromosomal length file (b37.genome) were obtained via the UCSC Table 
Browser (https://genome.ucsc.edu/cgi-bin/hgTables?command=start). 
2.8.3 Calculation of the false negative rate 
We calculated the false negative rate for the data according to the results of the 
Sanger based capillary sequencing of the putative de novo SNVs. The rate was 
calculated through dividing the number of putative de novo SNVs discovered to be 
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inherited from the parents through capillary sequencing to the total number of 
putative de novo SNVs tested by Sanger sequencing. 
2.9 Analysis of the Incidental Results 
We analyzed the whole genome sequencing data of the four individuals participated 
in this study to assess the (a) loss of function (LoF) mutations and (b) potentially 
damaging missense mutations. We focused on the true genetic variation through 
taking the advantage of the quad family sequencing. We identified all homozygous 
and heterozygous variants present in the genomes of the four individuals through 
comparative genotype analysis using SnpSift.[92] Herein, we considered the 
Mendelian transmission patterns for the variant selection. This analysis allowed us to 
select the true homozygous and heterozygous mutations and to reduce the false 
positives (genotyping and variants calling errors). 
 
Subsequent to the identification of the homozygous and heterozygous 
mutations of the four individuals, we annotated the variants against human database 
(GRCh37.68 version in the SnpEff repository) using SnpEff.[91] We selected the 
LoF and missense mutations and filtered the remaining variants. We considered the 
(a) stop codon introducing (stopgain), (b) stop codon removing (stoploss), (c) splice 
site disrupting SNVs and (d) frameshift indels as LoF mutations.[97] 
Of the LoF and missense variants, we focused on the rare novel variants and 
the variants that are reported in SNP database dbSNP137 with a low minor allele 
frequency (< 0.01). We filtered those variants that are reported in dbSNP137 with 
minor allele frequency of greater than 0.01 using a bash script. 
 
We assessed the deleteriousness of the missense variants using SIFT, 
Polyphen2 and MutationTaster.[98, 99, 100] We evaluated the genes that carry the 
selected variants (both LoF and missense) in terms of being reported for a disease 
phenotype in OMIM database. Herein, we used the Biomart data mining tool of the 
Ensembl for disease gene analysis. We classified the homozygous and heterozygous 
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LoF and damaging missense mutations into two categories: (a) the variants located 
on the genes that are reported to be causal for a recessive or dominant disease in 
OMIM database and (b) the variants located on the genes that do not have any 
clinical significance. On the basis of these findings, we evaluated the carrier status of 
each individual for recessive diseases as well as the possible presence of late-onset 
dominant diseases.  
2.10 Enzymes, Chemicals and Reagents 
2.10.1 Enzymes 
 
Table 2.1: List of the enzymes used in the experiments 
 
Enzyme Company 
Proteinase K Appligene, CA, USA 
OneTaq® DNA Polymerase New England Biolabs, UK 
OneTaq® Hot Start New England Biolabs, UK 
Phusion Hot Start II High-Fidelity Finnzymes, Finland 
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2.10.2 Chemicals and reagents 
 
Table 2.2: List of the chemicals and reagents used in the experiments 
 
Chemicals and Reagents Company 
Acetic acid Sigma, MO, USA 
Agarose Basica LE, EU 
Bromophenol blue Sigma, MO, USA 
dNTPs Fermentas, NY, USA 
EDTA Fermentas, NY, USA 
Ethanol Merck, Germany 
Ethidium bromide Sigma, MO, USA 
Tris-Base Bio-Rad, CA, USA 
Tris-HCl Sigma, MO, USA 
Xylene Cyanol Sigma, MO, USA 
 
2.10.3 Standard solutions and buffers 
 
Table 2.3: List of the standard solutions and buffers used in the experiments 
 
Solutions and Buffer Content 
Ethidium bromide: 10 mg/ml in water (stock solution) 
 
30 ng/ml (working solution) 
  
Agarose gel loading buffer (6X): 15% coll 
 
0.05% bromophenol 
 
0.05% xylene cyanol 
  
1X TAE (Tris-acetic acid-EDTA): 40mM Tris-acetate, 
 
2 nM EDTA 
 
pH 8.0 
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2.11 Web Sources 
 
Table 2.4: Web sources used in the study design and data analysis 
 
Description Web address 
Figure B.1 donut.cs.bilkent.edu.tr/twinstudy/ 
1000 Genomes browser.1000genomes.org  
NCBI dbSNPs www.ncbi.nlm.nih.gov/projects/SNP/  
UCSC Genome Browser genome.ucsc.edu  
UCSC Tables genome.ucsc.edu/cgi-bin/hgTables?command=start 
NCBI   www.ncbi.nlm.nih.gov/  
BWA bio-bwa.sourceforge.net/  
BioMart www.ensembl.org/info/data/biomart.html 
SAMtools samtools.sourceforge.net/  
GATK www.broadinstitute.org/gatk/  
GATK bundle ftp.broadinstitute.org/bundle/2.5/  
HomozygosityMapper http://www.homozygositymapper.org/ 
IGV www.broadinstitute.org/igv/  
SnpEff snpeff.sourceforge.net/  
SnpSift snpeff.sourceforge.net/SnpSift.html 
BEDTools code.google.com/p/bedtools/ 
Primer3 bioinfo.ut.ee/primer3-0.4.0/ 
PerlPrimer perlprimer.sourceforge.net/  
BLAT genome.ucsc.edu/cgi-bin/hgBlat 
In-Slico PCR genome.ucsc.edu/cgi-bin/hgPcr 
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Chapter 3 
Results 
3.1 Whole Genome Sequencing 
We performed paired-end whole genome sequencing of a healthy monozygotic twin 
pair and their parents (Figure 3.1).  
 
 
 
 
 
 
Figure 3.1: Pedigree of the quad family 
12-022 12-023 
12-020 12-024 
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3.1.1 Sample preparation and library construction 
We isolated the genomic DNA from the whole blood samples of the twin pair and 
their parents using NucleoSpin® Blood (Macherey-Nagel) kit according to the 
manufacturer‘s protocol. We evaluated the quality and quantity of the DNA samples 
by densitometry analysis through 1% agarose gel electrophoresis (Figure 3.2) and 
spectrophotometric measurement (Table 3.1).  
 
 
 
 
Figure 3.2: Densitometry analysis of the DNA samples using agarose gel 
electrophoresis. DNA samples were run horizontally on 1% agarose gel at 90V for 
50 minutes.  Lane 1: MassRuler DNA Ladder Mix (1 µl); Lane 2: DNA sample of 
the 12-020; Lane3: DNA sample of the 12-024. Gel image was captured with BioRad 
Gel Doc 2000 system. 
 
 
 
 
 
 
MassRuler 12-020 12-024 
10k 
8k 
1k 
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Table 3.1: Spectrophotometric measurement of the concentrations of DNA samples 
 
Sample Concentration (ng/µl) 260/280 260/230 
Twin I 187.24 1.89 2.22 
Mother 111.55 1.85 2.14 
Father 108.30 1.84 2.04 
Twin II 206.87 1.88 2.22 
 
Abbreviations used in this table: ng, nano gram; µl, microliters 
 
Whole blood derived DNA samples were prepared for the paired-end whole 
genome sequencing using Illumina TruSeq
TM
 DNA sample preparation kit. We 
constructed one library for each of the parents and two libraries for each of the twins. 
Prior to the sequencing, we assessed the qualities of the libraries and performed the 
purification regarding the Illumina‘s recommendations. 
3.1.2 Paired-end whole genome sequencing  
We performed deep whole genome sequencing of the twin pair and their parents 
using Illumina Hiseq 2000 instrument. We sequenced the paired-end libraries on 
eight lanes for each of the twins and four lanes for each of the parents, generating the 
101- and 104-bp sequencing reads. 
3.1.3 Whole genome sequencing data analysis: Mapping and variants calling 
We generated a total of 538 Gb genomic sequence for the four individuals with a 
mean coverage depth of 59.96 fold for twin I, 42.51 fold for twin II, 34.10 fold for 
mother, and 33.42 fold for father. We mapped the paired-end sequencing reads to the 
human reference genome (version GRCh37) using BWA.[88] At this point, 85.59 – 
93.01 % of the reads were mapped to the reference genome successfully (Table 3.2). 
99% of the whole genome was covered by at least two reads (Table 3.3). 
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 We discovered the genomic variants (SNVs and indels) using GATK [90] 
according to the GATK-recommended pipeline.[87] In brief, we marked and 
removed the PCR duplicates using SAMtools [89] and performed local indel 
realignment using RealignerTargetCreator and IndelRealigner modules of the 
GATK. We discovered the variants using multisample calling options of the GATK‘s 
UnifiedGenotyper based on the 170 fold total coverage. Following the application of 
variant quality score recalibration (VQSR), we identified a total of 6,953,274 raw 
genomic variants for the four individuals.  
 
We performed hard filtering to further evaluate the raw variants based on the 
strand bias and mapping quality and removed the very low quality calls with Phred 
quality score of maximum 10. After the hard filtering, we identified approximately 
3,400,000 SNVs and 750,000 small indels for each of the four individuals. We 
calculated the transition to transversion (Ts/Tv) ratio using vcf-tools.[82] The ratio 
was discovered to be 2.12 per genome consistent with the expected ratio for the 
whole genome sequencing data (Table 3.4). 
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Table 3.2: Statistics on the genome sequence produced by the paired-end whole genome sequencing 
 
Sample Twin I Twin II Mother Father 
Total sequence
a
 186 Gb 138 Gb 106 Gb 108 Gb 
Mapped reads
b
 1,667,768,752 1,154,518,105 950,095,509 930,901,596 
Percentage of total reads
c
 92.10 85.59 93.01 89.35 
Target base coverage (%)
d
 99.99 99.90 99.35 99.94 
Mean coverage (fold)
e
 59.96 42.51 34.10 33.42 
 
aLength of the sequence produced by WGS based on the total number of reads. bNumber of sequencing reads mapped with BWA. cPercentage of the mapped reads among total reads. dPercentage of the 
bases covered by at least one aligned read. eEffective fold coverage of the whole genome 
Abbreviations used in this table: Gb, gigabase 
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Table 3.3: Percentage of coverage per genome 
 
Depth (fold)  Twin I  Twin II  Mother  Father 
0 0,001 0,001 0,65 0,06 
≥2  99,930 99,857 99,27 99,87 
≥4  99,900 99,752 99,13 99,72 
≥10  99,590 99,133 98,07 98,53 
≥15  99,216 97,605 95,46 95,30 
≥20 98,419 94,153 90,32 88,83 
≥30 94,053 80,050 68,06 64,77 
≥40 85,258 53,518 34,58 32,07 
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Table 3.4: Statistics on all variants identified through whole genome sequencing 
 
Sample 
All variants 
Ts/Tv 
Novel Variants 
SNVs Indels SNVs Indels 
Twin I 3,496,649 783,415 2.12 49,800 70,500 
Twin II 3,493,010 781,583 2.12 49,182 69,927 
Mother 3,468,324 754,789 2.11 50,340 64,396 
Father 3,464,691 749,592 2.12 48,971 63,853 
 
Abbreviations used in this table: SNV, single nucleotide variation; Indel, insertions and deletions; Ts, transition; Tv, transversion 
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3.2 Discovery of the Putative De Novo SNVs 
We restricted our de novo mutation analysis with the SNVs. Our strategy to discover 
the de novo SNVs is based on the comparative analysis of the genotypes of the four 
individuals (twin pair and the parents) for each of the SNVs concurrently followed 
by a selective filtering. The discovery and filtering steps are described in the 
―Materials and Methods‖ section in detail. 
3.2.1 Discovery of the putative de novo SNVs shared by the twin pair 
We compared the genotypes of the twin pair and their parents through evaluating all 
possible genotype combinations for each of the SNVs synchronously using 
SnpSift.[92] We initially identified a total of 8,994 putative de novo SNVs shared by 
the twin pair. To discriminate the true de novo SNVs from the sequencing and 
variants calling artifacts, using a combination of sequence data analysis software and 
tools described in the methods section, we performed a progressive filtering based on 
the (a) novelty of the variants vis-à-vis dbSNP137, (b) presence of the coverage 
depth of minimum three for the site encompassing the variant, (c) presence of the 
variants on the sites that do not intersect the segmental duplications and simple 
repeats and (d) non-appearance of the variants as genotyping errors. Subsequent to 
this filtering which step-by-step removes the erroneous de novo SNV calls, we 
identified a total of 159 high-confidence putative de novo SNVs shared by the twin 
pair (Table 3.5).  
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Table 3.5: Identification of the putative de novo SNVs shared by the twin pair and application of the filters 
 
Genotypes
a
 
 
SNVs 
 
Number of de novo SNVs after filtering 
Twin I Twin II Mother Father 
 
All
b
 
 
Novel
c
 
 
Read Depth
d
 
 
Genomic Context
e
 
 
Genotyping Error 
1/1 1/1 0/0 0/0 
 
576 
 
105 
 
24 
 
0 
 
No 
0/1 0/1 0/0 0/0 
 
3,330 
 
662 
 
534 
 
159 
 
No 
1/1 0/1 0/0 0/0 
 
86 
 
15 
 
2 
 
1 
 
Yes 
0/1 1/1 0/0 0/0 
 
200 
 
35 
 
4 
 
0 
 
Yes 
1/1 1/1 0/1 0/0 
 
822 
 
40 
 
20 
 
5 
 
Yes 
1/1 1/1 0/0 0/1 
 
708 
 
23 
 
11 
 
2 
 
Yes 
1/1 1/1 0/0 1/1 
 
1,231 
 
64 
 
3 
 
1 
 
Yes 
1/1 1/1 1/1 0/0 
 
2,041 
 
54 
 
8 
 
0 
 
Yes 
Total 
 
8,994 
 
998 
 
606 
 
168 
 
159 
 
aComparison of the genotypes simultaneously; 1 and 0 refer alteration and reference, respectively. bTotal number of de novo SNV candidates before applying filters. cSNVs reported in dbSNP137 were 
filtered. dSNVs with read depth of less than 3 were filtered. eSNVs intersecting segmental duplications and simple repeats were filtered 
Abbreviations used in this table: SNV, single nucleotide variation 
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3.2.2 Discovery of the twin-specific putative de novo SNVs 
We discovered the putative de novo SNVs that are specific to each of the twins using 
the strategy described for the discovery of de novo SNVs shared by the twin pair 
above. We first identified a total of 1,417 putative de novo SNVs specific to twin I 
and 1,852 putative de novo SNVs specific to twin II through comparing the 
genotypes of the twin pair and the parents using SnpSift .[92] After the application of 
the filters progressively, a total of 131 high confidence putative de novo SNVs were 
identified. Of these, 83 were specific for twin I (Table 3.6) and 48 were specific for 
twin II (Table 3.7). 
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Table 3.6: Identification of the putative de novo SNVs specific to twin I and application of the filters 
 
Genotypes
a
 
 
SNVs 
 
Number of de novo SNVs after filtering 
Twin I Twin II Mother Father 
 
All
b
 
 
Novel
c
 
 
Read Depth
d
 
 
Genomic Context
e
 
 
Genotyping Error 
1/1 0/0 0/0 0/0 
 
138 
 
36 
 
1 
 
1 
 
No 
0/1 0/0 0/0 0/0 
 
919 
 
322 
 
299 
 
82 
 
No 
1/1 0/0 0/1 0/0 
 
61 
 
9 
 
2 
 
0 
 
Yes 
1/1 0/1 0/1 0/0 
 
71 
 
8 
 
1 
 
0 
 
Yes 
1/1 0/0 0/0 0/1 
 
22 
 
6 
 
0 
 
0 
 
Yes 
1/1 0/1 0/0 0/1 
 
60 
 
4 
 
2 
 
1 
 
Yes 
1/1 0/1 0/0 1/1 
 
60 
 
7 
 
2 
 
0 
 
Yes 
1/1 0/1 1/1 0/0 
 
86 
 
6 
 
2 
 
1 
 
Yes 
Total 
 
1,417 
 
398 
 
309 
 
85 
 
83 
 
aComparison of the genotypes simultaneously; 1 and 0 refer alteration and reference, respectively. bTotal number of de novo SNV candidates before applying filters. cSNVs reported in dbSNP137 were 
filtered. dSNVs with read depth of less than 3 were filtered. eSNVs intersecting segmental duplications and simple repeats were filtered 
Abbreviations used in this table: SNV, single nucleotide variation 
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Table 3.7: Identification of the putative de novo SNVs specific to twin II and application of the filters 
 
Genotypes
a
  SNVs  Number of de novo SNVs after filtering 
Twin I Twin II Mother Father  All
b
  Novel
c
  Read Depth
d
  Genomic Context
e
  Genotyping Error 
0/0 1/1 0/0 0/0  49  14  1  0  No 
0/0 0/1 0/0 0/0  791  270  239  48  No 
0/0 1/1 0/1 0/0  29  1  1  0  Yes 
0/1 1/1 0/1 0/0  306  32  20  12  Yes 
0/0 1/1 0/0 0/1  13  2  1  1  Yes 
0/1 1/1 0/0 0/1  249  32  19  8  Yes 
0/1 1/1 0/0 1/1  197  10  3  1  Yes 
0/1 1/1 1/1 0/0  218  13  1  1  Yes 
Total  1,852  374  285  71  48 
 
aComparison of the genotypes simultaneously; 1 and 0 refer alteration and reference, respectively. bTotal number of de novo SNV candidates before applying filters. cSNVs reported in dbSNP137 were 
filtered. dSNVs with read depth of less than 3 were filtered. eSNVs intersecting segmental duplications and simple repeats were filtered 
Abbreviations used in this table: SNV, single nucleotide variation 
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3.2.3 Assessment of the validity of filtering process 
We evaluated the efficacy of our filters in the removal of genotyping and variants 
calling errors while keeping the true de novo SNV candidates in the call-set. We 
performed this evaluation based on the ―true genetic variation‖ that is present in the 
genomes of the four individuals.[101] 
 
We identified a total of 3,437,507 SNVs that are present in the genomes of 
the twin pair and in both parents (Table 3.8) and classified these variants as control 
group SNVs. We assessed the validity of the homozygous and heterozygous control 
group SNVs based on the reference allele frequency (RAF). RAF calculated to be 
0.01 for homozygous variants and 0.5 for heterozygous variants for each individual, 
suggesting that the group of SNVs selected as controls represented the true genetic 
variation (Table 3.9). 
 
 We calculated the ratio of ―fraction of putative de novo SNVs removed with 
filters‖ to ―fraction of control group SNVs removed with filters‖ (Fpdn/Fcontrol) for the 
putative de novo SNVs (a) shared by the twin pair, (b) specific to twin I and specific 
to twin II (Table 3.10). For each group of the putative de novo SNVs, the filters 
removed more de novo SNV candidates than the control group SNVs. This suggested 
the efficiency of the filters in the removal of genotyping/variants calling errors. 
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Table 3.8: Identification of the control group SNVs and application of the filters 
 
Genotypes
a
  SNVs  Number of SNVs after filtering 
Twin I Twin II Mother Father  All
b
  Read Depth
c
  
0/1 0/1 0/1 0/1  350,297  350,196  
0/1 0/1 0/1 0/0  477,590  477,181  
0/1 0/1 0/0 0/1  498,992  498,545  
0/1 0/1 0/1 1/1  180,920  180,717  
0/1 0/1 1/1 0/1  190,813  190,701  
0/1 0/1 0/0 1/1  201,997  201,587  
0/1 0/1 1/1 0/0  213,447  213,048  
1/1 1/1 0/1 0/1  168,375  168,321  
1/1 1/1 0/1 1/1  191,449  191,171  
1/1 1/1 1/1 0/1  192,291  192,141  
1/1 1/1 1/1 1/1   775,330   773,899   
Total   3,441,501   3,437,507   
 
aComparison of the genotypes simultaneously; 1 and 0 refer alteration and reference, respectively. bTotal number of control group SNVs before applying filters. cSNVs with read depth of less than 3 were 
filtered. 
Abbreviations used in this table: SNV, single nucleotide variation 
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Table 3.9: Calculation of the RAF and average depth of coverage for the control group SNVs 
 
Class of SNVs 
Twin I Twin II Mother Father 
Average RAF Average Depth Average RAF Average Depth Average RAF Average Depth Average RAF Average Depth 
Control group SNVs (n=3,437,507)   
Homozygous in both twins (n=1,325,532) 0.02 (0.1 std.) 
57.15 
0.01 (0.1 std.) 
38.73 
0.02 (0.1 std.) 
32.94 
0.02 (0.1 std.) 
32.21 
Heterozygous in both twins (n=2,111,975) 0.5 (0.1 std.) 0.5 (0.1 std.) 0.5 (0.1 std.) 0.5 (0.1 std.) 
 
Abbreviations used in this table: SNV, single nucleotide variation; RAF, reference allele frequency; std, standard deviation 
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Table 3.10: Evaluation of the efficiency of the filters in the removal of false de novo calls 
 
Type of filter 
Control group SNVs Shared de novo SNVs Twin I-specific de novo SNVs Twin II-specific de novo SNVs 
Percentage Percentage Fpdn/Fcontrol Percentage Fpdn/Fcontrol Percentage Fpdn/Fcontrol 
No Filter 3,441,501 (100%) 998 (100%) - 398 (100%) - 374 (100%) - 
Read Depth Filter 3,437,507 (99.88%) 606 (60.72%) 327 309 (77%) 191 285 (76.20%) 198 
Genomic Context Filter  N/A 168(16.83%) N/A 85 (21.35%) N/A 71 (18.98%) N/A 
 
Abbreviations used in this table: SNV, single nucleotide variation; Fpdn, fraction of putative de novo SNVs removed by filters; Fcontrol, fraction of control group SNVs removed by filters; N/A, ―Genomic 
Context Filter‖ was not applied to the control group SNVs; Percentage, number and percentage of the variants remained after filtering 
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3.3 Selection of the Putative De Novo SNVs for Sanger Sequencing 
We identified a total of 290 high-confidence putative de novo SNVs (159 shared by 
the twin pair, 83 specific to twin I and 48 specific to twin II) as a result of the 
genotype comparison and the progressive filtering. Herein, to further clean the 
spurious de novo SNV calls prior to the Sanger based capillary sequencing; we 
evaluated the de novo SNV candidates based on the visual examination of the 
sequencing data and the sequence coverage depth.  
3.3.1 Visual examination-based evaluation and selection 
We performed visual examination of the BAM files of the four individuals (the twin 
pair and the parents) concurrently for the total of 290 high-confidence de novo SNV 
candidates using IGV (see Appendix B).[94] We filtered 40/290 variants as 
―inherited‖; 8/290 variants as ―no variant‖; and 122/290 variants as ―located on a low 
quality read‖, based on the visual inspection and the analysis of the allelic depth for 
each of the SNVs in each individual (Table 3.11). We selected the remaining 120 de 
novo SNV candidates (73 shared by the twin pair; 29 specific to twin I and 18 
specific to twin II) as true putative de novo SNVs (see Appendix C for the full list of 
the total of 290 putative de novo SNVs and the predictions for each of the variants). 
This set of putative de novo SNVs were selected for validation. The criteria 
underlying the classification and filtering of the variants according to the visual 
inspection are described in the ―Materials and Methods‖ section comprehensively. 
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Table 3.11: Classification of the putative de novo SNVs based on the visual inspection of the sequence alignment data 
 
Class of de novo SNVs Initial call-set Inherited No variant Low quality read Final call-set 
Shared by the twin pair 159 26 5 55 73 
Twin I-specific  83 8 3 43 29 
Twin II-specific 48 6 0 24 18 
Total 290 40 8 122 120 
 
Abbreviations used in this table: SNV, single nucleotide variation 
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3.3.2 Sequencing data-based evaluation of the putative de novo SNVs 
Subsequent to the visual inspection, we further assessed the validity of the putative 
de novo SNVs based on the RAF and the depth of coverage. We calculated the 
average RAF and coverage depth in each of the four individuals for the de novo SNV 
candidates that are shared by the twin pair (group I) and that are specific for each of 
the twins (group II) (Table 3.12). At this point, the RAF for the mother and father 
was discovered to range between 0.95 and 0.97 for each class of the putative de novo 
SNVs, supporting the absence of the variant in the parental genomes. For the putative 
de novo SNVs that are shared by the twin pair, the RAF values of 0.59 for the twin I 
and 0.55 for the twin II supported the heterozygous presence of the variant. We 
calculated the RAF of 0.68 for the twin I specific and 0.69 for the twin II specific de 
novo SNV candidates. These frequencies for the twin specific variants suggested the 
presence of the putative de novo SNVs that have an early post-zygotic origin in a 
mosaic fashion. 
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Table 3.12: Average RAF and the depth of coverage for each class of the de novo SNV candidates 
 
Class of putative de novo SNVs  
Twin I Twin II Mother Father 
Average RAF Average Depth Average RAF Average Depth Average RAF Average Depth Average RAF Average Depth 
De novo SNVs shared by the twin pair  0.59 (0.1 std.) 38.72 0.55 (0.1 std.) 24.89 0.96 (0.1 std.) 23.55 0.95 (0.1 std.) 21.01 
Twin I-specific de novo SNVs  0.68 (0.1 std.) 36.65 0.95 (0.1 std.) 26.79 0.96 (0.1 std.) 23.24 0.95 (0.1 std.) 18.96 
Twin II-specific de novo SNVs  0.96 (0.05 std.) 38.50 0.69 (0.1std.) 21.39 0.97 (0.04 std.) 25.50 0.95 (0.1 std.) 20.55 
 
Abbreviations used in this table: SNV, single nucleotide variation; RAF, reference allele frequency; std, standard deviation 
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3.4 Classification of the Putative De Novo SNVs Regarding the 
Genomic Context 
We performed functional and positional annotation of the total of 290 putative de 
novo SNVs (159 shared by the twin pair, 83 specific to twin I and 48 specific to twin 
II) against human database (GRCh37.68 version in the SnpEff repository) using 
SnpEff (see Appendix C).[91]  
 
We classified the total of 120 putative de novo SNVs that were selected for 
Sanger based capillary sequencing as located on the (a) downstream of the genes 
(n=25), (b) upstream of the genes (n=1), (c) intergenic regions (n=32), (d) introns 
(n=58), and (e) exons (n=4) (Figure 3.3). Herein, the major proportion of the putative 
de novo SNVs was discovered to present in the non-coding regions of the genome. 
We did not observe any gene that is subjected to the de novo SNVs recurrently. The 
biased distribution of the putative de novo SNVs towards the non-coding regions was 
attributed to the (a) presence of the less forceful evolutionary pressure on the non-
coding regions of the genome, (b) structure of the human genome (98% non-coding),  
and (c) our study design which is concerned with the analysis of the genomes of 
healthy individuals.[9]  
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Figure 3.3: Classification of the putative de novo SNVs regarding the genomic 
context. Annotation was performed against human database GRCh37.68 using 
SnpEff.[91]  
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3.5 Experimental Validation of the De Novo SNVs 
We sought to validate the total of 120 high-confidence de novo SNV candidates (73 
shared, 29 twin I-specific, 18 twin II-specific) that pass our filtering criteria through 
Sanger sequencing. We designed the primer pairs using Primer3 (see Appendix A for 
the full list of primers).[95] Subsequent to the PCR amplification and the 
purification, we sequenced the blood-derived DNA samples of the twin pair and their 
parents for 83 of the 120 putative de novo SNVs and analyzed the sequencing data of 
the four individuals simultaneously using CLC Main Workbench software package 
(CLCBio Inc). We could not test 37 de novo SNV candidates due to unavailability of 
the primer pairs or PCR products of good quality for Sanger sequencing. 
3.5.1 Validation of the de novo SNVs shared by the twin pair 
We performed Sanger based capillary sequencing of the whole blood derived DNA 
samples of the twin pair and their parents to test the 49/73 high confidence putative 
de novo SNVs. 24/73 de novo SNV candidates could not be tested due to the 
limitations described above.  
 
Of the 49 de novo SNV candidates that are shared by the twin pair and tested 
by Sanger sequencing, 23 confirmed to be true de novo SNV present in a 
heterozygous state in both twins (Figure 3.4). 8/49 discovered to be inherited from 
the parents (Figure 3.5) and 11/49 discovered to be not present in the genomes of the 
twin pair (Figure 3.6). The sequencing results were uninformative for 7/49 de novo 
SNV candidates (see Table C.1 for the Sanger sequencing results for each of the 
tested variants and Appendix D for the Sanger sequencing chromatograms of the 23 
validated de novo SNVs).  
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Figure 3.4: A representative Sanger sequencing electropherogram for a shared de 
novo SNV present in a heterozygous state and validated by capillary sequencing. 
(Chromosome 4: 145566227: C/T). 
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Figure 3.5: A representative Sanger sequencing electropherogram for a putative de 
novo SNV discovered to be inherited based on the capillary sequencing result 
(Chromosome 6: 169662202: G/A). 
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Figure 3.6: A representative Sanger sequencing electropherogram for a putative de 
novo SNV discovered to be not present in the genomes of the twin pair 
(Chromosome 4: 33630506: A/C). 
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3.5.2 Validation of the twin-specific de novo SNVs 
We tested the putative de novo SNVs that are specific to each of the twins through 
Sanger based capillary sequencing of the whole blood derived DNA samples. Herein, 
we could perform Sanger sequencing for 19 of the 29 and 15 of the 18 high-
confidence putative de novo SNVs specific to twin I and twin II, respectively (see 
Table C.2 and Table C.3 for the Sanger sequencing result for each of the tested 
variants).  
 
Analysis of the capillary sequencing data of the twin pair and the parents 
synchronously resulted with the validation of 8/19 twin I-specific and 1/15 twin II-
specific de novo SNVs (Figure 3.7 and see Appendix E for the Sanger sequencing 
electropherograms for the total of 9 validated twin-specific de novo SNVs ). Of the 
34 twin-specific putative de novo SNVs tested by capillary sequencing, 4 were 
discovered to be inherited and 17 were discovered to be not present in the twins. 
Sequencing results were uninformative for 9/34 variants.  
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Figure 3.7: A representative Sanger sequencing electropherogram for a twin I-
specific de novo SNV (Chromosome 2: 61728351: A/T). 
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3.5.3 Evaluation of the Sanger sequencing results 
Subsequent to the validation of the presence of 32 de novo SNVs (23 shared by the 
twin pair, 8 specific to twin-I and 1 specific to twin II) through Sanger-based 
capillary sequencing, we calculated the false negative rate for the call-set (0.06 – 
0.15) based on the number of putative de novo SNVs discovered to be inherited from 
the parents (Table .3.13). 
 
We observed the twin-specific de novo SNVs in a mosaic state. Herein, for 
each of the twin-specific de novo SNVs, the peak for the mutant allele on the 
capillary sequence trace was reduced comparing to the wild-type allele, indicating 
the mosaic representation of the variants (see Appendix E).[67] 
 
We calculated the RAF for each group of de novo SNVs validated by Sanger 
sequencing. For the de novo SNVs shared by the twin pair, average RAF was 0.53 
and 0.46 for the twin I and twin II, respectively. For the twin-specific de novo SNVs 
of early post-zygotic origin, the average RAF of 0.65 for the twin I and 0.78 for the 
twin II were calculated. These reference allele frequencies for the twin-specific de 
novo SNVs supported the presence of the variants in a mosaic state (Table 3.14). 
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Table 3.13: Statistics on de novo SNVs tested by Sanger sequencing 
 
Class of de novo SNVs All Primer Design Failed PCR Failed Inherited No variant Uninformative De novo FNR 
Shared by the twin pair 73 8 16 8 11 7 23 0.14 
Twin I-specific 29 5 5 3 5 3 8 0.15 
Twin II-specific 18 2 1 1 12 1 1 0.06 
Total 120 15 22 12 28 11 32  
 
Abbreviations used in this table: FNR, false negative rate 
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Table 3.14: Average RAF and depth of coverage for the de novo SNVs tested by Sanger sequencing 
 
Class of de novo SNVs tested by  
Sanger sequencing  
Twin I Twin II Mother Father 
Average RAF Average Depth Average RAF Average Depth Average RAF Average Depth Average RAF Average Depth 
De novo SNVs shared by the twin pair  0.53 (0.1 std.) 54.91 0.46 (0.1 std) 34.13 0.99 (0.02 std.) 32.17 0.99 (0.0 std.) 30.47 
Twin I-specific de novo SNVs  0.65 (0.1 std.) 50.50 1.00 (0.0 std.) 38.75 0.99 (0.01 std.) 28.63 1.00 (0.0 std.) 29.13 
Twin II-specific de novo SNVs  1 63 0.78 41 1 40 0.96 (0.1 std.) 27 
Inherited  0.65 (0.2 std.) 34.43 0.67 (0.2 std.) 20.41 0.92 (0.2 std.) 19.61 0.88 (0.1 std.) 16.86 
No variant  0.81 (0.2 std.) 36.46 0.74 (0.1 std.) 24.18 0.94 (0.1 std.) 25.78 0.93 (0.1 std.) 20.92 
 
Abbreviations used in this table: RAF, reference allele frequency; std, standard deviation 
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3.6 Investigation of the Possible Effect of the Parental Mosaicism 
There is a probability of interpreting an SNV as de novo in the twin pair erroneously 
due to the mosaicism in the parental genomes.[67, 102, 103] To exclude this 
possibility, we examined the DNA from the cells of different embryonic origin, 
including the DNA isolated from the buccal wash specimen (ectoderm) and urine 
samples (endoderm) of the parents, in addition to the previously tested blood-derived 
DNA (mesoderm).[104]  
 
We randomly selected 10 of the 23 de novo SNVs shared by the twin pair and 
performed capillary sequencing of the buccal wash- and urine cell-derived DNA 
samples of the mother and father for these variants. We did not observe the de novo 
SNVs in the endoderm- and ectoderm-derived DNA samples of the parents, and 
excluded the probability of parental mosaicism which may result with the 
misinterpretation of the data (see Appendix F for the Sanger sequencing 
electropherograms).  
3.7 Examination of the dbSNP137-Reported Variants 
We filtered the common single nucleotide polymorphisms (SNPs) present in the 
dbSNP137 database during the filtering process since we intended to discover the 
private de novo SNVs that are not reported previously. The mutations may occur at 
every single position in the genome, even at the sites that are mutated in the common 
population. We therefore extended our analysis to the common SNPs to prevent the 
underestimation of the mutation rate. 
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We identified a total of 3,619 dbSNP137-reported de novo SNP candidates 
(a) shared by the twin pair (n=2,728) (Table 3.15), (b) specific to twin I (n=329) 
(Table 3.16), and (c) specific to twin II (n=562) (Table 3.17).  
 
We examined the minor allele frequencies (MAF) for all 3,619 de novo SNP 
candidates and discovered that the most (63.75%) of these SNPs had MAF>10% in 
the 1000 Genomes Project populations. We identified 65 SNVs (55 shared by the 
twins, 3 specific to twin I, and 7 specific to twin II) that have MAF of less than 1% 
(Table 3.18). For each of these 65 potentially de novo SNVs, we examined the depth 
of coverage and the genotype quality in both parents, resulting with the identification 
of 3 candidate de novo SNVs (1 shared by the twins, 1 specific to twin I, and 1 
specific to twin II). The remaining 62 SNVs had either zero, or very low (<5X) 
coverage in either parent's genome, or had low genotyping quality (>60) (Table 
3.19).  
 
We further examined these 3 de novo SNV candidates based on the genotype 
quality, depth of coverage, genotype in the parents, and the presence of a CNV in 
that position (Table 3.20). We used the GenomeSTRiP [105] tool to genotype 
deletions in the quad family and we identified a deletion which encompasses the de 
novo SNV shared by the twin pair. We excluded the twin II specific de novo SNV 
candidate because of low coverage in the genome of twin II, as it is supported only 
by four reads. These analyses resulted with only one twin I specific de novo SNV 
candidate with high coverage and high genotyping quality. However, this SNV also 
seemed to pass our allele bias threshold (in hard filtering 0.2) with a slight difference 
(0.26; or 13/44). Allele bias ratio is defined as the number of reads that support the 
alternative allele versus the number of reads that support the reference allele. Hence, 
we neglected this SNV in our mutation rate estimation. 
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Table 3.15: Discovery of the dbSNP137 reported de novo SNP candidates shared by 
the twins 
 
Twin I Twin II Mother Father All Genomic context 
1/1 1/1 0/0 0/0 471 177 
0/1 0/1 0/0 0/0 2,668 927 
1/1 0/1 0/0 0/0 71 34 
0/1 1/1 0/0 0/0 165 95 
1/1 1/1 0/1 0/0 782 292 
1/1 1/1 0/0 0/1 685 146 
1/1 1/1 0/0 1/1 1,167 299 
1/1 1/1 1/1 0/0 1,987 758 
Total 7,996 2,728 
 
 
 
 
 
Table 3.16: Discovery of the dbSNP137 reported de novo SNP candidates specific to 
twin I 
 
Twin I Twin II Mother Father All Genomic context 
1/1 0/0 0/0 0/0 102 51 
0/1 0/0 0/0 0/0 597 147 
1/1 0/0 0/1 0/0 52 24 
1/1 0/1 0/1 0/0 63 22 
1/1 0/0 0/0 0/1 16 4 
1/1 0/1 0/0 0/1 56 27 
1/1 0/1 0/0 1/1 53 17 
1/1 0/1 1/1 0/0 80 37 
Total 1,019 329 
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Table 3.17: Discovery of the dbSNP137 reported de novo SNP candidates that are 
specific to twin II 
 
Twin I Twin II Mother Father All Genomic context 
0/0 1/1 0/0 0/0 35 16 
0/0 0/1 0/0 0/0 521 118 
0/0 1/1 0/1 0/0 28 14 
0/1 1/1 0/1 0/0 274 138 
0/0 1/1 0/0 0/1 11 3 
0/1 1/1 0/0 0/1 217 90 
0/1 1/1 0/0 1/1 187 91 
0/1 1/1 1/1 0/0 205 92 
Total 1,478 562 
 
 
 
 
 
 
Table 3.18: Global minor allele frequency distribution for the de novo SNP 
candidates 
 
  Number of de novo SNPs 
Minor allele frequency Shared by the twins Twin I specific Twin II specific 
0.5 - 0.1 1,794 172 342 
0.1 - 0.05 227 23 50 
0.05 - 0.01 212 19 39 
0.01 - 0.005 25 2 4 
< 0.005 30 1 3 
Not reported 440 112 124 
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Table 3.19: Filtering of the de novo SNPs which have a minor allele frequency (MAF) smaller than 1% based on the depth and genotype 
quality 
 
  Application of the Filters 
  Mother  Father  Mother | Father  Remaining  Del_intersect
 
De novo Calls
 
Total DP=0 0<DP<5 GQ<60  DP=0 0<DP<5 GQ<60  Low GQ     
Shared by the twins 55 21 4 6  12 2 9  15  1  Yes 
Twin I-specific 3 0 1 1  0 0 1  1  1  No 
Twin II-specific 7 1 1 4  0 0 1  4  1  No
c
 
 
Abbreviations used in this table: DP, depth; GQ, genotype quality; Del_intersect, variant is intersecting a deletion 
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Table 3.20: List of high-confidence SNPs discovered as de novo 
 
            Twin I Mother Father Twin II Twin I Mother Father Twin II Twin I Mother Father Twin II 
Chr Pos ID Ref Alt MAF Genotype Genotype Genotype Genotype DPb DP DP DP GQc GQ GQ GQ 
8 20599745 rs79776133 G C 0,00964 Hom Ref Het Hom 33 22 28 21 99 63 99 57 
10 105839182 rs184555413 G A 0,00046 Het Ref Ref Ref 55 42 43 36 99 99 99 99 
16 70472322 rs138210796 A G 0,00781 Het Ref Het Hom 33 27 15 6 99 69 68 12 
 
Abbreviations used in this table: Chr, chromosome; Pos, position, Ref, reference allele; Alt, alternative allele; MAF, minor allele frequency; DP, depth; GQ, genotype quality 
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3.8 Calculation of the De Novo SNV Rate 
The de novo SNV rate for each of the twins was calculated based on the number of 
validated de novo SNVs, number of the callable bases and the false negative rate. 
The formula of ―µ = (N x (1+FNR)) /L‖ was used for mutation rate estimation.[13] 
Herein, µ is the mutation rate, N is the number of Sanger-confirmed de novo SNVs, 
FNR is the false negative rate for the call-set (Table 3.13), and L is the total number 
of callable bases. The bases were considered as callable if they have a read depth of 
minimum three and do not intersect the segmental duplications and simple repeats. 
We calculated 2,703,445,479 bases for twin I and 2,702,251,568 for twin II. 
 
We estimated the rate of pre-zygotic de novo SNVs (shared by the twin pair) 
as 0.97 × 10-8 for the twin pair based on the 23 de novo SNVs verified by Sanger 
sequencing. The rate of the early post-zygotic de novo SNVs (specific to twins) was 
estimated to be 0.34 × 10-8 for the twin I and 0.04 × 10-8 for the twin II. We 
discovered the overall de novo SNV rate of 1.01 × 10-8 and 1.31 × 10-8 for twin I and 
twin II, respectively (Table 3.21). These data implicate the substantial contribution of 
early post-zygotic de novo SNVs to the overall mutation rate. 
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Table 3.21: De novo mutations of the twin pair and the mutation rate estimation 
 
Sample   All SNVs  Novel SNVs  De novo SNVs  Validated de novo SNVs  Mutation Rate(x10
-8
)
 
 
 dbSNP137 Novel  Inherited De novo  Group I Group II Total  Group I Group II Total  Group I Group II Total 
Twin I  3,446,849 49,800  48,405 1,396  
159 
83 242  
23 
8 31  
0.97 
0.34 1.31 
Twin II  3,443,828 49,182  47,810 1,372  48 207  1 24  0.04 1.01 
 
Abbreviations used in this table: SNV, single nucleotide variation 
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3.9 Examination of the Incidental Findings 
We examined the incidental results in the whole genome sequencing data of the four 
individuals (the twin pair and their parents). In the context of the incidental result 
examination, we focused on the LoF mutations and potentially damaging missense 
mutations.  
 
First, we selected all homozygous and heterozygous mutations present in the 
genomes of the twin pair and their parents through considering the Mendelian 
transmission patterns to eliminate the genotyping and variants calling errors. Herein, 
to select the true mutations, our strategy is based on the selection of the mutations 
through comparative analysis of the genotypes for each of the variants (SNVs and 
indels) using SnpSift.[92] We performed functional and positional annotation of the 
selected variants against human reference genome (GRCh37.68) using SnpEff.[91] 
We filtered the mutations that are reported in dbSNP137 with a minor allele 
frequency of greater than 0.01. Finally we extracted the LoF mutations and missense 
mutations (Table 3.22).  
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Table 3.22: Identification of the homozygous and heterozygous LoF and missense mutations of the four individual 
 
Genotypes 
 
Number of LoF and Missense Mutations 
Twin I Twin II Mother Father  
Novel  
 
dbSNP137-reported (MAF  < 0.01) 
 
Stopgain Stoploss Splice site Frameshift Missense 
 
Stopgain Stoploss Splice site Frameshift Missense 
1/1 1/1 1/1 1/1 
 
0 0 1 7 2 
 
0 0 6 7 7 
1/1 1/1 0/1 0/1 
 
0 0 1 2 0 
 
0 0 0 0 3 
1/1 1/1 1/1 0/1 
 
0 0 0 1 0 
 
0 0 1 1 4 
1/1 1/1 0/1 1/1 
 
0 0 0 1 0 
 
0 0 1 1 7 
0/1 0/1 0/0 0/1 
 
0 0 2 8 105 
 
1 0 5 3 157 
0/1 0/1 0/0 1/1 
 
0 0 1 4 5 
 
0 0 0 3 8 
0/1 0/1 0/1 0/0 
 
1 0 4 8 104 
 
1 0 0 0 138 
0/1 0/1 1/1 0/0   0 0 1 2 5   0 0 0 1 12 
 
Abbreviations used in this table: LoF, loss of function; MAF, minor allele frequency 
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3.9.1 Analysis of the LoF mutations 
We considered the (a) stop codon introducing (stopgain), (b) stop codon removing 
(stoploss), (c) splice site disrupting SNVs and (d) frameshift indels as LoF 
mutations.[97]  
3.9.1.1 LoF mutations of the twin pair 
3.9.1.1.1 Homozygous LoF mutations of the twin pair 
We discovered a total of 30 LoF mutations present in the genomes of the twin pair in 
homozygous state. 13 of the 30 mutations were novel, not reported in dbSNP137. 
These 13 novel LoF mutations are located on 12 different genes. We examined the 
genes that carry these mutations in terms of being reported in OMIM database related 
to a disease phenotype. Herein, we discovered that 2 of the 13 novel LoF mutations 
occurred in the genes that are previously reported to be causal for 2 different diseases 
(Table 3.23). Of the 17 dbSNP137-reported LoF mutations (MAF <0.01), one splice 
site mutation (rs112378876) discovered to be located on MTMR2 gene which is 
involved in the pathogenesis of the autosomal recessively inherited Charcot-Marie-
Tooth disease (#601382) (Table 3.24). 
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Table 3.23: Novel homozygous LoF mutations of the twin pair 
 
Chr Position Ref Alt Gene Function 1000G  OMIM Disease Inheritance 
1 152195729 T - HRNR frameshift deletion NA - - 
5 139931628 - GT SRA1 frameshift insertion NA CAMPOMELIC DYSPLASIA (#114290) AD 
5 139931629 - G SRA1 frameshift insertion NA CAMPOMELIC DYSPLASIA (#114290) AD 
9 70900911 - A CBWD3 frameshift insertion NA - - 
10 116931101 - TT ATRNL1 frameshift insertion 0.96 - - 
11 76954788 - A GDPD4 frameshift insertion 0.23 - - 
12 55714406 - A OR6C1 frameshift insertion 0.34 - - 
17 6555546 - G C17orf100 frameshift insertion 1.00 - - 
17 71752500 - T LOC100134391 frameshift insertion 1.00 - - 
19 51835892 - G VSIG10L frameshift insertion NA - - 
X 122336600 - G GRIA3 frameshift insertion 1.00 MENTAL RETARDATION, X-LINKED (#300699) XR 
4 6086694 - A JAKMIP1 splice site NA - - 
8 96047806 - A NDUFAF6 splice site NA - - 
 
Abbreviations used in this table: Chr; chromosome, Ref; reference allele, Alt; alternative allele, A.A Change; aminoacid change, AD; autosomal dominant, XR; X-linked recessive, NA; not available 
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Table 3.24: dbSNP137-reported homozygous LoF mutations of the twin pair 
 
Chr Position dbSNP137 Ref Alt Gene Function 1000G OMIM Disease Inheritance 
1 156565049 rs112595382 - AC GPATCH4 frameshift insertion NA - - 
3 129814935 rs55800015 C - ALG1L2 frameshift deletion NA - - 
5 156721863 rs76159126 - C CYFIP2 frameshift insertion NA - - 
5 175811094 rs78549596 - GT NOP16 frameshift insertion NA - - 
15 31521506 rs141879900 GG - 
RP11-
16E12.2 frameshift deletion NA - - 
16 89291210 rs113560259 - GTGA ZNF778 frameshift insertion NA - - 
22 19189003 rs78649162 - C CLTCL1 frameshift insertion NA - - 
X 36162684 rs201605278 - TG CHDC2 frameshift insertion NA - - 
X 101395780 rs200987681 - G TCEAL6 frameshift insertion NA - - 
3 52872001 rs113892040 TGTGTGTGCACGTGCACG - TMEM110 splice site NA - - 
9 73458045 rs3833697 - A TRPM3 splice site NA - - 
11 46342259 rs79068197 - G CREB3L1 splice site NA - - 
11 95615662 rs112378876 TAAAA - MTMR2 splice site NA 
CHARCOT-MARIE-TOOTH DISEASE, TYPE 
4B1(#601382) AR 
12 7080212 rs17857448 T C EMG1 splice site NA - - 
17 61660890 rs66502552 G - DCAF7 splice site NA - - 
18 74208486 rs3841258 G - FLJ44313 splice site NA - - 
19 16268208 rs5827321 A - HSH2D splice site NA - - 
 
Abbreviations used in this table: Chr; chromosome, Ref; reference allele, Alt; alternative allele, AR; autosomal recessive, NA; not available
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3.9.1.1.2 Heterozygous LoF mutations of the twin pair 
We identified a total of 45 LoF mutations present in the genomes of the twin pair in 
heterozygous state. Of these, 31 were novel and 14 were reported in SNP database 
dbSNP137 with MAF of less than 0.01 (see Appendix G for the full list of 
heterozygous LoF mutations of the twin pair). 3/31 novel and 2/14 dbSNP137-
reported LoF mutations appeared on genes that were previously identified for 
autosomal dominant and recessive diseases in OMIM database (Table 3.25). 
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Table 3.25: List of heterozygous LoF mutations in the twin pair located on genes related to diseases 
 
Chr Position dbSNP137 Ref Alt Gene Function 1000G OMIM Disease Inheritance 
5 171765480 NA CAAA - SH3PXD2B 
frameshift 
deletion 
NA  FRANK-TER HAAR SYNDROME (#249420) AR 
8 103250839 NA - G RRM2B 
frameshift 
insertion 
0.06  PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA (#613077) AD 
17 57141768 NA - A TRIM37 splice site NA  MULIBREY NANISM (#253250) AR 
17 17697102 rs34083643 G - RAI1 
frameshift 
deletion 
NA SMITH-MAGENIS SYNDROME (#182290) AD 
18 42456670 rs3085861 - TCTT SETBP1 
frameshift 
insertion 
NA 
SCHINZEL-GIEDION MIDFACE RETRACTION SYNDROME 
(#269150) 
AD 
 
Abbreviations used in this table: Chr; chromosome, Ref; reference allele, Alt; alternative allele, AR; autosomal recessive, AD; autosomal dominant, NA; not available 
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3.9.1.2 LoF mutations of the parents 
3.9.1.2.1 Homozygous LoF mutations of the parents 
We identified 28 and 32 LoF mutations present in homozygous state in the genome 
of the mother and father, respectively (see Appendix H for the full list of 
homozygous LoF mutations of the parents). 12/28 mutations in the mother and 14/32 
mutations in the father discovered to be novel. Of the novel LoF mutations, 2/12 and 
1/14 appeared to be located on genes that are involved in autosomal dominant and X 
linked recessive diseases in mother and father, respectively. Of the dbSNP137-
reported LoF mutations, 1 mutation in both mother and father appeared on MTMR2 
gene which is reported to be causal for Charcot-Marie-Tooth disease (#601382) 
(Table 3.26). 
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Table 3.26: List of the homozygous LoF mutations located on disease genes in the parents 
 
Chr Position dbSNP137 Ref Alt Gene Function 1000G Individual OMIM Disease Inheritance 
8 103250839 NA - G RRM2B 
frameshift 
insertion 0.06 Mother 
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA 
(#613077) AD 
11 95615662 rs112378876 TAAAA - MTMR2 splice site NA Father&Mother 
CHARCOT-MARIE-TOOTH DISEASE, TYPE 
4B1(#601382) AR 
X 122336600 NA - G GRIA3 
frameshift 
insertion 1.00 Father&Mother MENTAL RETARDATION, X-LINKED (#300699) XR 
 
Abbreviations used in this table: Chr; chromosome, Ref; reference allele, Alt; alternative allele, AR; autosomal recessive, AD; autosomal dominant, XR; X linked recessive, NA; not available 
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3.9.1.2.2 Heterozygous LoF mutations of the parents 
We discovered a total of 45 LoF mutations present in heterozygous state in the 
genomes of the mother (n=20) and father (n=25) (see Appendix I for the full list of 
heterozygous LoF mutations of the parents).Of these, 31 (17 in the genome of mother 
and 14 in the genome of father) were novel. We analyzed the genes that carry all of 
the 45 heterozygous LoF mutations to evaluate the involvement of them in diseases. 
Herein, we observed that 6 of the 45 variants were located on genes that are reported 
to be causal for autosomal dominant and recessive diseases in OMIM (Table 3.27). 
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Table 3.27: List of the heterozygous LoF mutations located on disease genes in the parents 
 
Chr Position dbSNP137 Ref Alt Gene Function 1000G  Individual OMIM Disease Inheritance 
5 139931628 NA - GT SRA1 
frameshift 
insertion NA Mother and Father CAMPOMELIC DYSPLASIA (#114290) AD 
5 139931629 NA - G SRA1 
frameshift 
insertion NA Mother and Father CAMPOMELIC DYSPLASIA (#114290) AD 
5 171765480 NA CAAA - SH3PXD2B 
frameshift 
deletion NA Mother    FRANK-TER HAAR SYNDROME (#249420) AR 
17 57141768 NA - A TRIM37 splice site NA Mother  MULIBREY NANISM (#253250) AR 
17 17697102 rs34083643 G - RAI1 
frameshift 
deletion NA Father SMITH-MAGENIS SYNDROME (#182290) AD 
18 42456670 rs3085861 - TCTT SETBP1 
frameshift 
insertion NA Father 
SCHINZEL-GIEDION MIDFACE RETRACTION 
SYNDROME (#269150) AD 
 
Abbreviations used in this table: Chr; chromosome, Ref; reference allele, Alt; alternative allele, AR; autosomal recessive, AD; autosomal dominant, NA; not available 
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3.9.2 Analysis of the missense mutations 
In the genomes of the twin pair, we identified a total of 23 homozygous and 534 
heterozygous missense SNVs that pass our filtering criteria (novel and dbSNP137-
reported with MAF of less than 0.01). None of the genes that carry the 23 
homozygous missense SNVs were reported in OMIM database. We evaluated the 
deleteriousness of the variants based on the SIFT, Polyphen2 and 
MutationTaster.scores.[98, 99, 100] Herein, 7 of the 23 homozygous missense 
variants discovered to be damaging (Table 3.28) 
 
Of the 534 heterozygous missense SNVs (219 novel and 315 dbSNP137-
reported), 87 variants appeared on disease related genes. Despite their occurrence on 
the genes that are related to diseases, 22 of the 87 variants were predicted to be 
benign or neutral based on the SIFT, Polyphen2 and MuutationTaster (Table 3.29). 
Remaining 65 missense SNVs were predicted to be deleterious according to at least 
one of the mutation effect assessing tools. 
 
We evaluated the deleteriousness of the remaining 447 variants that are 
present on the genes which do not have any clinical significance. Herein, 304 of the 
447 variants predicted to be deleterious. 
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Table 3.28: Homozygous missense variants present in the genomes of the twin pair 
 
Chr Position dbSNP137 Ref Alt Gene 1000G SIFT PP2 PP2 MutTaster MutTaster 
2 98164020 rs76158480 C T ANKRD36B NA . . . . . 
3 195512186 rs202060675 T C MUC4 NA . 0.234 B . . 
5 140229086 rs251354 C G PCDHA9 NA 1.000.000 0.0 B 0.000025 D 
6 31238942 rs2308590 G T HLA-C NA 0.440000 0.0 B . . 
6 31239622 rs9264668 C A HLA-C NA 1.000.000 0.032 B . . 
6 32487309 rs3200405 T C HLA-DRB5 NA 1.000.000 0.0 B 0.001085 N 
6 32489856 rs77853982 C T HLA-DRB5 NA 0.300000 0.0 B 0.008476 N 
6 32497961 rs1064587 T A HLA-DRB5 NA 0.000000 0.001 B 0.000040 N 
6 32497962 rs701884 T C HLA-DRB5 NA 0.000000 0.0 B 0.000007 N 
6 32726803 rs1049110 C T HLA-DQB2 NA 0.020000 0.666 D . . 
9 33798017 rs855581 A G PRSS3 NA 0.430000 0.0 B 0.000224 N 
10 46999604 rs3127683 A G GPRIN2 NA 0.820000 0.0 B 0.000002 N 
11 61165741 rs10897158 G C TMEM216 NA . . . . . 
12 11035274 rs28607516 G T PRH1 NA 0.260000 . . . . 
14 74041748 rs149033118 A G ACOT2 NA 0.740000 0.001 B 0.005796 N 
16 1245509 rs60593994 G C CACNA1H 0.0018 0.030000 0.998 D 0.031773 N 
17 39253835 rs72625995 C T KRTAP4-8 NA 0.790000 0.0 B 0.000709 N 
17 39421781 rs12938374 A G KRTAP9-6 NA 1.000.000 . . 0.000191 D 
19 4511730 rs62115190 T C PLIN4 NA 0.890000 0.0 B . . 
21 34166190 rs74617086 A T C21orf62 NA 1.000.000 0.0 B 0.289388 N 
X 153881773 rs17855367 T C CTAG2 NA 1.000.000 0.833 D 0.000034 N 
3 195512042 NA T C MUC4 NA . 0.004 B -0.55 N 
3 195512107 NA T A MUC4 NA . 0.204 B -0.55 N 
 
Abbreviations used in this table: Chr; chromosome, Ref; reference allele, Alt; alternative allele, PP2; Polyphen2, MutTaster; 
MutationTaster 
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Table 3.29: Heterozygous missense variants located on disease related genes and present in the genomes of the twin pair 
 
Chr Position dbSNP137 Ref Alt Gene 1000G SIFT PP2 PP2 MutTaster MutTaster OMIM Disease Inheritance 
1 22202483 rs62642528 G A HSPG2 NA 0.100000 1.0 D 0.810966 D 
 DYSSEGMENTAL DYSPLASIA, 
SILVERMAN-HANDMAKER TYPE (#224410) AR 
1 52854931 . T C ORC1 NA 0.650000 0.074 B 0.565708 D 
 MEIER-GORLIN SYNDROME 1; MGORS1 
(#224690) AR 
1 78407816 rs200071700 G C NEXN NA 0.230000 0.005 B . . 
 CARDIOMYOPATHY, DILATED, 1CC 
(#613122) - 
1 152280900 rs74129452 T G FLG NA 0.180000 0.0 B 0.000210 N  DERMATITIS, ATOPIC, 2 (#605803) - 
1 152281007 rs7512553 A G FLG NA 0.560000 0.0 B 0.000005 N  DERMATITIS, ATOPIC, 2 (#605803) - 
1 152281228 rs7546186 C G FLG NA 0.540000 0.899 P 0.000131 N  DERMATITIS, ATOPIC, 2 (#605803) - 
1 152281304 rs7512857 A C FLG NA 0.210000 0.998 D 0.000289 N  DERMATITIS, ATOPIC, 2 (#605803) - 
1 155264432 . A G PKLR NA 0.610000 0.0 B 0.000626 N 
 PYRUVATE KINASE DEFICIENCY OF RED 
CELLS (#266200) AR 
1 197024952 . G T F13B NA 1.000.000 0.003 B 0.003300 N 
 FACTOR XIII, B SUBUNIT, DEFICIENCY OF 
(#613235) AR 
1 222826363 . T G MYH6 NA 0.760000 0.996 D . .  ATRIAL SEPTAL DEFECT 3 (#614089) - 
2 1426888 . G A TPO NA 0.620000 0.394 B 0.001875 N 
 THYROID DYSHORMONOGENESIS 2A 
(#274500) AR 
2 72359508 rs201193616 G A CYP26B1 NA 0.000000 1.0 D 0.998712 D 
 RADIOHUMERAL FUSIONS WITH OTHER 
SKELETAL AND CRANIOFACIAL 
ANOMALIES (#614416) AR 
2 74593127 . G A DCTN1 NA 0.010000 1.0 D 0.999997 D  PERRY SYNDROME (#168605) (late onset) AD 
2 179429917 . C T TTN NA 0.000000 0.271 B . . 
 CARDIOMYOPATHY, DILATED, 1G 
(#604145) - 
2 220420990 rs183329050 C T OBSL1 0.0027 0.450000 1.0 D . .  THREE M SYNDROME 2 (#612921) - 
2 233404771 rs148468628 G A CHRNG 0.0009 0.010000 1.0 D 0.507618 D 
 MULTIPLE PTERYGIUM SYNDROME, 
ESCOBAR VARIANT (#265000) AR 
2 234527117 . C T UGT1A8 NA 0.090000 0.573 P . . 
 CRIGLER-NAJJAR SYNDROME, TYPE I 
(#218800) AR 
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3 184040371 rs111924994 G C EIF4G1 0.0023 0.170000 0.001 B 0.000907 N  PARKINSON DISEASE 18 (#614251) AD 
3 186389577 rs201250387 T C HRG NA 0.780000 0.0 B 0.004688 N 
 THROMBOPHILIA DUE TO HISTIDINE-
RICH GLYCOPROTEIN DEFICIENCY 
(#613116) - 
3 189612100 . C T TP63 NA . 1.0 D 0.999556 D 
ANKYLOBLEPHARON-ECTODERMAL 
DEFECTS-CLEFT LIP/PALATE (#106260) AD 
3 189838136 rs200731219 C A LEPREL1 NA . 0.999 D 0.999975 D 
 MYOPIA, HIGH, WITH CATARACT AND 
VITREORETINAL DEGENERATION 
(#614292) AR 
4 2834080 rs148761331 C T SH3BP2 0.0027 0.010000 0.998 D 0.278408 N  CHERUBISM (#118400) AD 
4 52890281 rs200761715 G A SGCB 0 0.090000 1.0 D 0.999594 D 
 MUSCULAR DYSTROPHY, LIMB-GIRDLE, 
TYPE 2E (#604286) AR 
4 89013496 rs34783571 C T ABCG2 0.0023 0.300000 0.088 B 0.095330 N  BLOOD GROUP, JUNIOR SYSTEM (#614490) - 
4 114275061 . A T ANK2 NA . 0.725 P . . 
 CARDIAC ARRHYTHMIA, ANKYRIN-B-
RELATED (#600919) AD 
4 149356870 . C A NR3C2 NA . 0.018 B 0.144584 N 
 HYPERTENSION, EARLY-ONSET,WITH 
SEVERE EXACERBATION (#605115) AD 
4 187179340 . A G KLKB1 NA 0.260000 0.0 B 0.000057 N  PREKALLIKREIN DEFICIENCY (#612423) AR 
5 10262729 . A C CCT5 NA 0.480000 0.092 B 0.999953 D 
 NEUROPATHY, HEREDITARY SENSORY, 
WITH SPASTIC PARAPLEGIA (#256840) AR 
5 13914743 rs140782270 A T DNAH5 0.0018 0.010000 0.998 D 0.964611 D 
 CILIARY DYSKINESIA, PRIMARY, 1 
(#244400) AR 
5 125930919 . A G ALDH7A1 NA 0.010000 0.072 B . . 
 EPILEPSY, PYRIDOXINE-DEPENDENT 
(#266100) AR 
6 31473513 rs2240858 C T MICB NA 0.140000 0.002 B 0.001717 N  RHEUMATOID ARTHRITIS (#180300) - 
6 64488001 rs74636274 T C EYS 0.0041 0.350000 0.087 B . .  RETINITIS PIGMENTOSA 25 (#602772) 
6 144508353 rs141499372 G A STX11 0.0009 0.070000 0.892 P 0.024250 N 
 HEMOPHAGOCYTIC 
LYMPHOHISTIOCYTOSIS, FAMILIAL, 4 
(#603552) AR 
6 152668337 . G T SYNE1 NA 0.810000 0.988 D 0.986771 D 
 EMERY-DREIFUSS MUSCULAR 
DYSTROPHY 4 (#612998),  AD 
7 87031444 . C A ABCB4 NA 0.000000 0.991 D 0.999984 D 
 CHOLESTASIS, INTRAHEPATIC, OF 
PREGNANCY 3 (#614972) AD, AR 
7 107418636 . C T SLC26A3 NA 0.020000 1.0 D 0.569841 D 
 DIARRHEA 1, SECRETORY CHLORIDE, 
CONGENITAL (#214700) AR 
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7 153750131 . G A DPP6 NA 0.480000 0.997 D . . 
 VENTRICULAR FIBRILLATION, 
PAROXYSMAL FAMILIAL, 2 (#612956) - 
8 1844586 rs201912073 A G ARHGEF10 0.0005 0.250000 0.004 B 0.547177 D 
 SLOWED NERVE CONDUCTION VELOCITY 
(#608236) AD 
8 96064423 rs61743028 G A NDUFAF6 0.0041 0.360000 0.01 B 0.999087 D 
 MITOCHONDRIAL COMPLEX I 
DEFICIENCY (#252010) AR 
8 141321405 rs148453804 C T TRAPPC9 NA 0.480000 0.003 B 0.000311 N 
 MENTAL RETARDATION, AUTOSOMAL 
RECESSIVE 13 (#613192) AR 
8 144995699 . G A PLEC NA 0.520000 0.669 P 0.993196 D 
 EPIDERMOLYSIS BULLOSA SIMPLEX 
WITH MUSCULAR DYSTROPHY (#226670) AR 
9 406999 rs34390308 C T DOCK8 0.0014 0.230000 1.0 D 0.999437 D 
 HYPER-IgE RECURRENT INFECTION 
SYNDROME (#243700) AR 
9 13136783 rs200891478 T C MPDZ NA 0.110000 1.0 D 0.883966 D 
 HYDROCEPHALUS, NONSYNDROMIC, 
AUTOSOMAL RECESSIVE 2 (#615219) AR 
9 35079502 rs35984312 G A FANCG 0.0014 0.030000 0.119 B 0.003211 N 
 FANCONI ANEMIA, COMPLEMENTATION 
GROUP G; FANCG (#614082) - 
9 77411729 rs143164660 C G TRPM6 0.0041 0.000000 1.0 D 0.981199 D 
 HYPOMAGNESEMIA 1, INTESTINAL 
(#602014) AR 
9 79897155 rs148656796 A G VPS13A 0.0032 0.310000 0.964 D 0.940622 D  CHOREOACANTHOCYTOSIS (#200150) AR 
9 111640962 . T C IKBKAP NA 0.000000 1.0 D 0.999581 D 
 NEUROPATHY, HEREDITARY SENSORY 
AND AUTONOMIC, TYPE III (#223900) AR 
9 130634139 . G A AK1 NA 0.000000 1.0 D 0.999998 D 
 ADENYLATE KINASE DEFICIENCY 
(#612631) AR 
9 135786013 rs118203504 G A TSC1 NA 0.370000 0.976 D . . 
 FOCAL CORTICAL DYSPLASIA OF 
TAYLOR (#607341) Isolated cases 
10 31810670 rs148358382 G A ZEB1 NA 0.110000 1.0 D 0.836949 D 
 CORNEAL DYSTROPHY, FUCHS 
ENDOTHELIAL, 6 (#613270) - 
10 43600559 rs139790943 T C RET NA 0.000000 0.917 P 0.346327 N 
 CENTRAL HYPOVENTILATION 
SYNDROME (#209880) AD 
10 55700727 . G A PCDH15 NA 0.020000 0.998 D 0.999997 D 
 DEAFNESS, AUTOSOMAL RECESSIVE 23 
(#609533),  USHER SYNDROME (#601067) AR 
10 73453990 rs181255269 C T CDH23 0.0009 0.410000 0.981 D 0.824721 D 
 DEAFNESS, AUTOSOMAL RECESSIVE 12 
(#601386) AR 
11 1253980 rs202127660 A G MUC5B NA 0.000000 0.0 B . . 
 PULMONARY FIBROSIS, IDIOPATHIC 
(#178500) AD 
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11 18305355 rs61755718 C T HPS5 0.0037 0.110000 0.002 B 0.006767 N 
 HERMANSKY-PUDLAK SYNDROME 5 
(#614074) - 
11 57367469 . G A SERPING1 NA 0.010000 0.002 B 0.005601 N 
 ANGIOEDEMA, HEREDITARY, TYPE I 
(#106100) AD 
11 117252491 rs59763167 C G CEP164 NA 0.040000 0.95 P 0.013561 N  NEPHRONOPHTHISIS 15 (#614845) AR 
11 119213319 rs145881139 C A MFRP 0.0041 . 0.744 P . .  MICROPHTHALMIA, ISOLATED 5 (#611040) AR 
12 33031395 rs150821281 G A PKP2 0.0014 0.040000 0.007 B 0.070427 N 
 ARRHYTHMOGENIC RIGHT 
VENTRICULAR DYSPLASIA (#609040) AD 
12 49444965 . G A KMT2D NA 0.000000 0.0 B . .  KABUKI SYNDROME 1; KABUK1 (#147920) AD 
12 110784210 rs140234740 A G ATP2A2 NA . 0.001 B . . 
 ACROKERATOSIS VERRUCIFORMIS 
(#101900) AD 
12 122277716 . A G HPD NA 0.000000 1.0 D 1.000.000 D  HAWKINSINURIA (#140350) AD 
13 20716248 . C G GJA3 NA 0.540000 0.022 B 0.120999 N  CATARACT 14, MULTIPLE TYPES (#601885) AD 
13 23909676 rs111540787 A C SACS 0.0009 0.050000 0.999 D 0.995938 D 
 SPASTIC ATAXIA, CHARLEVOIX-
SAGUENAY TYPE (#270550) AR 
14 20943258 . G A PNP NA 0.340000 0.77 P 0.978143 D 
 PURINE NUCLEOSIDE PHOSPHORYLASE 
DEFICIENCY (#613179) AR 
14 23855315 . G A MYH6 NA 0.050000 0.003 B 0.384519 N  CARDIOMYOPATHY, DILATED (#613252) - 
14 54417527 . G C BMP4 NA 0.170000 0.75 P 0.948209 D 
 MICROPHTHALMIA, SYNDROMIC 6 
(#607932) AD 
15 34634289 . T A NOP10 NA 0.050000 0.928 P 0.981674 D 
 DYSKERATOSIS CONGENITA, 
AUTOSOMAL RECESSIVE, 1 (#224230) AR 
16 1263845 . A C CACNA1H NA 0.000000 1.0 D 0.331794 N 
 EPILEPSY, CHILDHOOD ABSENCE, 
SUSCEPTIBILITY TO, 6 (#611942) - 
16 2140294 rs148478410 C T PKD1 0.0041 0.170000 0.987 D 0.004136 N  POLYCYSTIC KIDNEY DISEASE 1 (#173900) AD 
16 3293403 rs104895094 T C MEFV 0.0032 0.150000 0.939 P 0.001830 N 
 FAMILIAL MEDITERRANEAN FEVER 
(#134610) AD 
16 74773946 rs147632811 C T FA2H 0.0005 0.670000 0.041 B 0.000283 N  SPASTIC PARAPLEGIA 35 (#602319) AR 
17 6913317 . C T ALOX12 NA 0.010000 0.998 D 0.827348 D  COLORECTAL CANCER (#114500) AD 
17 40947281 . C A WNK4 NA 0.450000 0.617 P 0.000970 N 
 PSEUDOHYPOALDOSTERONISM, TYPE IIB 
(#614491) AD 
17 59560453 rs140662248 C G TBX4 0 . 0.983 D 0.012565 N  SMALL PATELLA SYNDROME (#147891) AD 
17 73513281 rs148146916 C G TSEN54 0.0009 0.250000 0.753 P 0.046230 N 
 PONTOCEREBELLAR HYPOPLASIA, TYPE 
2A (#277470) AR 
18 21519197 . A C LAMA3 NA 0.510000 1.0 D 0.949775 D  EPIDERMOLYSIS BULLOSA, JUNCTIONAL, AR 
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HERLITZ TYPE (#226700) 
19 856130 rs17216663 C T ELANE 0.0046 0.160000 0.01 B 0.005241 N  CYCLIC NEUTROPENIA (#162800) AD 
19 11556233 rs200168017 G A PRKCSH 0.0009 0.850000 0.839 P 0.804291 D  POLYCYSTIC LIVER DISEASE (#174050) AD 
19 13988258 . A C CDHR1 NA 0.520000 0.002 B 0.115886 N  CONE-ROD DYSTROPHY 15 (#613660) AR 
19 17322578 rs199695802 C T MYO9B 0.0009 0.130000 0.271 B 0.005599 N 
 CELIAC DISEASE, SUSCEPTIBILITY TO, 4 
(#609753) - 
19 30193732 rs146492790 C T C19orf12 0.0005 0.080000 0.994 D 0.196292 N 
 NEURODEGENERATION WITH BRAIN 
IRON ACCUMULATION 4 (#614298) AR 
19 38968441 . G A RYR1 NA 0.640000 0.01 B 0.010457 N 
 MINICORE MYOPATHY WITH EXTERNAL 
OPHTHALMOPLEGIA (#255320) AR 
19 50332235 rs200785685 C T MED25 NA 0.060000 1.0 D 0.998578 D 
 CHARCOT-MARIE-TOOTH DISEASE, 
AXONAL, TYPE 2B2 (#605589) AR 
20 32881908 rs11552695 T C AHCY 0.0027 0.070000 0.0 B 0.999552 D 
 HYPERMETHIONINEMIA WITH S-
ADENOSYLHOMOCYSTEINE HYDROLASE 
DEFICIENCY AR 
22 18567938 rs149153003 C T PEX26 0.0005 0.780000 0.037 B 0.033637 N 
 PEROXISOME BIOGENESIS DISORDER 7A 
(ZELLWEGER) (#614872) - 
22 19165823 . C G SLC25A1 NA NA NA NA NA NA 
 COMBINED D-2- AND L-2-
HYDROXYGLUTARIC ACIDURIA (#615182) AR 
22 26860200 rs147435410 G A HPS4 0.0009 . 0.002 B 0.032402 N 
 HERMANSKY-PUDLAK SYNDROME 4 
(#614073) - 
X 153006093 rs201878013 A G ABCD1 NA 1.000.000 0.0 B 0.000145 N  ADRENOLEUKODYSTROPHY (#300100) XR 
 
Abbreviations used in this table: Chr; chromosome, Ref; reference allele, Alt; alternative allele, PP2; Polyphen2, MutTaster; Mutationtaster, AR; autosomal recessive, AD; autosomal dominant, XR; X 
linked recessive 
 
 
 
 
 97 
 
3.9.3 Analysis of the homozygous stretches  
We analyzed the homozygous stretches segregated within the family using 
HomozygosityMapper (http://www.homozygositymapper.org/). To identify the 
homozygous stretches, we introduced the twin pair as affected and the parents as 
healthy to the program. Herein, we identified 4 homozygous regions present in the 
genomes of the twin pair (Figure 3.8 and Table 3.30).  
 
 
 
 
 
 
 
Figure 3.8: Homozygousity mapping analysis in the twin pair. Y axis is the genome 
wide homozygosity scores. Red lines indicates the common homozygous intervals. 
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Table 3.30: Homozygous intervals in the twin pair 
 
Chr from (bp) to (bp) length (bp) from SNP to SNP 
2 186374432 187390507 1016075(1Mb) rs186374432 rs187390507 
6 30955182 31171257 216075 (0.2 Mb) rs30955182 rs31171257 
10 70199633 70786474 586841 (0.5 Mb) rs70199633 rs70786474 
11 42856020 43598428 742408 (0.7 Mb) rs42856020 rs43598428 
 
Abbreviations used in this table: Chr; chromosome, bp; base pair, SNP; single nucleotide polymorphism 
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We examined the homozygous stretches to assess the genes that are 
intersecting these regions. On the 1 Mb homozygous block located on chromosome 
2, we identified 8 genes (ELF2P4,  FSIP2, LOC100420895, RPL21P32, 
RRPL23AP35, MED28P3, ZC3H15, DPRXP1). Of these 6 were discovered to be 
pseudogenes. We analyzed the remaining 2 protein coding genes (FSIP2 and 
ZC3H15) and observed that they did not have any clinical significance (Table 3.31). 
 
We identified a total of 12 genes (MUC21, MUC22, HCG22, C6orf15, 
PSORS1C1, CDSN, PSORS1C2, CCHCR1, TCF19, POU5F1, PSORS1C3, HCG27) 
within the homozygous block located on chromosome 6, spanninc 0.2 Mb. Of these, 
9 were protein coding and 3 were non-coding RNA genes. None of these genes had a 
clinical significance. 
 
A total of 16 genes discovered to be located on the homozygous block on the 
chromosome 10, spanning 0.5 Mb. 2 of the 16 genes had clinical importance. One of 
them is STOX1gene. Heterozygous mutations of the STOX1 gene reported to be 
causal for Preeclampsia 4 (#609404). Other gene, KIAA1279, reported to be 
involved in Goldberg-Shprintzen syndrome (#609460) which is inherited in 
autosomal recessive fashion. 
 
We discovered 7 genes (LOC100533710, HNRNPKP3, API5, TTC17, 
CTBP2P6, MIR670, MIR670HG) located on the 0.7 Mb homozygous stretch on 
chromosome 11. None of these genes involved in disease pathogenesis. 
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Chapter 4 
Discussion 
Characterizing the new mutations regarding their origins and rates has great 
importance in terms of providing insights into the disease pathogenesis as well as the 
evolutionary processes. Studies concerned with the de novo mutation rate estimation 
have largely focused on the SNVs. This is due to the limitations of current 
technologies in the investigation of the other types of genetic variation.[3, 25]  
 
Direct estimation of the de novo SNV rate in healthy individuals which is 
based on the whole genome sequencing of parent-offspring trios yielded rates 
ranging between 0.82 – 1.70 x 10-8 per base per generation.[12, 13, 55, 56] These 
studies that provided the direct de novo SNV mutation rates were restricted with the 
scope of the trio sequencing. At this point, the early post-zygotic de novo SNVs 
could not been distinguished from those which have a pre-zygotic origin. Therefore, 
the rate of the early post-zygotic de novo SNVs within the overall de novo SNV 
burden remained unknown.[3] 
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At this point, to elucidate the origins of de novo SNVs and to estimate the de 
novo SNV rate in healthy individuals regarding the developmental timing of 
mutagenesis, we performed deep whole genome sequencing of a healthy 
monozygotic twin pair together with their parents. We anticipated that de novo SNVs 
which are present in the genomes of both twins would have meiotic origin, occur 
during the gametogenesis pre-zygotically yet those that are specific to one of the 
twins could have mitotic origin, occur early during development possibly in the post-
twinning embryo.[6, 65, 69, 106] On the basis of this hypothesis, we characterized 
twenty three de novo SNVs that have a pre-zygotic origin; eight early post-zygotic de 
novo SNVs in twin I, and one early post-zygotic de novo SNV in the genome of the 
twin II. 
 
We report an overall de novo SNV rate of 1.01 x 10
-8
 and 1.31 x 10
-8
 for each 
of the twins. This estimate is consistent with the previous direct de novo SNV rate 
estimations.[12, 13, 55, 56] Furthermore, we estimated the rate of the early post-
zygotic de novo SNVs within the overall de novo SNV rate as 0.34 x 10
-8 
and 0.04 x 
10
-8
 for twin I and twin II, respectively. Our findings indicate that the direct 
measurement of the early post-zygotic vs. pre-zygotic de novo SNV rate could be 
possible through whole genome sequencing of the monozygotic twins together with a 
progressive filtering and validation approach. 
 
We selected a total of 120 high-confidence putative de novo SNVs for Sanger 
sequencing-based validation. We could not test 37 (24 shared, 10 twin I-specific and 
3 twin II-specific) of the 120 selected putative de novo SNVs due to unavailability of 
the appropriate primer pairs or PCR products of good quality. Herein, to evaluate the 
degree of mutation rate underestimation due to these technical limitations, we 
considered the proportion of the validated variants (50%) among those that could be 
tested successfully. Herein, re-calculation resulted with an overall mutation rate of 
2.02 x 10
-8
 for twin I and 1.51 x 10
-8
 for twin II. Moreover, rate of the early post-
zygotic de novo SNVs increased to 0.55 x 10
-8
 for twin I.  
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The most previous studies concerned with the estimation of the somatic 
mutation rate has been restricted with the cancer studies as well as the in vitro cell 
models.[62, 63, 64] In healthy individuals, the average somatic mutation rate was 
reported to be 7.7 x 10
-10
 per base per cell division.[59] In 2011, Conrad and his 
colleagues discriminated the germline mutations and non-germline mutations and 
they estimated the non-germline de novo SNV rate as 2.52 x 10
-7
.[56] Still, this rate 
might be an overestimation due to the probability of the interference of the rate with 
the cell-line derived mutations. In a very recent study, somatic de novo mutation rate 
was reported for the common single nucleotide polymorphisms (SNPs) present in the 
human genome through surveying the whole genomes of the monozygotic twins. 
However, this estimate (1.2 x 10
-7
 per nucleotide) might not reflect the true somatic 
mutation rate because the rare and private variations were neglected through focusing 
on only the reported variation.[65] In our study, rate of the early post-zygotic de 
novo SNVs is between the upper and lower boundaries of the previous somatic 
mutation rate estimations. 
 
We observed that early post-zygotic de novo SNV rate varied between two 
monozygotic twins considerably. This is due to the characterization of 8 early post-
zygotic de novo SNVs in one of the twins, while the number was 1 for another twin. 
At this point, the difference between post-zygotic mutation rates might be explained 
by stochastic events that affect the twin pair during the intra-uterine 
development.[107] Furthermore, in a paper by Steven Frank from UC Irvine, it is 
explained neatly that mutations that arise during the early development may follow 
the so called Luria-Delbruck distribution and the degree of mosaicism may vary 
between individuals.[72] We, still, point out that a larger sample size is required to 
make a firmer conclusion about the post-zygotic mutation rate. 
 
It has been reported that the de novo mutations that are present in the genome 
of only one of the monozygotic twins might be cell line derived.[108]Since we 
sequenced the whole blood derived DNA samples, we excluded the possibility of 
overestimation of the de novo SNV rate due to cell line derived mutations. To note 
that, although our estimate is not interfered with the cell line derived mutations, it 
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might reflect an underestimation. The reason is the probability of observing the very 
low-frequency mosaic SNVs that occurred in later stages of the embryo development 
as mapping and variants calling errors.[109] 
 
In our study, classification of the putative de novo SNVs regarding genomic 
context revealed a biased distribution towards non-coding regions of the genome. 
This is expected because (a) non-coding regions constitute the great proportion of the 
human genome and (b) the evolutionary pressure acting on de novo mutations is less 
stringent. We did not observe clustering of the de novo mutations at any region of the 
genome selectively. In previous studies, hotspots for de novo mutations in 
individuals affected with ASD have been documented.[44] In the context of our 
study, identification of the hotspots for the early post-zygotic and pre-zygotic de 
novo mutations in the genomes of the healthy individuals could be the subject of the 
further studies.  
 
Previous publications on de novo rate in humans did not evaluate the 
possibility of mosaicism in parents which could be interpreted as de novo in the 
offspring.[3, 13] Although it is highly unlikely that the de novo mutations presented 
in our study have occurred in the soma of the parents, we still evaluated the 
possibility of mosaicism in the parents. To resolve this issue, we examined the buccal 
smear (ectoderm) and urine samples (endoderm) of the parents. Consequently, we 
observed that the parental mosaicism did not contribute to the de novo SNVs in the 
twin pair. 
 
We observed that the early post-zygotic de novo SNVs was present in a 
mosaic state in the genomes of the twins according to the Sanger sequencing 
chromatograms. Moreover, capillary sequencing chromatograms showed the 
different levels of mosaicism for each of the post-zygotic de novo SNVs which might 
be the consequence of the timing of the mutagenesis. In our view, this finding could 
be critically important for the research in the field of medical genetics which is 
concerned with the delineation of the molecular basis of the complex diseases in 
human.  
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Contribution of the genetic heterogeneity to disease pathogenesis has been 
well-documented. Thus, assessment of the phenotypic, locus and allelic 
heterogeneity have been important for the studies concerned with the disease gene 
discovery.[110] Despite the success of the next generation sequencing technologies 
in the identification of de novo mutations that are causal for common 
neurodevelopmental diseases, there is still numerous complex phenotypes that 
remained unresolved.[42, 111] At this point, timing of de novo mutations and thus 
resulting somatic mosaicism might be an added level of complexity. This motion 
might also be supported by the involvement of the somatic mosaicism in different 
single gene disorders since the complex phenotypes have been anticipated to result 
from mutations which represent a single event of large effect.[112,113, 114] 
 
Our findings are important in terms of being the first direct estimation of the 
early post-zygotic de novo SNV rate within the overall de novo SNV burden. 
Moreover, these results reiterate the importance of timing of mutagenesis and 
somatic mosaicism present in the human genome. Further work will be required to 
expand the scope of these studies through single cell sequencing and increasing the 
sample size for better understanding of the patterns and rates of early post-zygotic 
mutations. 
 
Examination and documentation of the incidental findings derived from the 
whole genome sequencing data have an important clinical significance. [80,81] As a 
second part of our study, we evaluated the incidental findings present in the whole 
genome sequencing data of the four individuals (the twin pair and their parents). We 
intended to document the LoF mutations and potentially damaging missense 
mutations of the healthy individuals.  
 
It has been reported that human genome contains approximately 100 LoF 
variants.[97] Here we identified a total of 75 LoF mutations present in the genomes 
of the twin pair, 48 LoF mutations in mother and 57 LoF mutations in father. 9 of the 
LoF mutations were located on genes that are implicated in the pathogenesis of 8 
different diseases. Moreover, we identified damaging missense mutations occurred 
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on disease genes as well as pathogenic variants on the genes that do not have any 
clinical significance. Despite the possibility of reduction in power in our analysis due 
to the small sample size, examination of the genotypes of a quad family led us to 
reduce the false positive rate.  
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Appendix A 
Primer List 
 
 
Table A.1: Primer pairs for validation of the group I and group II de novo SNVs 
 
Type Chr Pos Ref Alt Forward Reverse Product Size(bp) 
Group I 1 1334722 A C ACTCCCCTTCGGCTTCTTC CGCTAGGGACAGACATGCTT 249 
Group I 1 165599592 G C GATGAGGGATGTCCAGAGGA CACTCCCGAAGTGAATGGAT 487 
Group I 1 165599593 T G GATGAGGGATGTCCAGAGGA CACTCCCGAAGTGAATGGAT 487 
Group I 1 245093862 G A AGGATATGCTTGGCCTCCTT AGGAGTGAAGGTGCGTCTGT 386 
Group I 2 3720268 T C N/A N/A 
 Group I 2 7991048 A C AGGGGCTTCTGCTTAGTTCC CACTGCCTCGCAGTCTCA 209 
Group I 2 30755585 G A TACCTGGCCCATCAGAAAAG TTTCCCATGATCCTTGCTTC 489 
Group I 2 72375921 G A CCGAGCTGGGCTATTGTATC TCGCTTTGGACTCAAATTCA 203 
Group I 2 72375922 G A CCGAGCTGGGCTATTGTATC TCGCTTTGGACTCAAATTCA 203 
121 
 
Group I 2 114789320 A T GGGCATCTGGAAAGATGTGT TTTCTTCCTCCCTCCCACTT 285 
Group I 2 136342189 G A ACCTGACCTCGGTAGCATGT CCAAGCTTTGGAAATTGTTAGG 371 
Group I 2 197151126 T A TGCATTACCATGAAATGTTGAA CATAGAAGGCAGATGGCAAA 275 
Group I 2 197151129 A T TGCATTACCATGAAATGTTGAA CATAGAAGGCAGATGGCAAA 275 
Group I 3 3168559 T C GCGAGAAGGGCGTAATTAAA GACGTCACCAACGCACAT 229 
Group I 3 11943503 C G ATTCCTACGGGCACTTCACA GCTCGGCTGCATATTAGCTC 656 
Group I 3 50652860 A C GATTCTCAGGTTGGGCTCAG GGCTCCAGACAATAGCCTCA 497 
Group I 3 197614409 C G CCTGACCTGAAGCAGAGC TGGGAAACTGCTGACAGAAA 595 
Group I 4 701615 C T GACCCTGGAGCAGTCTTGTG CATGTCATGAGCCCTTCTCA 789 
Group I 4 1089608 T C N/A N/A 
 Group I 4 71768172 A G GATTCAAGACGAGCGCTACC GGCCTGGCTACTCACAACA 240 
Group I 4 145566227 C T TTGCAGGGATCCAGTAAACC CAGGTGGACGGAGAGAGAAG 332 
Group I 5 11043438 T G AGGAATTGGGCCTCTTTTGT GCGCAAATACAACTACCAAAGTT 359 
Group I 5 172006234 G A GGAACTTCATGCCTTTGCTC AGCAAGAAAGGGCTGACTGA 195 
Group I 6 29101417 C T TGCCCATTTGCCTAAGAGTC TGGGAAGTGGACAACAGTAGTTT 497 
Group I 6 104212493 C A AGGTTGCAGTGAGCCAAGAT GCAGTATACCAAGGGATGTGG 248 
Group I 6 162458275 T C GCCCTTTGCAACTCTACTCC ATGAGCACATTTGGTGATGC 182 
Group I 6 169662202 G A ATCCGGCAAGTATCCCCAGA TGCGTCAGAAACAGCAAATC 254 
Group I 7 459309 A G N/A N/A 
 Group I 7 9485054 T G GAAGGAGGGACATTATCAACCA AAGAAGCACAGGAGTCATGGA 534 
Group I 7 70309917 A G TCAACTGGAATGCTATTAGTCG GTCTGGCACAACCAGACAAA 484 
Group I 7 141955453 A G GGCAGGTTGGCTAATTTCAC TGCTTTGGCCTTTAATCCAG 550 
Group I 7 157192929 T C GAGCTGCAGTAACGGGAAAG CGTACAAGTGCGTACACGAAG 155 
Group I 7 158252534 G A ATCCACAGTCTCCAGGATGG GTGCAGGACAGAGCAGATGA 963 
Group I 8 119959498 G A TATTGGTCAGGTGGGTAGGG TTGCTAGGGTGTTGGATCGT 186 
Group I 9 32917739 C T CTCCCTGCACAAGACCAGAC CATCATGAGAAGGTGCCAGA 587 
Group I 9 140206420 C T CTGCCTGATACCCTGAGACC CAGGTAGCTGGGAGCCTTC 421 
Group I 10 7400806 C T CTGTATGGCCATGGAAGG TCAGGGCATACCTCCATTCT 383 
Group I 10 48410093 A G N/A N/A 
 Group I 10 102527333 C T TTCCCGAGACAGGACAATTC TGTGCTGTTGCTGGAAAGTC 270 
Group I 10 115563965 T C CTCCAAGTTTGCACATCACG CACCCTGGAATGTTTGCTCT 506 
Group I 10 128805987 G A GTGATGTTAGCAAGCCTGGA TTTCCCGCAAACAATTAAGC 269 
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Group I 10 132099886 T G N/A N/A 
 Group I 10 133937827 C T CGGCCACATCACCTACATC GTGGGACAGGTGACTGCAT 185 
Group I 10 134392000 G A AGGTGAAGGTGAGCAAGACC CACATACTCTCCTCCCCTGAA 242 
Group I 11 1415375 A C N/A N/A 
 Group I 11 134534416 T A CACATGAAGGTCACCCACAC CCCTTTCAAACCACCACTGT 413 
Group I 12 3527384 T C CAGCACCTGCTGTTCTGAAA AACCAAGATTGGCACTGTCC 300 
Group I 13 97503636 T C ATTCGGGTTCTTTCCCTCCT CTGATGGGTGTGATCCCTCT 409 
Group I 13 114510560 T C CCCACGGAGGTGTAAGATGT ATGGGGATGAAGTGGATCTG 664 
Group I 14 32048285 T A CGGGCAGCTTGTTGTAATTC CCAGCACAAATTTGAGAGCA 355 
Group I 15 48937494 C T GGCGAGCTCTCTGGGTTTAT GCTCCGCGTCAGATGTTC 165 
Group I 15 57953050 A T CTGCCTTCAGGGAAGCTATG GCAGCAGACATGATTCTGGA 448 
Group I 15 80788986 G T CATTCATTGCCTGTCACCAG AGGGTGCCTCGCATACATAC 419 
Group I 16 59139115 A G TCTCCCATAACATTGCCTCA CACAGTTTCATGGGAAACAGAA 496 
Group I 16 87715100 C T ATTACCCATCGCAGGAGTCA GGGGACACCTTCTGGAACTA 678 
Group I 16 88497459 G A GGCGAGAAGAGGAAGGAAGT GACTCTTCGGCAGTTTCAGG 350 
Group I 17 79276311 C T GCTTACTGGGCAGTCCTACG AGGGAGATGGGAACCAGAGT 229 
Group I 17 80942321 C T GAGCACACAGGAGGCCATA ACGACCCTGTAGCCTCTCC 354 
Group I 18 3412160 G A GGAAGGGTTCAGGAAACACA CTGGGTTTCTCGATGAGGAG 304 
Group I 18 32459844 T C GTTCCCTCACCAACCTCTGA CAAGGCAGGCTCTTGATAGG 350 
Group I 19 523438 C T TACGCCAGAGCATTTCAGTG CAGGATTTAAGCCCACCTCA 925 
Group I 19 14732346 G A TGGCACTTTTACTCTTGTTGAGA CAGTTAGGTAGCTTTAGGGCAAT 596 
Group I 19 49842785 A C TCGGCCCTAAATCCCTAGAT ACTTCCAGTGTCAGGCTGGT 487 
Group I 19 53659085 C T CAGGGATGAATTCCCTTGAA CTGGGACTACAGGCATGAGC 476 
Group I 20 14840274 T C ATCATGATTGCTGGTGTGGA GCAAACCACAGACCATAGCA 489 
Group I 20 50012140 C G TGTGACAAAGGCAAGTGCTC CCTTTCCAGTTGCAGGCTTA 214 
Group I 20 50690005 T A N/A N/A 
 Group I 20 62836674 T C AGATTCCTGGGCGGTAGATT CCCTCCAGCTTCCTCTTCTT 472 
Group I 20 62866083 T G N/A N/A 
 Group I 21 23811291 C T GCGGCTGTTGGTTAACAGAT AAATTTCAGGGCCTTGTCCT 428 
Group I 21 44743604 A C AGCAGGTCAGCAGTGGAACT CTGTGGCAAAGTGAATGTGG 436 
Group I 22 19167292 G A TTGTCGGCTAAAGCTGGTCT GTTGTCACCACCCACCCTAC 206 
Group I X 2836434 G A CCTGGTGCCATTTTCCTAAA AAGGGTTCTGACATGGATGC 228 
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Group II-Twin I 1 245499265 A G ACGCGGAGAAGGAGGAGT TGCAGAGTGGAACAGCAATC 388 
Group II-Twin I 2 61728351 A T GGATGCAATTTGAGCCTTGA TCCTTTGATTTCCTCGTCCTT 490 
Group II-Twin I 3 1493383 C T TCCATCCCTTTCTCTTCTCAA GGAGAAGGCAAACTAGAAGTGTC 202 
Group II-Twin I 3 51441939 A C CGTAGCTGCCACTCAAGACA AAGTCCACAAAGCGGAGCTA 344 
Group II-Twin I 3 72959480 G A CCAAGAGAAACCATGGAGGA AGTTGCAGATGGGGAAACTG 484 
Group II-Twin I 4 651520 G A AGATCCAGCTCATCCTGGTG GTCCCTGCCACAGATCCAT 775 
Group II-Twin I 4 6564000 G A CAGCAGGGAGGTAGGAAACA AGTCCTCTTTGGCATGTGCT 261 
Group II-Twin I 6 41586146 G A GAGCAGGGTGGACTGACTTC CGATTCACTGGTGCTTGAGA 489 
Group II-Twin I 6 134981681 T G CTGGCGAATTCAGTGTTCTG TTAGGGATAGAAGCAAGGAACA 464 
Group II-Twin I 7 29606885 G A TGGAAAGCAAATCACAGTGC GTTCCAGTCCAGGTGTTGCT 377 
Group II-Twin I 7 155510228 T G TCGTTGTCAATTCCACCTGA GGGCTGAACTGTTTGCAACT 427 
Group II-Twin I 7 157981209 G C CGGAAGGGATGTCCTAGTGC CGGAGTGCTCTGGAAGCAG 693 
Group II-Twin I 8 66686049 G A TTCCACATCACTGGATCAGG GGCTGTGGGTAAGGAAATCA 499 
Group II-Twin I 8 118838053 A G CCACCATATGCCACCTCACT ATGCCAGGGTCAGGTTGTTA 529 
Group II-Twin I 10 45869059 C A AACCTTCTCCACACCCTTCC GAGCACAGAGGCTCCTTCAG 229 
Group II-Twin I 12 653012 T C N/A N/A 
 Group II-Twin I 12 9557500 T C ACAGCCAGCAACTCTTCTGC CCTGCGTTGGGTGTCTTA 443 
Group II-Twin I 12 95569608 G A AACCAGGGTGGCTACATCAG TTGACACCTTGATGTCTTCCAT 498 
Group II-Twin I 12 131691875 G A ACCTGGAAGCTGTTGTCGAG CATACCCAATGATGCCTGTG 250 
Group II-Twin I 12 133352895 G C GTGGACCAGGTGGCTTTG GGGTACCTGTGTGAGGCTCT 387 
Group II-Twin I 16 50424085 G A CCAAATCCCTGCACTGAACT TAGTAATGCCCTGGCAGCTT 431 
Group II-Twin I 18 34970824 C T TGATGGTGAGAGCACCTGTC CCCTCTGCTCCATTCCATTA 398 
Group II-Twin I 18 50453718 G T GCATTACTTGCATGAGGTCAAA TGCACTGCCTGTAGTGGAAA 772 
Group II-Twin I 20 53271335 C T TTTCAACGTCGCTGCAATAG AGGACAGAAAGCAGCCTCAC 348 
Group II-Twin I X 2833489 C G N/A N/A 
 Group II-Twin I X 7544103 T C N/A N/A 
 Group II-Twin I X 144597121 C A N/A N/A 
 Group II-Twin I X 148731301 C A ACCTTGGCCACATACTCCAG AGACCCAGCAGACCTGAAGA 582 
Group II-Twin I Y 8094333 C A N/A N/A 
 Group II-Twin II 1 211950090 G A TCAAGAATGAGGGCTGCTTT AGTGGGTGCCCAAAGTGTAG 287 
Group II-Twin II 1 228146563 C A ACTGGGTTGGTAGCCCTTCT CACTCCCTGGAATCGTGTTT 544 
Group II-Twin II 2 70925457 G T GGCTGATGTTGGGAGGTCTA TGAGCCCTCCTGTTCTCTTC 242 
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Group II-Twin II 2 241992247 C T CACGGATTTCTTCTGCCACT GTTGCCGTGATACGTTTCCT 587 
Group II-Twin II 6 133966995 G T CCCATGCTGTTTGAAGTTGA CACATGGCCACATGTCTTCT 241 
Group II-Twin II 7 158204835 C T N/A N/A 
 Group II-Twin II 9 14347587 G A GCTCAGGGCAAGCTAACAGT TTACACTCCGCACAGTCACC 187 
Group II-Twin II 11 1474891 G T GTCTCTTCATCGGGCAGAAC CTCTAGCACAGCCCGAGACT 512 
Group II-Twin II 12 132353193 A C GAGAAGGGCAAAGGGAAGTG AGGGACCTGGGATGTGGT 223 
Group II-Twin II 16 62015587 C T CACAGAGTCAGTTTCCCTGGAT ATTCTCCATGCTCCCACATC 245 
Group II-Twin II 21 36322701 A G CAGAATCACGGCTGAACTGA AAGGCATTTCCTTGTTAAGAGC 475 
Group II-Twin II 21 47479749 C T N/A N/A 
 Group II-Twin II X 7320881 C G TGGCCATAGCATTTAATCCA GATGCCCGGAAAATTGTTAG 248 
Group II-Twin II X 71177022 T C ACCAAATCAGGCCACAGAAC GAGGCAAAGTGCCAGGTAGA 213 
Group II-Twin II X 71177023 A T ACCAAATCAGGCCACAGAAC GAGGCAAAGTGCCAGGTAGA 213 
Group II-Twin II X 104517151 A G TTCACCTGGCAAATCATTCA AAAGTCTCCAACCAGGGACTC 164 
Group II-Twin II X 128927246 C G AAGAGGCCCAAGCCTAAGAC TTTGATCCAAAGGAGGTTGG 568 
Group II-Twin II X 134054618 A T GACATGTTGCATTGCCAGTC ACAGGGCAGTTTCTCTGTGG 389 
 
Abbreviations used in this table: chr, chromosome; pos, position; ref, reference allele; alt, alternative allele; bp, base pair 
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Appendix B 
Visual Examination of the BAM Files 
 
 
Figure B.1: IGV screenshots for the total of 290 high-confidence putative de novo SNVs. The figure (in the format of pdf file) is 
available in our website http://donut.cs.bilkent.edu.tr/twinstudy/ . The index table which shows the number of pages on the pdf file that 
corresponds to each of the examined variants is provided as Table B.1. 
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Table B.1: Index table for the Figure B.1 
 
         
Twin I (n) Twin II (n) Mother (n) Father (n) 
Group Page Chr Pos Ref Alt Gene IGV prediction Sanger Ref Alt Ref Alt Ref Alt Ref Alt 
Group I-Shared 1 1 1334722 A C MRPL20 de novo N/A PCR product 5 4 3 3 6 0 8 0 
Group I-Shared 2 1 38066423 G A 
 
low quality 
 
41 21 32 13 22 6 33 9 
Group I-Shared 3 1 47691626 G C TAL1 low quality 
 
5 4 4 1 10 0 4 1 
Group I-Shared 4 1 54706147 G A C1orf191 low quality 
 
12 8 4 1 11 1 8 0 
Group I-Shared 5 1 165599592 G C 
 
de novo de novo 21 19 7 13 22 0 20 0 
Group I-Shared 6 1 165599593 T G 
 
de novo de novo 20 19 7 13 21 1 20 0 
Group I-Shared 7 1 245093862 G A 
 
de novo de novo 30 32 21 18 37 0 27 0 
Group I-Shared 8 2 740342 T C 
 
low quality 
 
13 8 11 1 13 0 5 1 
Group I-Shared 9 2 3720195 T C ALLC low quality 
 
16 5 8 5 23 0 9 2 
Group I-Shared 10 2 3720268 T C ALLC de novo N/A primer pair 20 18 12 4 30 2 15 0 
Group I-Shared 11 2 7991048 A C 
 
de novo no variant 46 14 28 17 34 4 23 3 
Group I-Shared 12 2 10189061 G A KLF11 inherited 
 
47 17 26 11 19 5 29 4 
Group I-Shared 13 2 23053960 A C 
 
low quality 
 
5 11 4 3 18 4 15 8 
Group I-Shared 14 2 30755585 G A LCLAT1 de novo inherited 12 16 21 30 6 0 31 0 
Group I-Shared 15 2 72375921 G A 
 
de novo uninformative 4 7 1 2 3 0 3 0 
Group I-Shared 16 2 72375922 G A 
 
de novo uninformative 4 7 1 2 3 0 3 0 
Group I-Shared 17 2 114789320 A T 
 
de novo N/A PCR product 23 11 16 4 32 0 12 2 
Group I-Shared 18 2 136342189 G A R3HDM1 de novo de novo 
 
0 30 18 12 0 46 0 
Group I-Shared 19 2 197151126 T A HECW2 de novo no variant 27 10 27 6 19 2 40 0 
Group I-Shared 20 2 197151129 A T HECW2 de novo no variant 30 8 27 5 19 2 34 0 
Group I-Shared 21 2 241565199 A G GPR35 low quality 
 
12 4 5 2 18 4 4 1 
Group I-Shared 22 3 3168559 T C 
 
de novo uninformative 12 6 3 3 14 0 9 1 
Group I-Shared 23 3 11943503 C G NUP210P2 de novo no variant 39 12 19 3 18 0 11 0 
Group I-Shared 24 3 13651179 T G FBLN2 no variant 
 
9 5 6 3 12 1 4 0 
Group I-Shared 25 3 50652860 A C MAPKAPK3 de novo N/A PCR product 72 21 43 12 54 4 39 0 
Group I-Shared 26 3 196189887 C G 
 
no variant 
 
16 8 15 5 28 2 24 4 
Group I-Shared 27 3 197614409 C G LRCH3 de novo N/A PCR product 18 15 11 4 14 1 15 1 
Group I-Shared 28 4 701615 C T PCGF3 de novo N/A PCR product 15 6 7 5 11 1 4 1 
Group I-Shared 29 4 1089608 T C RNF212 de novo N/A primer pair 29 9 7 8 22 1 9 1 
Group I-Shared 30 4 2062572 G A NAT8L low quality 
 
2 3 10 2 8 0 3 0 
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Group I-Shared 31 4 39264692 A C WDR19 low quality 
 
10 6 5 4 6 2 2 3 
Group I-Shared 32 4 71768172 A G MOB1B de novo uninformative 6 5 5 3 5 1 7 0 
Group I-Shared 33 4 145566227 C T HHIP-AS1 de novo de novo 23 32 13 14 25 0 27 0 
Group I-Shared 34 4 190582718 G A RP11-462G22.1 inherited  
 
155 34 92 20 141 21 131 0 
Group I-Shared 35 4 190605292 A T 
 
inherited 
 
109 18 87 17 69 9 108 0 
Group I-Shared 36 5 1230092 G T SLC6A19 low quality 
 
24 4 13 6 19 3 12 1 
Group I-Shared 37 5 11043438 T G CTNND2 de novo de novo 20 17 18 27 15 0 24 0 
Group I-Shared 38 5 172006234 G A 
 
de novo uninformative 35 7 15 4 19 0 13 0 
Group I-Shared 39 6 29101417 C T OR2N1P de novo de novo 28 44 40 31 38 0 52 1 
Group I-Shared 40 6 40598213 T G 
 
no variant 
 
22 12 19 3 9 3 8 3 
Group I-Shared 41 6 41472781 G C RP11-328M4.2 low quality+no variant 6 2 3 4 12 0 4 2 
Group I-Shared 42 6 83777484 C G UBE3D no variant 
 
12 3 2 4 6 0 6 0 
Group I-Shared 43 6 104212493 C A 
 
de novo N/A PCR product 36 14 32 14 18 3 29 5 
Group I-Shared 44 6 146092022 G A 
 
low quality 
 
19 12 33 6 9 1 18 4 
Group I-Shared 45 6 154769585 G A CNKSR3 low quality+no variant 39 14 23 13 21 5 30 8 
Group I-Shared 46 6 162458275 T C PARK2 de novo de novo 27 24 30 20 34 1 35 0 
Group I-Shared 47 6 169662202 G A 
 
de novo inherited 24 28 16 12 27 0 22 9 
Group I-Shared 48 6 169662209 A G 
 
inherited 
 
24 27 17 12 28 0 24 8 
Group I-Shared 49 7 459309 A G 
 
de novo N/A primer pair 11 3 4 5 12 0 46 0 
Group I-Shared 50 7 9485054 T G 
 
de novo inherited 13 17 18 26 4 1 36 0 
Group I-Shared 51 7 70309917 A G 
 
de novo inherited 14 15 12 12 9 0 16 2 
Group I-Shared 52 7 81335206 T G HGF inherited 
 
40 13 35 25 13 4 22 4 
Group I-Shared 53 7 140191996 T C 
 
low quality 
 
20 11 11 12 22 2 20 0 
Group I-Shared 54 7 141955453 A G PRSS58 de novo de novo 32 40 18 17 28 0 33 0 
Group I-Shared 55 7 157192929 T C DNAJB6 de novo N/A PCR product 38 9 11 6 26 1 17 0 
Group I-Shared 56 7 158037904 T C PTPRN2 no variant 
 
12 4 3 1 17 0 18 0 
Group I-Shared 57 7 158252534 G A PTPRN2 de novo N/A PCR product 13 4 8 3 10 0 20 2 
Group I-Shared 58 8 1266955 G C 
 
low quality  
 
19 9 9 3 12 1 12 3 
Group I-Shared 59 8 119959498 G A TNFRSF11B de novo N/A PCR product 12 10 15 4 18 1 30 0 
Group I-Shared 60 8 142602829 G A 
 
low quality 
 
0 ## 11 4 31 0 7 2 
Group I-Shared 61 8 144890487 G A MIR937 inherited 
 
36 7 14 6 41 8 16 0 
Group I-Shared 62 9 32504067 C A DDX58 inherited 
 
33 15 12 1 25 1 16 0 
Group I-Shared 63 9 32917739 C T 
 
de novo de novo 41 47 12 21 37 0 31 0 
Group I-Shared 64 9 88703373 T A GOLM1 inherited 
 
20 7 16 4 7 0 22 2 
Group I-Shared 65 9 102011855 G A 
 
inherited 
 
53 21 33 13 35 10 29 0 
Group I-Shared 66 9 102011909 A G 
 
inherited 
 
65 11 37 8 51 7 26 0 
Group I-Shared 67 9 138010720 T G OLFM1 low quality 
 
33 10 12 8 16 3 17 1 
Group I-Shared 68 9 139526735 C G 
 
low quality + no variant 14 3 9 7 18 2 13 2 
Group I-Shared 69 9 140206420 C T EXD3 de novo N/A PCR product 7 4 4 4 15 0 8 0 
128 
 
Group I-Shared 70 10 2357274 A G 
 
low quality 
 
69 4 14 5 15 13 12 1 
Group I-Shared 71 10 7400791 C G SFMBT2 inherited 
 
37 11 35 8 33 0 19 2 
Group I-Shared 72 10 7400796 G A SFMBT2 low quality 
 
40 0 31 0 31 0 21 1 
Group I-Shared 73 10 7400806 C T SFMBT2 de novo inherited 87 9 41 5 12 24 
 
0 
Group I-Shared 74 10 48410093 A G GDF2 de novo N/A primer pair 29 6 6 3 18 3 20 0 
Group I-Shared 75 10 82233478 C T TSPAN14 low quality 
 
47 15 22 13 20 8 21 4 
Group I-Shared 76 10 88123119 G T GRID1 low quality 
 
12 7 4 8 12 0 3 0 
Group I-Shared 77 10 97753629 T A CC2D2B inherited 
 
25 4 42 11 13 0 19 2 
Group I-Shared 78 10 102527333 C T PAX2 de novo de novo 1146 ## 19 19 43 0 27 0 
Group I-Shared 79 10 115563965 T C 
 
de novo uninformative 29 38 23 19 41 0 40 0 
Group I-Shared 80 10 128805987 G A DOCK1 de novo de novo 32 36 13 20 56 0 30 0 
Group I-Shared 81 10 132099886 T G 
 
de novo N/A primer pair 14 6 9 3 8 0 16 0 
Group I-Shared 82 10 133937827 C T JAKMIP3 de novo de novo  22 12 11 9 19 0 13 0 
Group I-Shared 83 10 134392000 G A INPP5A de novo no variant 43 10 19 8 20 3 24 0 
Group I-Shared 84 10 134837450 A G 
 
low quality 
 
28 10 12 5 24 1 4 5 
Group I-Shared 85 10 134996444 G A KNDC1 low quality 
 
7 4 5 1 8 0 3 0 
Group I-Shared 86 11 1415375 A C BRSK2 de novo N/A primer pair 33 12 17 5 25 0 28 1 
Group I-Shared 87 11 134534416 T A 
 
de novo N/A PCR product 10 4 9 4 18 0 5 0 
Group I-Shared 88 11 134605169 A G 
 
low quality 
 
17 8 10 2 21 2 6 1 
Group I-Shared 89 12 162687 G A 
 
inherited 
 
139 35 88 28 118 0 78 11 
Group I-Shared 90 12 718423 T A NINJ2 low quality 
 
28 7 13 2 20 2 13 1 
Group I-Shared 91 12 3527384 T C PRMT8 de novo de novo 21 32 13 5 27 0 28 0 
Group I-Shared 92 12 113724257 C T TPCN1 inherited 
 
33 11 20 6 24 3 18 0 
Group I-Shared 93 12 129572447 C A TMEM132D low quality 
 
27 7 18 6 12 0 15 3 
Group I-Shared 94 12 131132579 T C RIMBP2 inherited 
 
44 11 31 11 26 0 25 3 
Group I-Shared 95 13 41929042 G T NAA16 inherited 
 
32 20 18 13 11 12 15 11 
Group I-Shared 96 13 97503636 T C 
 
de novo de novo 38 30 19 33 42 0 37 0 
Group I-Shared 97 13 112669460 C T 
 
low quality 
 
29 7 14 3 12 0 10 0 
Group I-Shared 98 13 114220087 G C 
 
low quality 
 
14 6 9 2 18 1 13 1 
Group I-Shared 99 13 114510530 C T FAM70B low quality 
 
14 6 7 2 11 0 11 0 
Group I-Shared 100 13 114510547 C G FAM70B low quality 
 
13 7 8 4 6 0 10 0 
Group I-Shared 101 13 114510560 T C FAM70B de novo N/A PCR product 14 8 6 4 5 0 6 0 
Group I-Shared 102 13 114514458 T C FAM70B low quality 
 
9 3 2 1 3 1 5 0 
Group I-Shared 103 13 114514468 G A FAM70B low quality 
 
7 3 4 1 4 1 6 0 
Group I-Shared 104 13 114965572 C T 
 
inherited 
 
7 3 11 4 8 2 10 0 
Group I-Shared 105 14 32048285 T A NUBPL de novo de novo 39 33 25 20 45 0 29 0 
Group I-Shared 106 14 105245986 A G AKT1 low quality 
 
21 5 15 3 17 0 5 0 
Group I-Shared 107 14 105345084 G A KIAA0284 inherited 
 
20 7 19 7 15 0 15 0 
Group I-Shared 108 14 105499889 A G 
 
low quality 
 
13 7 6 1 12 2 6 0 
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Group I-Shared 109 15 41256583 A C 
 
low quality+no variant 5 5 3 3 11 1 1 2 
Group I-Shared 110 15 48937494 C T FBN1 de novo inherited 7 4 10 6 14 0 3 1 
Group I-Shared 111 15 57953050 A T GCOM1 de novo de novo 31 37 14 33 49 0 53 0 
Group I-Shared 112 15 80788986 G T ARNT2 de novo de novo 26 32 10 10 50 0 36 0 
Group I-Shared 113 16 10858705 T A FAM18A low quality 
 
19 6 4 2 24 0 14 0 
Group I-Shared 114 16 22695512 T G 
 
inherited 
 
123 34 57 27 75 11 64 1 
Group I-Shared 115 16 59139115 A G RP11-410D17.2 de novo de novo 33 31 11 24 30 0 48 0 
Group I-Shared 116 16 84085063 G T MBTPS1 low quality 
 
65 16 27 9 43 4 36 0 
Group I-Shared 117 16 87715100 C T JPH3 de novo no variant 15 12 4 6 15 0 12 1 
Group I-Shared 118 16 88313175 A G LA16c-444G7.1 low quality 
 
19 11 11 11 36 2 13 3 
Group I-Shared 119 16 88497459 G A ZNF469 de novo no variant 8 4 6 4 17 0 3 1 
Group I-Shared 120 16 88560062 G A ZFPM1 low quality 
 
27 4 6 3 13 0 6 0 
Group I-Shared 121 17 546943 T C VPS53 inherited 
 
47 15 37 12 25 1 25 7 
Group I-Shared 122 17 21303735 A G KCNJ12 inherited 
 
95 36 42 11 70 9 59 0 
Group I-Shared 123 17 21307296 G C KCNJ12 inherited 
 
123 33 69 13 82 11 80 0 
Group I-Shared 124 17 79276311 C T LINC00482 de novo de novo 12 22 2 5 24 0 8 0 
Group I-Shared 125 17 79906331 C T NOTUM inherited 
 
47 13 27 3 39 5 20 0 
Group I-Shared 126 17 80346681 C G C17orf101 low quality 
 
4 4 1 2 4 0 2 2 
Group I-Shared 127 17 80942321 C T RP11-1197K16.2 de novo N/A PCR product 37 14 21 9 24 0 21 2 
Group I-Shared 128 17 81024707 C T 
 
inherited 
 
12 11 4 2 19 6 10 0 
Group I-Shared 129 18 3412160 G A TGIF1 de novo inherited 16 24 12 10 20 0 5 1 
Group I-Shared 130 18 32459844 T C DTNA de novo de novo 48 32 12 15 
 
0 40 0 
Group I-Shared 131 18 77204733 G C NFATC1 low quality 
 
6 3 9 2 13 0 6 0 
Group I-Shared 132 19 523438 C T TPGS1 de novo N/A PCR product 7 26 11 11 10 0 10 12 
Group I-Shared 133 19 682321 T A PRSS57 inherited 
 
16 14 12 4 14 6 23 0 
Group I-Shared 134 19 11564606 A C ELAVL3 low quality + no variant 15 19 14 7 12 4 8 1 
Group I-Shared 135 19 14732346 G A EMR3 de novo uninformative 44 12 12 4 24 1 31 0 
Group I-Shared 136 19 39330862 A G HNRNPL low quality 
 
6 3 2 5 6 2 4 3 
Group I-Shared 137 19 49842785 A C TEAD2 de novo no variant 6 11 7 4 11 8 9 2 
Group I-Shared 138 19 50197909 T G C19orf76 low quality 
 
31 20 15 14 17 10 17 7 
Group I-Shared 139 19 53659085 C T ZNF347 de novo N/A PCR product 25 18 9 11 23 0 20 0 
Group I-Shared 140 20 653248 C T SCRT2 low quality 
 
12 9 4 6 14 0 12 3 
Group I-Shared 141 20 14840274 T C MACROD2 de novo no variant 35 30 33 30 26 0 39 0 
Group I-Shared 142 20 50012140 C G NFATC2 de novo no variant 13 5 16 4 14 1 20 1 
Group I-Shared 143 20 50690005 T A ZFP64 de novo N/A primer pair 28 41 15 22 43 0 34 1 
Group I-Shared 144 20 52184901 A C ZNF217 low quality 
 
44 34 28 20 26 16 24 10 
Group I-Shared 145 20 61607457 T C 
 
low quality 
 
18 5 12 4 7 1 7 1 
Group I-Shared 146 20 62836674 T C MYT1 de novo N/A PCR product 18 6 6 1 12 0 8 0 
Group I-Shared 147 20 62866083 T G MYT1 de novo N/A primer pair 19 13 6 5 13 0 6 0 
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Group I-Shared 148 21 17686365 T A LINC00478 inherited 
 
9 3 18 10 15 2 12 1 
Group I-Shared 149 21 23811291 C T 
 
de novo de novo 28 29 13 16 26 0 25 0 
Group I-Shared 150 21 44743604 A C LINC00322 de novo inherited 23 11 13 7 19 0 3 3 
Group I-Shared 151 21 45206930 C T TMEM97P1 low quality 
 
29 3 13 7 21 0 13 2 
Group I-Shared 152 21 46304683 T G ITGB2 low quality 
 
17 9 11 4 20 5 7 4 
Group I-Shared 153 22 19167292 G A CLTCL1 de novo de novo 24 25 13 13 25 0 13 0 
Group I-Shared 154 22 19704712 T G SEPT5 low quality 
 
5 5 1 2 4 2 114 13 
Group I-Shared 155 22 40898746 T C MKL1 low quality 
 
10 5 15 2 8 0 16 0 
Group I-Shared 156 22 49761849 A G 
 
low quality 
 
44 9 18 3 21 1 21 1 
Group I-Shared 157 22 49840787 G A C22orf34 low quality 
 
28 5 18 6 15 0 11 1 
Group I-Shared 158 X 2836434 G A ARSD de novo no variant 16 7 19 7 35 0 16 2 
Group I-Shared 159 X 145422663 T C 
 
low quality 
 
12 6 7 2 11 0 5 0 
Group II-Twin I 160 1 162730172 A G DDR2 inherited 
 
36 9 46 1 17 0 29 1 
Group II-Twin I 161 1 245499265 A G KIF26B de novo inherited 30 6 23 3 27 0 14 1 
Group II-Twin I 162 2 61728351 A T XPO1 de novo de novo 34 14 45 0 27 0 25 0 
Group II-Twin I 163 2 111926337 T G BCL2L11 inherited 
 
27 22 29 15 17 9 15 7 
Group II-Twin I 164 2 241627105 T G AQP12A low quality 
 
9 7 3 0 9 0 7 1 
Group II-Twin I 165 3 1493383 C T 
 
de novo de novo 30 9 42 0 22 0 25 0 
Group II-Twin I 166 3 20897127 T C 
 
low quality 
 
27 12 16 2 24 1 17 3 
Group II-Twin I 167 3 51090509 G T DOCK3 low quality 
 
13 4 21 0 13 1 12 2 
Group II-Twin I 168 3 51441939 A C VPRBP de novo no variant 34 20 28 6 293 0 17 9 
Group II-Twin I 169 3 66701546 T G 
 
low quality 
 
20 17 13 7 12 5 10 9 
Group II-Twin I 170 3 72959480 G A GXYLT2 de novo de novo 35 ## 54 0 35 0 37 0 
Group II-Twin I 171 3 135876070 C T TDGF1P6 low quality 
 
33 8 29 1 22 0 18 2 
Group II-Twin I 172 3 187442688 A C BCL6 low quality 
 
29 7 16 1 30 0 29 1 
Group II-Twin I 173 3 196430415 C T CEP19 low quality 
 
35 11 35 1 20 1 17 1 
Group II-Twin I 174 4 651520 G A PDE6B de novo N/A PCR product 11 4 7 2 13 0 8 0 
Group II-Twin I 175 4 6564000 G A PPP2R2C de novo de novo 33 15 24 0 18 1 14 0 
Group II-Twin I 176 4 7920679 G A AFAP1 low quality 
 
55 14 34 0 26 2 22 1 
Group II-Twin I 177 4 189032254 C G RP11-713C19.1 low quality 
 
25 11 47 3 30 0 30 4 
Group II-Twin I 178 4 189792261 C G 
 
low quality 
 
1 3 46 3 42 1 69 7 
Group II-Twin I 179 5 1956661 A G RP11-259O2.1 low quality 
 
48 13 27 3 17 2 786 72 
Group II-Twin I 180 5 54561146 A G DHX29 inherited 
 
62 14 43 4 30 1 36 3 
Group II-Twin I 181 5 82195939 G A 
 
low quality 
 
40 16 36 10 23 6 23 8 
Group II-Twin I 182 5 141576736 A C 
 
inherited 
 
41 23 32 6 35 10 26 11 
Group II-Twin I 183 6 16943658 A C 
 
low quality 
 
37 26 32 10 32 11 17 8 
Group II-Twin I 184 6 20235579 T G RP11-239H6.2 low quality 
 
17 7 7 5 9 3 7 1 
Group II-Twin I 185 6 41586146 G A 
 
de novo inherited 47 12 30 0 37 0 24 0 
Group II-Twin I 186 6 134981681 T G 
 
de novo no variant 38 16 35 2 23 10 22 3 
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Group II-Twin I 187 7 1824582 T C 
 
low quality 
 
43 11 32 1 20 1 34 3 
Group II-Twin I 188 7 1824583 G A 
 
inherited 
 
44 11 34 1 20 1 33 3 
Group II-Twin I 189 7 29606885 G A PRR15 de novo de novo 59 23 44 0 31 0 40 0 
Group II-Twin I 190 7 40103905 T G CDK13 low quality 
 
36 18 31 5 25 4 17 9 
Group II-Twin I 191 7 76922180 A C CCDC146 low quality 
 
39 29 27 9 19 14 20 11 
Group II-Twin I 192 7 155510228 T G RBM33 de novo no variant 26 14 23 1 25 3 14 4 
Group II-Twin I 193 7 157981209 G C PTPRN2 de novo N/A PCR product 12 5 16 0 6 0 5 0 
Group II-Twin I 194 8 66686049 G A MTFR1 de novo uninformative 29 9 58 0 23 0 26 0 
Group II-Twin I 195 8 118838053 A G EXT1 de novo de novo 
 
0 
 
0 
 
0 
 
0 
Group II-Twin I 196 8 143671111 G C 
 
low quality 
 
34 8 17 4 35 0 16 0 
Group II-Twin I 197 9 140816091 C A CACNA1B inherited 
 
39 16 27 7 22 2 21 4 
Group II-Twin I 198 10 3940738 G A 
 
low quality 
 
39 9 23 2 20 1 26 2 
Group II-Twin I 199 10 10872261 G A 
 
low quality 
 
26 6 31 3 17 2 29 4 
Group II-Twin I 200 10 45869059 C A 
 
de novo N/A PCR product 9 6 6 3 8 0 2 1 
Group II-Twin I 201 10 48410018 G C GDF2 low quality 
 
9 8 3 0 22 2 14 0 
Group II-Twin I 202 10 77154164 C T ZNF503 low quality 
 
24 14 23 5 19 9 17 5 
Group II-Twin I 203 11 65374709 T G MAP3K11 low quality 
 
10 8 4 1 9 0 4 1 
Group II-Twin I 204 12 653012 T C B4GALNT3 de novo N/A primer pair 23 7 8 1 17 0 9 0 
Group II-Twin I 205 12 9557500 T C RP11-599J14.2 de novo no variant 5 4 4 0 13 0 9 0 
Group II-Twin I 206 12 64229411 T G 
 
low quality 
 
18 15 27 6 24 9 21 19 
Group II-Twin I 207 12 95569608 G A FGD6 de novo uninformative 43 23 32 4 30 11 26 8 
Group II-Twin I 208 12 131691875 G A RP11-638F5.1 de novo inherited 31 10 12 1 27 0 10 0 
Group II-Twin I 209 12 133052676 T C 
 
low quality 
 
27 12 12 3 25 3 10 0 
Group II-Twin I 210 12 133352895 G C GOLGA3 de novo N/A PCR product 33 12 24 2 25 0 13 1 
Group II-Twin I 211 13 51812216 T G FAM124A low quality 
 
18 16 15 7 14 6 13 4 
Group II-Twin I 212 13 87083684 C A 
 
low quality 
 
14 5 42 0 5 0 16 1 
Group II-Twin I 213 14 52997360 A T TXNDC16 low quality 
 
9 4 28 0 10 0 10 0 
Group II-Twin I 214 14 80678369 C T DIO2 low quality 
 
38 19 31 10 26 9 23 6 
Group II-Twin I 215 14 100044559 A G CCDC85C no variant 
 
30 11 15 3 22 3 27 3 
Group II-Twin I 216 16 1970303 A G 
 
low quality 
 
20 15 4 2 15 3 12 0 
Group II-Twin I 217 16 10858718 A G FAM18A low quality 
 
19 6 10 0 26 0 11 1 
Group II-Twin I 218 16 50424085 G A RP11-21B23.2 de novo de novo 26 10 22 0 21 0 14 0 
Group II-Twin I 219 16 70714811 C G MTSS1L low quality 
 
14 8 6 2 8 0 9 2 
Group II-Twin I 220 16 77724703 G T 
 
low quality 
 
34 22 18 7 22 14 14 5 
Group II-Twin I 221 17 92938 C T RPH3AL low quality 
 
15 7 38 1 25 1 59 0 
Group II-Twin I 222 17 71734490 T C CTD-2532D12.4 inherited 
 
28 9 20 2 28 4 20 0 
Group II-Twin I 223 17 73824833 G C UNK low quality 
 
559 0 11 1 11 6 9 6 
Group II-Twin I 224 18 34970824 C T CELF4 de novo uninformative 27 6 9 0 16 0 11 0 
Group II-Twin I 225 18 50453718 G T DCC de novo N/A PCR product 30 6 52 2 16 1 28 1 
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Group II-Twin I 226 19 309882 A G CTD-3113P16.5 no variant 
 
13 14 29 0 5 1 3 0 
Group II-Twin I 227 19 33105233 T G ANKRD27 low quality 
 
42 36 36 0 20 13 21 4 
Group II-Twin I 228 20 53271335 C T DOK5 de novo de novo 55 17 37 0 39 0 28 0 
Group II-Twin I 229 20 56815552 G C PPP4R1L low quality 
 
10 0 4 1 6 1 2 3 
Group II-Twin I 230 20 62810452 T C MYT1 inherited 
 
23 16 12 5 31 2 22 8 
Group II-Twin I 231 21 34512162 C A 
 
low quality 
 
28 25 24 8 21 6 14 7 
Group II-Twin I 232 X 2833489 C G ARSD de novo N/A primer pair 21 7 15 1 30 0 14 0 
Group II-Twin I 233 X 7544103 T C 
 
de novo N/A primer pair 8 7 5 0 18 1 10 0 
Group II-Twin I 234 X 7544110 T C 
 
low quality 
 
0 3 8 0 17 2 10 0 
Group II-Twin I 235 X 10107413 T A WWC3 low quality 
 
18 10 9 3 61 6 7 0 
Group II-Twin I 236 X 68384591 T G PJA1 low quality 
 
3 7 4 1 3 2 3 0 
Group II-Twin I 237 X 116523014 T A 
 
low quality 
 
13 5 30 1 29 1 23 2 
Group II-Twin I 238 X 144597115 T A 
 
low quality 
 
2 3 14 0 7 0 12 0 
Group II-Twin I 239 X 144597121 C A 
 
de novo N/A primer pair 2 3 14 0 6 0 8 0 
Group II-Twin I 240 X 148731301 C A RP5-937E21.1 de novo no variant 16 7 18 1 26 6 15 1 
Group II-Twin I 241 X 150242328 A G 
 
no variant 
 
15 8 11 1 23 1 5 0 
Group II-Twin I 242 Y 8094333 C A 
 
de novo N/A primer pair 9 5 23 0 0 0 6 0 
Group II-Twin II 243 1 211950090 G A LPGAT1 de novo no variant 55 9 28 11 25 4 24 3 
Group II-Twin II 244 1 228146563 C A 
 
de novo no variant 37 0 15 5 37 0 17 0 
Group II-Twin II 245 2 362130 G T 
 
inherited 
 
70 8 36 10 37 3 58 0 
Group II-Twin II 246 2 362131 A T 
 
inherited 
 
71 7 35 12 37 3 58 0 
Group II-Twin II 247 2 1404408 C A TPO low quality 
 
38 18 36 15 28 7 23 8 
Group II-Twin II 248 2 10476221 G T HPCAL1 inherited 
 
53 9 29 11 30 1 49 0 
Group II-Twin II 249 2 70925457 G T ADD2 de novo no variant 56 0 26 5 676 0 34 0 
Group II-Twin II 250 2 154061708 G T AC079150.2 low quality 
 
31 15 19 12 19 7 18 10 
Group II-Twin II 251 2 241992247 C T SNED1 de novo uninformative 34 1 15 7 13 1 17 1 
Group II-Twin II 252 4 3827696 A C 
 
low quality 
 
26 0 21 7 42 4 15 0 
Group II-Twin II 253 5 194385 A C PLEKHG4B low quality 
 
59 10 22 10 27 2 23 1 
Group II-Twin II 254 5 16525233 G A FAM134B inherited 
 
33 6 12 6 19 4 23 0 
Group II-Twin II 255 5 137885670 T A HSPA9 inherited 
 
66 0 44 12 42 0 50 2 
Group II-Twin II 256 6 57541536 G T 
 
inherited 
 
155 24 108 22 94 12 100 0 
Group II-Twin II 257 6 86090624 G A 
 
low quality 
 
36 8 25 12 23 2 23 9 
Group II-Twin II 258 6 133966995 G T 
 
de novo no variant 40 5 24 9 21 1 19 4 
Group II-Twin II 259 7 10338952 G T 
 
low quality 
 
63 12 37 15 36 6 36 3 
Group II-Twin II 260 7 56559682 A G RBM22P3 low quality 
 
46 2 15 6 25 3 18 0 
Group II-Twin II 261 7 158204835 C T PTPRN2 de novo N/A Primer Pair 17 1 4 3 14 0 8 0 
Group II-Twin II 262 7 158248408 C T PTPRN2 low quality 
 
31 5 26 5 23 2 23 0 
Group II-Twin II 263 8 142602825 C T 
 
low quality 
 
23 4 12 5 34 0 8 1 
Group II-Twin II 264 9 14347587 G A NFIB de novo inherited 26 0 8 4 15 0 9 0 
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Group II-Twin II 265 9 106166434 C T RP11-436F21.1 low quality 
 
20 4 26 8 8 0 21 0 
Group II-Twin II 266 10 3357139 G A 
 
low quality 
 
31 2 9 6 18 0 11 1 
Group II-Twin II 267 10 30518280 A G 
 
low quality 
 
44 9 22 11 27 9 17 8 
Group II-Twin II 268 11 1474891 G T BRSK2 de novo no variant 25 0 7 4 17 0 8 0 
Group II-Twin II 269 11 129307937 T A BARX2 low quality 
 
32 7 19 10 22 2 12 2 
Group II-Twin II 270 12 132353193 A C RP11-417L19.2 de novo N/A PCR product 14 3 6 9 14 2 12 4 
Group II-Twin II 271 13 114617416 G A LINC00452 low quality 
 
60 5 32 8 36 3 31 0 
Group II-Twin II 272 13 114619650 A G LINC00452 low quality 
 
46 3 14 4 29 0 26 0 
Group II-Twin II 273 15 76884600 G T SCAPER low quality 
 
27 3 27 9 20 2 42 0 
Group II-Twin II 274 16 62015587 C T CDH8 de novo no variant 77 4 33 9 41 0 32 3 
Group II-Twin II 275 17 4782495 T G Metazoa_SRP low quality 
 
35 7 8 6 25 0 15 1 
Group II-Twin II 276 17 79646774 T G ARL16 low quality 
 
37 17 12 8 21 9 15 7 
Group II-Twin II 277 17 81042516 T C METRNL low quality 
 
33 5 12 5 23 0 16 3 
Group II-Twin II 278 18 18623582 G A ROCK1 low quality 
 
18 0 44 9 13 0 26 2 
Group II-Twin II 279 21 36322701 A G RUNX1 de novo de novo 63 0 33 9 27 0 41 0 
Group II-Twin II 280 21 47479749 C T AP001476.3 de novo N/A Primer Pair 64 2 10 5 24 1 26 4 
Group II-Twin II 281 21 47479750 C G AP001476.3 low quality 
 
162 1 10 5 24 0 28 1 
Group II-Twin II 282 X 7320881 C G 
 
de novo no variant 32 0 15 6 32 0 22 0 
Group II-Twin II 283 X 71177022 T C NHSL2 de novo no variant 27 0 14 4 25 0 17 0 
Group II-Twin II 284 X 71177023 A T NHSL2 de novo no variant 27 0 14 4 25 0 17 0 
Group II-Twin II 285 X 104517151 A G IL1RAPL2 de novo no variant 24 0 12 4 37 0 19 0 
Group II-Twin II 286 X 122224237 A G 
 
no variant 
 
27 2 8 6 21 1 13 0 
Group II-Twin II 287 X 123370010 C T STAG2 low quality 
 
28 7 13 6 31 7 16 1 
Group II-Twin II 288 X 128927246 C G SASH3 de novo no variant 13 0 10 4 17 0 17 0 
Group II-Twin II 289 X 134054617 A C 
 
no variant 
 
27 0 9 5 32 0 18 0 
Group II-Twin II 290 X 134054618 A T 
 
de novo no variant 28 0 8 5 32 0 17 0 
 
Abbreviations used in this table: chr, chromosome; pos, position; ref, reference allele; alt, alternative allele; n, number of reads supporting the variant; N/A, not available 
 
 
 
 
 
134 
 
 
Appendix C 
Complete List of Putative De Novo SNVs 
 
 
Table C.1: List of the de novo SNV candidates (n=159) shared by the twin pair 
 
Chr Pos Ref Alt Genomic Context Gene Gene type Twin I Twin II Mother Father IGV Prediction Sanger 
1 1334722 A C DOWNSTREAM MRPL20 protein_coding Het Het Ref Ref de novo N/A PCR product 
1 38066423 G A INTERGENIC 
  
Het Het Ref Ref low quality 
 
1 47691626 G C DOWNSTREAM TAL1 processed_transcript Het Het Ref Ref low quality 
 
1 54706147 G A DOWNSTREAM C1orf191 protein_coding Het Het Ref Ref low quality 
 
1 165599592 G C INTERGENIC 
  
Het Het Ref Ref de novo de novo 
1 165599593 T G INTERGENIC 
  
Het Het Ref Ref de novo de novo 
1 245093862 G A INTERGENIC 
  
Het Het Ref Ref de novo de novo 
2 740342 T C INTERGENIC 
  
Het Het Ref Ref low quality 
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2 3720195 T C INTRON ALLC protein_coding Het Het Ref Ref low quality 
 
2 3720268 T C INTRON ALLC protein_coding Het Het Ref Ref de novo N/A primer pair 
2 7991048 A C INTERGENIC 
  
Het Het Ref Ref de novo no variant 
2 10189061 G A DOWNSTREAM KLF11 protein_coding Het Het Ref Ref inherited 
 
2 23053960 A C INTERGENIC 
  
Het Het Ref Ref low quality 
 
2 30755585 G A INTRON LCLAT1 protein_coding Het Het Ref Ref de novo inherited 
2 72375921 G A INTERGENIC 
  
Het Het Ref Ref de novo uninformative 
2 72375922 G A INTERGENIC 
  
Het Het Ref Ref de novo uninformative 
2 114789320 A T INTERGENIC 
  
Het Het Ref Ref de novo N/A PCR product 
2 136342189 G A INTRON R3HDM1 protein_coding Het Het Ref Ref de novo de novo 
2 197151126 T A INTRON HECW2 protein_coding Het Het Ref Ref de novo no variant 
2 197151129 A T INTRON HECW2 protein_coding Het Het Ref Ref de novo no variant 
2 241565199 A G INTRON GPR35 protein_coding Het Het Ref Ref low quality 
 
3 3168559 T C INTERGENIC 
  
Het Het Ref Ref de novo uninformative 
3 11943503 C G DOWNSTREAM NUP210P2 unprocessed_pseudogene Het Het Ref Ref de novo no variant 
3 13651179 T G INTRON FBLN2 protein_coding Het Het Ref Ref no variant 
 
3 50652860 A C DOWNSTREAM MAPKAPK3 processed_transcript Het Het Ref Ref de novo N/A PCR product 
3 196189887 C G INTERGENIC 
  
Het Het Ref Ref no variant 
 
3 197614409 C G DOWNSTREAM LRCH3 protein_coding Het Het Ref Ref de novo N/A PCR product 
4 701615 C T INTRON PCGF3 protein_coding Het Het Ref Ref de novo N/A PCR product 
4 1089608 T C DOWNSTREAM RNF212 retained_intron Het Het Ref Ref de novo N/A primer pair 
4 2062572 G A INTRON NAT8L protein_coding Het Het Ref Ref low quality 
 
4 39264692 A C INTRON WDR19 protein_coding Het Het Ref Ref low quality 
 
4 71768172 A G EXON MOB1B processed_transcript Het Het Ref Ref de novo uninformative 
4 145566227 C T INTRON HHIP-AS1 processed_transcript Het Het Ref Ref de novo de novo 
4 190582718 G A DOWNSTREAM 
RP11-
462G22.1 
lincRNA Het Het Ref Ref inherited  
 
4 190605292 A T INTERGENIC 
  
Het Het Ref Ref inherited 
 
5 1230092 G T DOWNSTREAM SLC6A19 protein_coding Het Het Ref Ref low quality 
 
5 11043438 T G INTRON CTNND2 protein_coding Het Het Ref Ref de novo de novo 
5 172006234 G A INTERGENIC 
  
Het Het Ref Ref de novo uninformative 
6 29101417 C T DOWNSTREAM OR2N1P unprocessed_pseudogene Het Het Ref Ref de novo de novo 
6 40598213 T G INTERGENIC 
  
Het Het Ref Ref no variant 
 
6 41472781 G C INTRON RP11-328M4.2 antisense Het Het Ref Ref low quality+no variant 
6 83777484 C G UPSTREAM UBE3D protein_coding Het Het Ref Ref no variant 
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6 104212493 C A INTERGENIC 
  
Het Het Ref Ref de novo N/A PCR product 
6 146092022 G A INTERGENIC 
  
Het Het Ref Ref low quality 
 
6 154769585 G A INTRON CNKSR3 protein_coding Het Het Ref Ref low quality+no variant 
6 162458275 T C INTRON PARK2 protein_coding Het Het Ref Ref de novo de novo 
6 169662202 G A INTERGENIC 
  
Het Het Ref Ref de novo inherited 
6 169662209 A G INTERGENIC 
  
Het Het Ref Ref inherited 
 
7 459309 A G INTERGENIC 
  
Het Het Ref Ref de novo N/A primer pair 
7 9485054 T G INTERGENIC 
  
Het Het Ref Ref de novo inherited 
7 70309917 A G INTERGENIC 
  
Het Het Ref Ref de novo inherited 
7 81335206 T G INTRON HGF protein_coding Het Het Ref Ref inherited 
 
7 140191996 T C INTERGENIC 
  
Het Het Ref Ref low quality 
 
7 141955453 A G SYNONYMOUS_CODING PRSS58 protein_coding Het Het Ref Ref de novo de novo 
7 157192929 T C INTRON DNAJB6 protein_coding Het Het Ref Ref de novo N/A PCR product 
7 158037904 T C INTRON PTPRN2 protein_coding Het Het Ref Ref no variant 
 
7 158252534 G A INTRON PTPRN2 protein_coding Het Het Ref Ref de novo N/A PCR product 
8 1266955 G C INTERGENIC 
  
Het Het Ref Ref low quality  
 
8 119959498 G A INTRON TNFRSF11B protein_coding Het Het Ref Ref de novo N/A PCR product 
8 142602829 G A INTERGENIC 
  
Het Het Ref Ref low quality 
 
8 144890487 G A DOWNSTREAM MIR937 miRNA Het Het Ref Ref inherited 
 
9 32504067 C A INTRON DDX58 protein_coding Het Het Ref Ref inherited 
 
9 32917739 C T INTERGENIC 
  
Het Het Ref Ref de novo de novo 
9 88703373 T A INTRON GOLM1 protein_coding Het Het Ref Ref inherited 
 
9 102011855 G A INTERGENIC 
  
Het Het Ref Ref inherited 
 
9 102011909 A G INTERGENIC 
  
Het Het Ref Ref inherited 
 
9 138010720 T G INTRON OLFM1 protein_coding Het Het Ref Ref low quality 
 
9 139526735 C G INTERGENIC 
  
Het Het Ref Ref low quality + no variant 
9 140206420 C T INTRON EXD3 protein_coding Het Het Ref Ref de novo N/A PCR product 
10 2357274 A G INTERGENIC 
  
Het Het Ref Ref low quality 
 
10 7400791 C G INTRON SFMBT2 protein_coding Het Het Ref Ref inherited 
 
10 7400796 G A INTRON SFMBT2 protein_coding Het Het Ref Ref low quality 
 
10 7400806 C T INTRON SFMBT2 protein_coding Het Het Ref Ref de novo inherited 
10 48410093 A G DOWNSTREAM GDF2 protein_coding Het Het Ref Ref de novo N/A primer pair 
10 82233478 C T INTRON TSPAN14 protein_coding Het Het Ref Ref low quality 
 
10 88123119 G T INTRON GRID1 protein_coding Het Het Ref Ref low quality 
 
10 97753629 T A DOWNSTREAM CC2D2B processed_transcript Het Het Ref Ref inherited 
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10 102527333 C T INTRON PAX2 protein_coding Het Het Ref Ref de novo de novo 
10 115563965 T C INTERGENIC 
  
Het Het Ref Ref de novo uninformative 
10 128805987 G A INTRON DOCK1 protein_coding Het Het Ref Ref de novo de novo 
10 132099886 T G INTERGENIC 
  
Het Het Ref Ref de novo N/A primer pair 
10 133937827 C T INTRON JAKMIP3 protein_coding Het Het Ref Ref de novo de novo  
10 134392000 G A INTRON INPP5A protein_coding Het Het Ref Ref de novo no variant 
10 134837450 A G INTERGENIC 
  
Het Het Ref Ref low quality 
 
10 134996444 G A DOWNSTREAM KNDC1 processed_transcript Het Het Ref Ref low quality 
 
11 1415375 A C INTRON BRSK2 protein_coding Het Het Ref Ref de novo N/A primer pair 
11 134534416 T A INTERGENIC 
  
Het Het Ref Ref de novo N/A PCR product 
11 134605169 A G INTERGENIC 
  
Het Het Ref Ref low quality 
 
12 162687 G A INTERGENIC 
  
Het Het Ref Ref inherited 
 
12 718423 T A INTRON NINJ2 protein_coding Het Het Ref Ref low quality 
 
12 3527384 T C INTRON PRMT8 protein_coding Het Het Ref Ref de novo de novo 
12 113724257 C T INTRON TPCN1 protein_coding Het Het Ref Ref inherited 
 
12 129572447 C A INTRON TMEM132D protein_coding Het Het Ref Ref low quality 
 
12 131132579 T C INTRON RIMBP2 protein_coding Het Het Ref Ref inherited 
 
13 41929042 G T INTRON NAA16 protein_coding Het Het Ref Ref inherited 
 
13 97503636 T C INTERGENIC 
  
Het Het Ref Ref de novo de novo 
13 112669460 C T INTERGENIC 
  
Het Het Ref Ref low quality 
 
13 114220087 G C INTERGENIC 
  
Het Het Ref Ref low quality 
 
13 114510530 C T DOWNSTREAM FAM70B processed_transcript Het Het Ref Ref low quality 
 
13 114510547 C G DOWNSTREAM FAM70B processed_transcript Het Het Ref Ref low quality 
 
13 114510560 T C DOWNSTREAM FAM70B processed_transcript Het Het Ref Ref de novo N/A PCR product 
13 114514458 T C INTRON FAM70B protein_coding Het Het Ref Ref low quality 
 
13 114514468 G A INTRON FAM70B protein_coding Het Het Ref Ref low quality 
 
13 114965572 C T INTERGENIC 
  
Het Het Ref Ref inherited 
 
14 32048285 T A INTRON NUBPL protein_coding Het Het Ref Ref de novo de novo 
14 105245986 A G INTRON AKT1 protein_coding Het Het Ref Ref low quality 
 
14 105345084 G A INTRON KIAA0284 protein_coding Het Het Ref Ref inherited 
 
14 105499889 A G INTERGENIC 
  
Het Het Ref Ref low quality 
 
15 41256583 A C INTERGENIC 
  
Het Het Ref Ref low quality+no variant 
15 48937494 C T INTRON FBN1 protein_coding Het Het Ref Ref de novo inherited 
15 57953050 A T INTRON GCOM1 protein_coding Het Het Ref Ref de novo de novo 
15 80788986 G T INTRON ARNT2 protein_coding Het Het Ref Ref de novo de novo 
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16 10858705 T A DOWNSTREAM FAM18A protein_coding Het Het Ref Ref low quality 
 
16 22695512 T G INTERGENIC 
  
Het Het Ref Ref inherited 
 
16 59139115 A G INTRON 
RP11-
410D17.2 
lincRNA Het Het Ref Ref de novo de novo 
16 84085063 G T DOWNSTREAM MBTPS1 protein_coding Het Het Ref Ref low quality 
 
16 87715100 C T INTRON JPH3 protein_coding Het Het Ref Ref de novo no variant 
16 88313175 A G INTRON 
LA16c-
444G7.1 
processed_transcript Het Het Ref Ref low quality 
 
16 88497459 G A Non_Synonymous ZNF469 protein_coding Het Het Ref Ref de novo no variant 
16 88560062 G A DOWNSTREAM ZFPM1 retained_intron Het Het Ref Ref low quality 
 
17 546943 T C INTRON VPS53 protein_coding Het Het Ref Ref inherited 
 
17 21303735 A G INTRON KCNJ12 protein_coding Het Het Ref Ref inherited 
 
17 21307296 G C INTRON KCNJ12 protein_coding Het Het Ref Ref inherited 
 
17 79276311 C T DOWNSTREAM LINC00482 lincRNA Het Het Ref Ref de novo de novo 
17 79906331 C T DOWNSTREAM NOTUM protein_coding Het Het Ref Ref inherited 
 
17 80346681 C G DOWNSTREAM C17orf101 protein_coding Het Het Ref Ref low quality 
 
17 80942321 C T DOWNSTREAM 
RP11-
1197K16.2 
antisense Het Het Ref Ref de novo N/A PCR product 
17 81024707 C T INTERGENIC 
  
Het Het Ref Ref inherited 
 
18 3412160 G A UPSTREAM TGIF1 protein_coding Het Het Ref Ref de novo inherited 
18 32459844 T C INTRON DTNA protein_coding Het Het Ref Ref de novo de novo 
18 77204733 G C INTRON NFATC1 protein_coding Het Het Ref Ref low quality 
 
19 523438 C T DOWNSTREAM TPGS1 protein_coding Het Het Ref Ref de novo N/A PCR product 
19 682321 T A DOWNSTREAM PRSS57 protein_coding Het Het Ref Ref inherited 
 
19 11564606 A C DOWNSTREAM ELAVL3 protein_coding Het Het Ref Ref low quality + no variant 
19 14732346 G A INTRON EMR3 protein_coding Het Het Ref Ref de novo uninformative 
19 39330862 A G SYNONYMOUS_CODING HNRNPL protein_coding Het Het Ref Ref low quality 
 
19 49842785 A C DOWNSTREAM TEAD2 protein_coding Het Het Ref Ref de novo no variant 
19 50197909 T G DOWNSTREAM C19orf76 protein_coding Het Het Ref Ref low quality 
 
19 53659085 C T INTRON ZNF347 protein_coding Het Het Ref Ref de novo N/A PCR product 
20 653248 C T INTRON SCRT2 protein_coding Het Het Ref Ref low quality 
 
20 14840274 T C INTRON MACROD2 protein_coding Het Het Ref Ref de novo no variant 
20 50012140 C G INTRON NFATC2 protein_coding Het Het Ref Ref de novo no variant 
20 50690005 T A INTRON ZFP64 protein_coding Het Het Ref Ref de novo N/A primer pair 
20 52184901 A C DOWNSTREAM ZNF217 protein_coding Het Het Ref Ref low quality 
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20 61607457 T C INTERGENIC 
  
Het Het Ref Ref low quality 
 
20 62836674 T C INTRON MYT1 protein_coding Het Het Ref Ref de novo N/A PCR product 
20 62866083 T G INTRON MYT1 protein_coding Het Het Ref Ref de novo N/A primer pair 
21 17686365 T A INTRON LINC00478 processed_transcript Het Het Ref Ref inherited 
 
21 23811291 C T INTERGENIC 
  
Het Het Ref Ref de novo de novo 
21 44743604 A C INTRON LINC00322 processed_transcript Het Het Ref Ref de novo inherited 
21 45206930 C T DOWNSTREAM TMEM97P1 processed_pseudogene Het Het Ref Ref low quality 
 
21 46304683 T G DOWNSTREAM ITGB2 protein_coding Het Het Ref Ref low quality 
 
22 19167292 G A DOWNSTREAM CLTCL1 nonsense_mediated_decay Het Het Ref Ref de novo de novo 
22 19704712 T G INTRON SEPT5 protein_coding Het Het Ref Ref low quality 
 
22 40898746 T C INTRON MKL1 protein_coding Het Het Ref Ref low quality 
 
22 49761849 A G INTERGENIC 
  
Het Het Ref Ref low quality 
 
22 49840787 G A INTRON C22orf34 nonsense_mediated_decay Het Het Ref Ref low quality 
 
X 2836434 G A DOWNSTREAM ARSD nonsense_mediated_decay Het Het Ref Ref de novo no variant 
X 145422663 T C INTERGENIC 
  
Het Het Ref Ref low quality 
 
 
Abbreviations used in this table: chr, chromosome; pos, position; ref, reference allele; alt, alternative allele; N/A, not available 
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Table C.2: List of the de novo SNV candidates (n=83) specific to twin I 
 
Chr Pos Ref Alt Genomic Context Gene Gene type Twin I Twin II Mother Father IGV Prediction Sanger 
1 162730172 A G INTRON DDR2 protein_coding Het Ref Ref Ref inherited 
 
1 245499265 A G INTRON KIF26B protein_coding Het Ref Ref Ref de novo inherited 
2 61728351 A T DOWNSTREAM XPO1 protein_coding Het Ref Ref Ref de novo de novo 
2 111926337 T G DOWNSTREAM BCL2L11 protein_coding Het Ref Ref Ref inherited 
 
2 241627105 T G UPSTREAM AQP12A protein_coding Het Ref Ref Ref low quality 
 
3 1493383 C T INTERGENIC 
  
Het Ref Ref Ref de novo de novo 
3 20897127 T C INTERGENIC 
  
Het Ref Ref Ref low quality 
 
3 51090509 G T INTRON DOCK3 protein_coding Het Ref Ref Ref low quality 
 
3 51441939 A C INTRON VPRBP protein_coding Het Ref Ref Ref de novo no variant 
3 66701546 T G INTERGENIC 
  
Het Ref Ref Ref low quality 
 
3 72959480 G A INTRON GXYLT2 protein_coding Het Ref Ref Ref de novo de novo 
3 135876070 C T DOWNSTREAM TDGF1P6 processed_pseudogene Het Ref Ref Ref low quality 
 
3 187442688 A C EXON BCL6 retained_intron Het Ref Ref Ref low quality 
 
3 196430415 C T DOWNSTREAM CEP19 protein_coding Het Ref Ref Ref low quality 
 
4 651520 G A DOWNSTREAM PDE6B protein_coding Het Ref Ref Ref de novo N/A PCR product 
4 6564000 G A INTRON PPP2R2C protein_coding Het Ref Ref Ref de novo de novo 
4 7920679 G A INTRON AFAP1 protein_coding Het Ref Ref Ref low quality 
 
4 189032254 C G DOWNSTREAM RP11-713C19.1 processed_pseudogene Het Ref Ref Ref low quality 
 
4 189792261 C G INTERGENIC 
  
Het Ref Ref Ref low quality 
 
5 1956661 A G INTRON RP11-259O2.1 lincRNA Het Ref Ref Ref low quality 
 
5 54561146 A G INTRON DHX29 protein_coding Het Ref Ref Ref inherited 
 
5 82195939 G A INTERGENIC 
  
Het Ref Ref Ref low quality 
 
5 141576736 A C INTERGENIC 
  
Het Ref Ref Ref inherited 
 
6 16943658 A C INTERGENIC 
  
Het Ref Ref Ref low quality 
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6 20235579 T G INTRON RP11-239H6.2 processed_transcript Het Ref Ref Ref low quality 
 
6 41586146 G A INTERGENIC 
  
Het Ref Ref Ref de novo inherited 
6 134981681 T G INTERGENIC 
  
Het Ref Ref Ref de novo no variant 
7 1824582 T C INTERGENIC 
  
Het Ref Ref Ref low quality 
 
7 1824583 G A INTERGENIC 
  
Het Ref Ref Ref inherited 
 
7 29606885 G A DOWNSTREAM PRR15 protein_coding Het Ref Ref Ref de novo de novo 
7 40103905 T G INTRON CDK13 protein_coding Het Ref Ref Ref low quality 
 
7 76922180 A C INTRON CCDC146 protein_coding Het Ref Ref Ref low quality 
 
7 155510228 T G INTRON RBM33 protein_coding Het Ref Ref Ref de novo no variant 
7 157981209 G C INTRON PTPRN2 protein_coding Het Ref Ref Ref de novo N/A PCR product 
8 66686049 G A DOWNSTREAM MTFR1 protein_coding Het Ref Ref Ref de novo uninformative 
8 118838053 A G INTRON EXT1 protein_coding Het Ref Ref Ref de novo de novo 
8 143671111 G C INTERGENIC 
  
Het Ref Ref Ref low quality 
 
9 140816091 C A INTRON CACNA1B protein_coding Het Ref Ref Ref inherited 
 
10 3940738 G A INTERGENIC 
  
Het Ref Ref Ref low quality 
 
10 10872261 G A INTERGENIC 
  
Het Ref Ref Ref low quality 
 
10 45869059 C A INTERGENIC 
  
Het Ref Ref Ref de novo N/A PCR product 
10 48410018 G C DOWNSTREAM GDF2 protein_coding Het Ref Ref Ref low quality 
 
10 77154164 C T DOWNSTREAM ZNF503 protein_coding Het Ref Ref Ref low quality 
 
11 65374709 T G DOWNSTREAM MAP3K11 protein_coding Het Ref Ref Ref low quality 
 
12 653012 T C INTRON B4GALNT3 protein_coding Het Ref Ref Ref de novo N/A primer pair 
12 9557500 T C INTRON RP11-599J14.2 unprocessed_pseudogene Het Ref Ref Ref de novo no variant 
12 64229411 T G INTERGENIC 
  
Het Ref Ref Ref low quality 
 
12 95569608 G A INTRON FGD6 protein_coding Het Ref Ref Ref de novo uninformative 
12 131691875 G A INTRON RP11-638F5.1 lincRNA Het Ref Ref Ref de novo inherited 
12 133052676 T C INTERGENIC 
  
Het Ref Ref Ref low quality 
 
12 133352895 G C INTRON GOLGA3 protein_coding Het Ref Ref Ref de novo N/A PCR product 
13 51812216 T G INTRON FAM124A protein_coding Het Ref Ref Ref low quality 
 
13 87083684 C A INTERGENIC 
  
Het Ref Ref Ref low quality 
 
14 52997360 A T INTRON TXNDC16 protein_coding Het Ref Ref Ref low quality 
 
14 80678369 C T INTRON DIO2 protein_coding Het Ref Ref Ref low quality 
 
14 100044559 A G INTRON CCDC85C protein_coding Het Ref Ref Ref no variant 
 
16 1970303 A G INTERGENIC 
  
Het Ref Ref Ref low quality 
 
16 10858718 A G DOWNSTREAM FAM18A protein_coding Het Ref Ref Ref low quality 
 
16 50424085 G A DOWNSTREAM RP11-21B23.2 lincRNA Het Ref Ref Ref de novo de novo 
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16 70714811 C G INTRON MTSS1L protein_coding Het Ref Ref Ref low quality 
 
16 77724703 G T INTERGENIC 
  
Het Ref Ref Ref low quality 
 
17 92938 C T DOWNSTREAM RPH3AL protein_coding Het Ref Ref Ref low quality 
 
17 71734490 T C INTRON CTD-2532D12.4 lincRNA Het Ref Ref Ref inherited 
 
17 73824833 G C DOWNSTREAM UNK protein_coding Het Ref Ref Ref low quality 
 
18 34970824 C T INTRON CELF4 protein_coding Het Ref Ref Ref de novo uninformative 
18 50453718 G T INTRON DCC protein_coding Het Ref Ref Ref de novo N/A PCR product 
19 309882 A G DOWNSTREAM CTD-3113P16.5 antisense Het Ref Ref Ref no variant 
 
19 33105233 T G INTRON ANKRD27 protein_coding Het Ref Ref Ref low quality 
 
20 53271335 C T DOWNSTREAM DOK5 protein_coding Het Ref Ref Ref de novo de novo 
20 56815552 G C DOWNSTREAM PPP4R1L processed_transcript Het Ref Ref Ref low quality 
 
20 62810452 T C INTRON MYT1 protein_coding Het Ref Ref Ref inherited 
 
21 34512162 C A INTERGENIC 
  
Het Ref Ref Ref low quality 
 
X 2833489 C G DOWNSTREAM ARSD retained_intron Het Ref Ref Ref de novo N/A primer pair 
X 7544103 T C INTERGENIC 
  
Het Ref Ref Ref de novo N/A primer pair 
X 7544110 T C INTERGENIC 
  
Het Ref Ref Ref low quality 
 
X 10107413 T A INTRON WWC3 protein_coding Het Ref Ref Ref low quality 
 
X 68384591 T G INTRON PJA1 protein_coding Hom Ref Ref Ref low quality 
 
X 116523014 T A INTERGENIC 
  
Het Ref Ref Ref low quality 
 
X 144597115 T A INTERGENIC 
  
Het Ref Ref Ref low quality 
 
X 144597121 C A INTERGENIC 
  
Hom Ref Ref Ref de novo N/A primer pair 
X 148731301 C A EXON RP5-937E21.1 processed_pseudogene Het Ref Ref Ref de novo no variant 
X 150242328 A G INTERGENIC 
  
Het Ref Ref Ref no variant 
 
Y 8094333 C A INTERGENIC     Het Ref Ref Ref de novo N/A primer pair 
 
Abbreviations used in this table: chr, chromosome; pos, position; ref, reference allele; alt, alternative allele; N/A, not available 
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Table C.3: List of the de novo SNV candidates (n=48) specific to twin II 
 
Chr Pos Ref Alt Genomic Context Gene Gene type Twin I Twin II Mother Father IGV Prediction Sanger 
1 211950090 G A DOWNSTREAM LPGAT1 processed_transcript Ref Het Ref Ref de novo no variant 
1 228146563 C A INTERGENIC 
  
Ref Het Ref Ref de novo no variant 
2 362130 G T INTERGENIC 
  
Ref Het Ref Ref inherited 
 
2 362131 A T INTERGENIC 
  
Ref Het Ref Ref inherited 
 
2 1404408 C A INTRON TPO processed_transcript Ref Het Ref Ref low quality 
 
2 10476221 G T INTRON HPCAL1 protein_coding Ref Het Ref Ref inherited 
 
2 70925457 G T INTRON ADD2 protein_coding Ref Het Ref Ref de novo no variant 
2 154061708 G T DOWNSTREAM AC079150.2 processed_pseudogene Ref Het Ref Ref low quality 
 
2 241992247 C T DOWNSTREAM SNED1 retained_intron Ref Het Ref Ref de novo uninformative 
4 3827696 A C INTERGENIC 
  
Ref Het Ref Ref low quality 
 
5 194385 A C DOWNSTREAM PLEKHG4B protein_coding Ref Het Ref Ref low quality 
 
5 16525233 G A INTRON FAM134B protein_coding Ref Het Ref Ref inherited 
 
5 137885670 T A DOWNSTREAM HSPA9 protein_coding Ref Het Ref Ref inherited 
 
6 57541536 G T INTERGENIC 
  
Ref Het Ref Ref inherited 
 
6 86090624 G A INTERGENIC 
  
Ref Het Ref Ref low quality 
 
6 133966995 G T INTERGENIC 
  
Ref Het Ref Ref de novo no variant 
7 10338952 G T INTERGENIC 
  
Ref Het Ref Ref low quality 
 
7 56559682 A G DOWNSTREAM RBM22P3 processed_pseudogene Ref Het Ref Ref low quality 
 
7 158204835 C T INTRON PTPRN2 protein_coding Ref Het Ref Ref de novo N/A Primer Pair 
7 158248408 C T INTRON PTPRN2 protein_coding Ref Het Ref Ref low quality 
 
8 142602825 C T INTERGENIC 
  
Ref Het Ref Ref low quality 
 
9 14347587 G A INTRON NFIB protein_coding Ref Het Ref Ref de novo inherited 
9 106166434 C T INTRON 
RP11-
436F21.1 
lincRNA Ref Het Ref Ref low quality 
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10 3357139 G A INTERGENIC 
  
Ref Het Ref Ref low quality 
 
10 30518280 A G INTERGENIC 
  
Ref Het Ref Ref low quality 
 
11 1474891 G T INTRON BRSK2 protein_coding Ref Het Ref Ref de novo no variant 
11 129307937 T A INTRON BARX2 protein_coding Ref Het Ref Ref low quality 
 
12 132353193 A C DOWNSTREAM 
RP11-
417L19.2 
lincRNA Ref Het Ref Ref de novo N/A PCR product 
13 114617416 G A INTRON LINC00452 lincRNA Ref Het Ref Ref low quality 
 
13 114619650 A G INTRON LINC00452 lincRNA Ref Het Ref Ref low quality 
 
15 76884600 G T INTRON SCAPER protein_coding Ref Het Ref Ref low quality 
 
16 62015587 C T INTRON CDH8 protein_coding Ref Het Ref Ref de novo no variant 
17 4782495 T G DOWNSTREAM Metazoa_SRP misc_RNA Ref Het Ref Ref low quality 
 
17 79646774 T G DOWNSTREAM ARL16 protein_coding Ref Het Ref Ref low quality 
 
17 81042516 T C INTRON METRNL protein_coding Ref Het Ref Ref low quality 
 
18 18623582 G A DOWNSTREAM ROCK1 retained_intron Ref Het Ref Ref low quality 
 
21 36322701 A G INTRON RUNX1 protein_coding Ref Het Ref Ref de novo de novo 
21 47479749 C T DOWNSTREAM AP001476.3 lincRNA Ref Het Ref Ref de novo N/A Primer Pair 
21 47479750 C G DOWNSTREAM AP001476.3 lincRNA Ref Het Ref Ref low quality 
 
X 7320881 C G INTERGENIC 
  
Ref Het Ref Ref de novo no variant 
X 71177022 T C INTRON NHSL2 protein_coding Ref Het Ref Ref de novo no variant 
X 71177023 A T INTRON NHSL2 protein_coding Ref Het Ref Ref de novo no variant 
X 104517151 A G INTRON IL1RAPL2 protein_coding Ref Het Ref Ref de novo no variant 
X 122224237 A G INTERGENIC 
  
Ref Het Ref Ref no variant 
 
X 123370010 C T INTRON STAG2 processed_transcript Ref Het Ref Ref low quality 
 
X 128927246 C G INTRON SASH3 protein_coding Ref Het Ref Ref de novo no variant 
X 134054617 A C INTERGENIC 
  
Ref Het Ref Ref no variant 
 
X 134054618 A T INTERGENIC     Ref Het Ref Ref de novo no variant 
 
Abbreviations used in this table: chr, chromosome; pos, position; ref, reference allele; alt, alternative allele; N/A, not available 
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Appendix D 
Electropherograms for the Shared De Novo 
SNVs Validated through Sanger Sequencing 
 
 
 
 
Figure D.1: Electropherogram for the 2 de novo SNVs shared by the twin pair 
(Chromosome1: 165599592: G/C and Chromosome1: 165599593: T/G). 
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Figure D.2: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome1: 245093862: G/A). 
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Figure D.3: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome2: 136342189: G/A). 
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Figure D.4: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome4: 145566227: C/T). 
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Figure D.5: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome5: 11043438: T/G). 
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Figure D.6: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome6: 29101417: C/T). 
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Figure D.7: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome6: 162458275: T/C). 
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Figure D.8: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome7: 141955453: A/G). 
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Figure D.9: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome9: 32917739: C/T). 
 
 
 
 
 
 
 
154 
 
 
 
 
 
 
 
 
 
Figure D.10: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome10: 102527333: C/T). 
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Figure D.11: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome10: 128805987: G/A). 
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Figure D.12: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome12: 3527384: T/C). 
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Figure D.13: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome13: 97503636: T/C). 
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Figure D.14: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome14: 32048285: T/A). 
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Figure D.15: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome15: 57953050: A/T). 
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Figure D.16: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome15: 80788986: G/T). 
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Figure D.17: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome16: 59139115: A/G). 
 
 
 
 
 
 
 
162 
 
 
 
 
 
 
 
 
 
Figure D.18: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome17: 79276311: C/T). 
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Figure D.19: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome18: 32459844: T/C). 
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Figure D.20: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome21: 23811291: C/T). 
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Figure D.21: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome22: 19167292: G/A). 
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Figure D.22: Electropherogram for the de novo SNV shared by the twin pair 
(Chromosome10: 133937827: C/T). 
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Appendix E 
Electropherograms for the Twin-Specific De 
Novo SNVs Validated through Sanger 
Sequencing 
 
 
 
Figure E.1: Electropherogram for the de novo SNV specific to Twin-I 
(Chromosome2: 61728351: A/T). 
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Figure E.2: Electropherogram for the de novo SNV specific to Twin-I 
(Chromosome3: 1493383: C/T). 
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Figure E.3: Electropherogram for the de novo SNV specific to Twin-I 
(Chromosome3: 72959480: G/A). 
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Figure E.4: Electropherogram for the de novo SNV specific to Twin-I 
(Chromosome4: 6564000: G/A). 
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Figure E.5: Electropherogram for the de novo SNV specific to Twin-I 
(Chromosome7: 29606885: G/A). 
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Figure E.6: Electropherogram for the de novo SNV specific to Twin-I 
(Chromosome8: 118838053: A/G). 
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Figure E.7: Electropherogram for the de novo SNV specific to Twin-I 
(Chromosome16: 50424085: G/A). 
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Figure E.8: Electropherogram for the de novo SNV specific to Twin-I 
(Chromosome20: 53271335: C/T). 
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Figure E.9: Electropherogram for the de novo SNV specific to Twin-II 
(Chromosome21: 36322701: A/G).  
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Appendix F 
Electropherograms for the De Novo SNVs 
Tested in the Parental Endoderm- and 
Ectoderm- -Derived DNA Samples 
 
 
Figure F.1: Electropherogram of the Sanger sequencing of the parental mouthwash 
and urine sample-derived DNA for the de novo SNV shared by the twin pair 
(Chromosome1: 245093862: G/A) 
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Figure F.2: Electropherogram of the Sanger sequencing of the parental mouthwash 
and urine sample-derived DNA for the de novo SNV shared by the twin pair 
(Chromosome5: 11043438: T/G). 
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Figure F.3: Electropherogram of the Sanger sequencing of the parental mouthwash 
and urine sample-derived DNA for the de novo SNV shared by the twin pair 
(Chromosome6: 29101417: C/T). 
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Figure F.4: Electropherogram of the Sanger sequencing of the parental mouthwash 
and urine sample-derived DNA for the de novo SNV shared by the twin pair 
(Chromosome7: 141955453: A/G). 
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Figure F.5: Electropherogram of the Sanger sequencing of the parental mouthwash 
and urine sample-derived DNA for the de novo SNV shared by the twin pair 
(Chromosome10: 128805987: G/A). 
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Figure F.6: Electropherogram of the Sanger sequencing of the parental mouthwash 
and urine sample-derived DNA for the de novo SNV shared by the twin pair 
(Chromosome12: 3527384: T/C). 
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Figure F.7: Electropherogram of the Sanger sequencing of the parental mouthwash 
and urine sample-derived DNA for the de novo SNV shared by the twin pair 
(Chromosome14: 32048285: T/A). 
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Figure F.8: Electropherogram of the Sanger sequencing of the parental mouthwash 
and urine sample-derived DNA for the de novo SNV shared by the twin pair 
(Chromosome16: 59139115: A/G). 
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Figure F.9: Electropherogram of the Sanger sequencing of the parental mouthwash 
and urine sample-derived DNA for the de novo SNV shared by the twin pair 
(Chromosome17: 79276311: C/T). 
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Figure F.10: Electropherogram of the Sanger sequencing of the parental mouthwash 
and urine sample-derived DNA for the de novo SNV shared by the twin pair 
(Chromosome21: 23811291: C/T). 
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Appendix G 
Heterozygous LoF Mutations Present in the Genomes of the Twin Pair 
 
 
Table G.1: List of novel heterozygous LoF mutations present in the genomes of the twin pair 
 
Chr Position Ref Alt Gene Function 1000G OMIM Disease Inheritance 
1 17085995 - C MST1L frameshift insertion NA - - 
1 54605318 - GG CDCP2 frameshift insertion NA - - 
1 112020739 A - C1orf162 frameshift deletion NA - - 
3 44763789 AGTG - ZNF502 frameshift deletion NA - - 
3 53910109 - G ACTR8 splice site NA - - 
3 54952510 CT - LRTM1 frameshift deletion NA - - 
3 121207510 AATAGTA - POLQ frameshift deletion NA - - 
4 54327211 - A LNX1) splice site NA - - 
5 171765480 CAAA - SH3PXD2B frameshift deletion NA  FRANK-TER HAAR SYNDROME (#249420) AR 
6 90577707 G - CASP8AP2 frameshift deletion NA - - 
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6 90577712 CTTTGCCCAGACATGGA - CASP8AP2 frameshift deletion NA - - 
7 81695842 - A CACNA2D1 splice site NA - - 
8 90796369 - A RIPK2 splice site NA - - 
8 103250839 - G RRM2B frameshift insertion 0.06  PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA (#613077) AD 
9 40774307 CTCC - ZNF658 frameshift deletion NA - - 
9 125273385 - T OR1J2 frameshift insertion 0.06 - - 
10 27702260 - T PTCHD3 frameshift insertion NA - - 
10 37425563 C T ANKRD30A stopgain SNV NA 
  11 1016471 T - MUC6 frameshift deletion NA - - 
11 4592708 - AG C11orf40 frameshift insertion 0.62 - - 
11 10711918 - A MRVI1 splice site NA - - 
12 48596875 - A OR10AD1 frameshift insertion 0.21 - - 
13 31287978 - GTGT ALOX5AP frameshift insertion NA  STROKE, ISCHEMIC susceptibility (#601367) - 
13 78173524 G A SCEL splice site NA - - 
16 1823390 G - EME2 frameshift deletion NA - - 
16 55844924 - A CES1 splice site NA - - 
17 46882287 CTTTCCAAAGTCGGGCA - TTLL6 frameshift deletion NA - - 
17 57141768 - A TRIM37 splice site NA  MULIBREY NANISM (#253250) AR 
19 20045260 AT - ZNF93 frameshift deletion NA - - 
19 35612163 CC - FXYD3 frameshift deletion NA - - 
19 53046581 - AA ZNF808 frameshift insertion NA - - 
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Table G.2: List of dbSNP137-reported (MAF < 0.01) heterozygous LoF mutations present in the genomes of the twin pair 
 
Chr Position Ref Alt Gene Function 1000G dbSNP137 OMIM Disease Inheritance 
6 109589014 T A LOC100996634 stopgain SNV 0.0005 rs191936197 - - 
12 53167416 C A KRT76 stopgain SNV 0.0037 rs149868801 - - 
3 112253058 - A ATG3 frameshift insertion NA rs139705694 - - 
6 31380161 - CT MICA frameshift insertion NA rs41293539 - - 
10 51768675 AA - AGAP6 frameshift deletion NA rs141217862 - - 
16 450140 - AG NME4 frameshift insertion NA rs35963490 - - 
16 58577316 A - CNOT1 frameshift deletion NA rs5817153 - - 
17 17697102 G - RAI1 frameshift deletion NA rs34083643 SMITH-MAGENIS SYNDROME (#182290) AD 
18 42456670 - TCTT SETBP1 frameshift insertion NA rs3085861 SCHINZEL-GIEDION MIDFACE RETRACTION SYNDROME (#269150) AD 
5 132085115 G C CCNI2 splice site 0.0005 rs140882152 - - 
10 46965887 - G SYT15 splice site NA rs112965082 - - 
10 50507279 G A C10orf71 splice site 0.0009 rs150519054 - - 
12 56500502 - A PA2G4 splice site NA rs34728522 - - 
21 47707039 - AAAAAA YBEY splice site NA rs71318058 - - 
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Appendix H 
Homozygous LoF Mutations Present in the Genomes of the Parents 
 
Table H.1: List of novel homozygous LoF mutations present in the genome of the mother 
 
Chr Position Ref Alt Gene Function 1000G  OMIM Disease Inheritance 
1 152195729 T - HRNR frameshift deletion NA - - 
10 116931101 - TT ATRNL1 frameshift insertion 0.96 - - 
11 76954788 - A GDPD4 frameshift insertion 0.23 - - 
12 55714406 - A OR6C1 frameshift insertion 0.34 - - 
17 6555546 - G C17orf100 frameshift insertion 1.00 - - 
17 71752500 - T LOC100134391 frameshift insertion 1.00 - - 
19 51835892 - G VSIG10L frameshift insertion NA - - 
X 122336600 - G GRIA3 frameshift insertion 1.00 MENTAL RETARDATION, X-LINKED (#300699) XR 
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8 103250839 - G RRM2B frameshift insertion 0.06 PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA (#613077) AD 
9 40774307 CTCC - ZNF658 frameshift deletion NA - - 
4 6086694 - A JAKMIP1 splice site NA - - 
16 55844924 - A CES1 splice site NA - - 
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Table H.2: List of dbSNP137-reported (MAF < 0.01) homozygous LoF mutations present in the genome of the mother 
 
Chr Position Ref Alt Gene Function 1000G snp137 OMIM Disease Inheritance 
1 156565049 - AC GPATCH4 
frameshift 
insertion NA rs112595382 - - 
3 129814935 C - ALG1L2 
frameshift 
deletion NA rs55800015 - - 
5 156721863 - C CYFIP2 
frameshift 
insertion NA rs76159126 - - 
5 175811094 - GT NOP16 
frameshift 
insertion NA rs78549596 - - 
10 51768675 AA - AGAP6 
frameshift 
deletion NA rs141217862 - - 
15 31521506 GG - 
RP11-
16E12.2 
frameshift 
deletion NA rs141879900 - 
- 
 
16 89291210 - GTGA ZNF778 
frameshift 
insertion NA rs113560259 - - 
22 19189003 - C CLTCL1 
frameshift 
insertion NA rs78649162 - - 
X 101395780 - G TCEAL6 
frameshift 
insertion NA rs200987681 - - 
3 52872001 TGTGTGTGCACGTGCACG - TMEM110 splice site NA rs113892040 - - 
9 73458045 - A TRPM3 splice site NA rs3833697 - - 
11 46342259 - G CREB3L1 splice site NA rs79068197 - - 
11 95615662 TAAAA - MTMR2 splice site NA rs112378876 
CHARCOT-MARIE-TOOTH DISEASE, TYPE 
4B1(#601382) AR 
12 7080212 T C EMG1 splice site NA rs17857448 - - 
17 61660890 G - DCAF7 splice site NA rs66502552 - - 
19 16268208 A - HSH2D splice site NA rs5827321 - - 
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Table H.3: List of novel homozygous LoF mutations present in the genome of the father 
 
Chr Position Ref Alt Gene Function 1000G  OMIM Disease Inheritance 
1 17085995 - C MST1L frameshift insertion NA - - 
1 54605318 - GG CDCP2 frameshift insertion NA - - 
1 152195729 T - HRNR frameshift deletion NA - - 
3 53910109 - G ACTR8 splice site NA - - 
4 6086694 - A JAKMIP1 splice site NA - - 
9 70900911 - A CBWD3 frameshift insertion NA - - 
9 125273385 - T OR1J2 frameshift insertion 0.06 - - 
10 27702260 - T PTCHD3 frameshift insertion NA - - 
10 116931101 - TT ATRNL1 frameshift insertion 0.96 - - 
12 55714406 - A OR6C1 frameshift insertion 0.34 - - 
17 6555546 - G C17orf100 frameshift insertion 1.00 - - 
17 71752500 - T LOC100134391 frameshift insertion 1.00 - - 
19 51835892 - G VSIG10L frameshift insertion NA - - 
X 122336600 - G GRIA3 frameshift insertion 1.00 MENTAL RETARDATION, X-LINKED (#300699) XR 
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Table H.4: List of dbSNP137-reported (MAF < 0.01) homozygous LoF mutations present in the genome of the father 
 
Chr Position Ref Alt Gene Function 1000G snp137 OMIM Disease Inheritance 
1 156565049 - AC GPATCH4 frameshift insertion NA rs112595382 - - 
5 156721863 - C CYFIP2 frameshift insertion NA rs76159126 - - 
5 175811094 - GT NOP16 frameshift insertion NA rs78549596 - - 
15 31521506 GG - RP11-16E12.2 frameshift deletion NA rs141879900 - - 
16 89291210 - GTGA ZNF778 frameshift insertion NA rs113560259 - - 
22 19189003 - C CLTCL1 frameshift insertion NA rs78649162 - - 
X 101395780 - G TCEAL6 frameshift insertion NA rs200987681 - - 
3 52872001 TGTGTGTGCACGTGCACG - TMEM110 splice site NA rs113892040 - - 
11 46342259 - G CREB3L1 splice site NA rs79068197 - - 
11 95615662 TAAAA - MTMR2 splice site NA rs112378876 CHARCOT-MARIE-TOOTH DISEASE  (#601382) AR 
12 7080212 T C EMG1 splice site NA rs17857448 - - 
17 61660890 G - DCAF7 splice site NA rs66502552 - - 
19 16268208 A - HSH2D splice site NA rs5827321 - - 
X 36162684 - TG CHDC2 frameshift insertion NA rs201605278 - - 
18 74208486 G - FLJ44313 splice site NA rs3841258 - - 
3 112253058 - A ATG3 frameshift insertion NA rs139705694 - - 
16 450140 - AG NME4 frameshift insertion NA rs35963490 - - 
16 58577316 A - CNOT1 frameshift deletion NA rs5817153 - - 
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Appendix I 
Heterozygous LoF Mutations Present in the Genomes of the Parents 
 
Table I.1: List of novel heterozygous LoF mutations present in the genome of the mother 
 
Chr Position Ref Alt Gene Function 1000G  OMIM Disease Inheritance 
3 121207510 AATAGTA - POLQ frameshift deletion NA - - 
5 139931628 - GT SRA1 frameshift insertion NA CAMPOMELIC DYSPLASIA (#114290) AD 
5 139931629 - G SRA1 frameshift insertion NA CAMPOMELIC DYSPLASIA (#114290) AD 
5 171765480 CAAA - SH3PXD2B frameshift deletion NA  FRANK-TER HAAR SYNDROME (#249420) AR 
6 90577707 G - CASP8AP2 frameshift deletion NA - - 
6 90577712 CTTTGCCCAGACATGGA - CASP8AP2 frameshift deletion NA - - 
8 90796369 - A RIPK2 splice site NA - - 
8 96047806 - A NDUFAF6 splice site NA - - 
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9 70900911 - A CBWD3 frameshift insertion NA - - 
10 37425563 C T ANKRD30A stopgain SNV NA 
  11 10711918 - A MRVI1 splice site NA - - 
13 31287978 - GTGT ALOX5AP frameshift insertion NA  STROKE, ISCHEMIC susceptibility (#601367) - 
13 78173524 G A SCEL splice site NA - - 
16 1823390 G - EME2 frameshift deletion NA - - 
17 57141768 - A TRIM37 splice site NA  MULIBREY NANISM (#253250) AR 
19 20045260 AT - ZNF93 frameshift deletion NA - - 
19 35612163 CC - FXYD3 frameshift deletion NA - - 
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Table I.2: List of dbSNP137-reported heterozygous LoF mutations present in the genome of the mother 
 
Chr Position Ref Alt Gene Function 1000G dbSNP137 
OMIM 
Disease Inheritance 
6 109589014 T A LOC100996634 stopgain SNV 0.0005 rs191936197 - - 
X 36162684 - TG CHDC2 frameshift insertion NA rs201605278 - - 
18 74208486 G - FLJ44313 splice site NA rs3841258 - - 
 
 
 
Table I.3: List of novel heterozygous LoF mutations present in the genome of the father 
 
Chr Position Ref Alt Gene Function 1000G  OMIM Disease Inheritance 
5 139931628 - GT SRA1 frameshift insertion NA CAMPOMELIC DYSPLASIA (#114290) AD 
5 139931629 - G SRA1 frameshift insertion NA CAMPOMELIC DYSPLASIA (#114290) AD 
8 96047806 - A NDUFAF6 splice site NA - - 
11 76954788 - A GDPD4 frameshift insertion 0.23 - - 
1 112020739 A - C1orf162 frameshift deletion NA - - 
3 44763789 AGTG - ZNF502 frameshift deletion NA - - 
3 54952510 CT - LRTM1 frameshift deletion NA - - 
11 1016471 T - MUC6 frameshift deletion NA - - 
11 4592708 - AG C11orf40 frameshift insertion 0.62 - - 
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12 48596875 - A OR10AD1 frameshift insertion 0.21 - - 
17 46882287 CTTTCCAAAGTCGGGCA - TTLL6 frameshift deletion NA - - 
19 53046581 - AA ZNF808 frameshift insertion NA - - 
4 54327211 - A LNX1) splice site NA - - 
7 81695842 - A CACNA2D1 splice site NA - - 
 
 
 
 
Table I.4: List of dbSNP137-reported heterozygous LoF mutations present in the genome of the father 
 
Chr Position Ref Alt Gene Function 1000G dbSNP137 OMIM Disease Inheritance 
3 129814935 C - ALG1L2 frameshift deletion NA rs55800015 - - 
9 73458045 - A TRPM3 splice site NA rs3833697 - - 
12 53167416 C A KRT76 stopgain SNV 0.0037 rs149868801 - - 
6 31380161 - CT MICA frameshift insertion NA rs41293539 - - 
17 17697102 G - RAI1 frameshift deletion NA rs34083643 SMITH-MAGENIS SYNDROME (#182290) AD 
18 42456670 - TCTT SETBP1 frameshift insertion NA rs3085861 
SCHINZEL-GIEDION MIDFACE RETRACTION SYNDROME 
(#269150) AD 
5 132085115 G C CCNI2 NA 0.0005 rs140882152 - - 
10 46965887 - G SYT15 NA NA rs112965082 - - 
10 50507279 G A C10orf71 NA 0.0009 rs150519054 - - 
12 56500502 - A PA2G4 NA NA rs34728522 - - 
21 47707039 - AAAAAA YBEY NA NA rs71318058 - - 
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ABSTRACT
Background Human de novo single-nucleotide
variation (SNV) rate is estimated to range between
0.82–1.70×10−8 mutations per base per generation.
However, contribution of early postzygotic mutations
to the overall human de novo SNV rate is unknown.
Methods We performed deep whole-genome
sequencing (more than 30-fold coverage per individual)
of the whole-blood-derived DNA samples of a healthy
monozygotic twin pair and their parents. We examined
the genotypes of each individual simultaneously for each
of the SNVs and discovered de novo SNVs regarding the
timing of mutagenesis. Putative de novo SNVs were
validated using Sanger-based capillary sequencing.
Results We conservatively characterised 23 de novo
SNVs shared by the twin pair, 8 de novo SNVs speciﬁc
to twin I and 1 de novo SNV speciﬁc to twin II. Based
on the number of de novo SNVs validated by Sanger
sequencing and the number of callable bases of each
twin, we calculated the overall de novo SNV rate of
1.31×10−8 and 1.01×10−8 for twin I and twin II,
respectively. Of these, rates of the early postzygotic de
novo SNVs were estimated to be 0.34×10−8 for twin
I and 0.04×10−8 for twin II.
Conclusions Early postzygotic mutations constitute a
substantial proportion of de novo mutations in humans.
Therefore, genome mosaicism resulting from early mitotic
events during embryogenesis is common and could
substantially contribute to the development of diseases.
INTRODUCTION
Mutations provide the means of genetic diversity
on which natural selection operates. Characterising
the patterns and rate of de novo mutations is
crucial to the understanding of mutational pro-
cesses that may lead to evolution and human
disease.1 Recent studies based on the direct obser-
vation of de novo single-nucleotide variation (SNV)
in parent–offspring trios revealed a rate that spans
a wide range (0.82–1.70×10−8 mutations per base
per generation).2 3 However, the proportion of pre-
zygotic versus early postzygotic mutations within
the de novo mutation rate is not yet known.
In an attempt to further elucidate the origins of
de novo mutations, we performed deep whole-
genome sequencing of a healthy monozygotic twin
pair and their parents (ﬁgure 1A). Our working
hypothesis is that those de novo mutations
observed in only one twin would be of mitotic
origin, occur early during development possibly in
the post-twinning embryo and be detectable in
whole-blood-derived constitutive DNA (ﬁgure 1B).
We indeed observed, following a conservative char-
acterisation and validation, 23 shared, 8 twin
I-speciﬁc and 1 twin II-speciﬁc de novo SNVs
(table 1). These results implicate that a substantial
proportion of de novo SNVs in the genome of an
individual could be of early postzygotic origin.
STUDY SAMPLES AND METHODS
Study samples
A quad family consisting of a male 25-year-old
healthy monozygotic twin pair and their parents
(59 and 49 years old) participated in this study.
They were recruited to the control group of a study
on movement disorders, which was approved by
the institutional review boards (IRB) at Bilkent,
Hacettepe, Başkent and Çukurova Universities
(decisions: BEK02, 28.08.2008; TBK08/4,
22.04.2008; KA07/47, 02.04.2007; and 21/3,
08.11.2005, respectively). Zygosity of the twin pair
was assessed by comparing the SNVs of each twin
(99.8% similar). A Mendelian disorder has not
been documented in the family. The participants
had no exposure to chemotherapeutics. Written
informed consent prepared according to the guide-
lines of the Ministry of Health in Turkey was
attained from all individuals prior to the initiation
of this study. Blood, buccal smear and urine
samples were obtained from all participants. DNA
isolation from whole blood of each individual was
done using NucleoSpin Blood (Macherey-Nagel)
kit, according to the manufacturer’s protocol.
Buccal smear and urine cell-derived DNA were iso-
lated using DNeasy Tissue Kit (QIAGEN).
Whole-genome sequencing
Whole-genome sequencing data were generated
from blood DNA using Illumina HiSeq 2000
instrument. DNA samples were prepared for
whole-genome sequencing using Illumina TruSeq
DNA sample preparation kit according to the man-
ufacturer’s recommended protocols. For each of
the parent single library and for each of the twins
two libraries were prepared. For library prepar-
ation, 1–3 μg of genomic DNA was fragmented
through sonication. The resulting DNA fragments
were end-repaired and adapter ligation was done.
End-repaired and adapter-ligated DNA fragments
were run on 2% agarose gel for size selection.
Following the isolation of the fragments of
approximately 400 bp in size from the gel using
QIAGEN MinElute Gel Extraction Kit, size-
selected libraries were subjected to PCR ampliﬁca-
tion. Enriched libraries were puriﬁed and their
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Figure 1 Discovery and characterisation of de novo single-nucleotide variations (SNVs) in a monozygotic twin pair. (A) Pedigree of the
whole-genome sequenced quad family. (B) Prezygotic versus postzygotic de novo SNVs found in twins I and II. (C) Annotation of the putative de
novo SNVs against human database GRCh37.68 using SnpEff,13 twin I and twin II: de novo SNVs shared between the twin pair. Twin I, twin II: twin
I-speciﬁc and twin II-speciﬁc de novo SNVs, respectively. The number of validated SNVs is shown above each bar. The only validated exonic SNV
shared by the twins is a synonymous mutation in PRSS58. (D) Sanger sequencing chromatogram for a twin I-speciﬁc intronic de novo SNV (XPO1
gene, chr2: 61728351, A>T).
Table 1 De novo mutations of the twin pair and the mutation rate estimation
All SNVs* Novel SNVs† De novo SNVs‡ Validated de novo SNVs§ Mutation rate (×10−8)¶
Sample dbSNP137 Novel Inherited De novo** Group I†† Group II‡‡ Total Group I Group II Total Group I Group II Total
Twin I 3 446 849 49 800 48 405 1396 159 83 242 23 8 31 0.97 0.34 1.31
Twin II 3 443 828 49 182 47 810 1372 48 207 1 24 0.04 1.01
*Number of all SNVs based on the variants calling through GATK.
†Number of SNVs that are not reported dbSNP137.
‡Number of de novo SNVs after applying filters (see online supplementary tables S5–S7).
§De novo SNVs validated through Sanger sequencing.
¶Mutation rate calculated based on the validated de novo SNVs and callable bases of each twin.
**Number of novel SNVs detected as de novo before applying filters (see online supplementary tables S5–S7).
††De novo SNVs classified as occurred in parental gametes or before separation of the zygote into two embryos.
‡‡De novo SNVs classified as occurred after separation of the zygote into two embryos but very early during development.
GATK, Genome Analysis Toolkit; SNV, single-nucleotide variation.
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quality was controlled with respect to the recommendations
provided by Illumina. Resulting libraries were sequenced on
eight lanes for each twin and four lanes for each parent using an
Illumina Hiseq 2000 instrument, employing 2×101–104 cycles
of incorporation. Imaging was performed using Illumina SBS
kits TruSeq V.3. Image analysis and base calling were done using
Illumina’s Real Time Analysis software V.1.13 with default
parameters.
Analysis of the whole-genome sequencing data
We converted base calling data into FASTQ ﬁles by using
Illumina’s CASAVA V.1.8.2 software package. The paired-end
reads were aligned to the NCBI Build 37 version (GRCh37) of
the human reference genome using Burrows-Wheeler Aligner
(BWA)4 V.0.6.1 with standard parameters. BAM ﬁles were gener-
ated from the resulting alignment ﬁles and merged into a single
BAM ﬁle using SAMtools5 V.0.1.18. We also used SAMtools to
mark and remove the PCR duplicates found in the resulting
BAM ﬁle. SNVs and insertions and/or deletions (indels) were
discovered using Genome Analysis Toolkit (GATK)6 software
V.1.6–13 with standard ﬁltering parameters. In order to minim-
ise spurious SNV calls due to misalignment of bases in regions
around indels, the reads were locally realigned using
RealignerTargetCreator and IndelRealigner tools of GATK.
UniﬁedGenotyper tool of GATK was used to generate an initial
list of raw variants. Finally, variant recalibration with the variant
quality score recalibration was applied to the SNVs/indels in
order to generate the ﬁnal list of variants of four individuals in
a single VCF ﬁle. GATK-recommended hard ﬁltering for very
low quality call-sets was applied with ‘AB <0.2||MQ0 >50||SB
>−0.10||QUAL <10’ parameters.
Discovery of the putative de novo SNVs shared by the twins
(group I)
We used the following approaches to discover putative de novo
SNVs and to classify them according to the timing of mutagen-
esis. We selectively extracted SNVs (both novel and reported in
dbSNP137) using GATK’s ‘SelectVariants’ module. We compared
the genotypes of the parents and the twin pair for each of the
SNVs concurrently using SnpSift7 V.1.1.3. We evaluated all pos-
sible genotype combinations, including those that could be classi-
ﬁed as genotyping errors (such as those SNVs in a homozygous
state in one of the twins yet not present in one of the parents).
Using BEDtools,8 we ﬁrst ﬁltered the SNVs reported in SNP data-
base dbSNP137. Novel putative de novo SNVs were removed
when they were in non-variant sites or in sites for which the read
depth is less than 3 in each individual simultaneously. We ﬁltered
the variants intersecting segmental duplications and/or simple
repeats in the genome using the intersectBed tool within the
BEDtools8 suite. Finally, we excluded de novo SNV candidates
classiﬁed as genotyping errors. Remaining de novo SNV candi-
dates were selected for further analysis. We considered the timing
of mutagenesis for the shared de novo SNVs as parental or post-
zygotic yet prior to twining.
Discovery of twin-speciﬁc putative de novo SNVs (group II)
This class of de novo SNVs was discovered using the above-
mentioned strategy including the comparison of the genotypes
of the mother, father and the twin pair for all SNVs simultan-
eously. SNVs observed in one of the twins and not observed in
the other twin as well as both parents were considered as candi-
date de novo SNVs. Same set of ﬁlters described above was
applied to the resulting candidate de novo SNVs to generate a
list of high-conﬁdence putative twin-speciﬁc de novo SNVs. We
considered the timing of mutagenesis for the twin-speciﬁc de
novo SNVs as early postzygotic after the twinning event.
Evaluation of the putative de novo SNVs based on visual
examination
We used Integrative Genomics Viewer (IGV)9 to examine the
Sequence Alignment/Map (BAM) ﬁles to further evaluate the
putative de novo SNVs. We classiﬁed the variants in our initial
call-set as (a) inherited, (b) no variant, (c) located on a low-
quality read and (d) de novo. In the presence of more than
three reads supporting the variant in one or both parents, the
variant was classiﬁed as inherited and ﬁltered. When the SNVor
indel density was high around the region ﬂanking 40 bp the
putative de novo SNVs, we classiﬁed the sequencing reads sup-
porting the variants as ‘low-quality reads’ and ﬁltered them.
Additionally, the putative de novo SNVs that are not supported
by at least three reads and located on the ‘low-quality reads’
were classiﬁed as ‘no variant’, and thus ﬁltered. We included the
remaining putative de novo SNVs in our ﬁnal call-set and
selected them for validation by Sanger-based capillary sequen-
cing (see online supplementary table S1).
Validation of de novo SNVs with Sanger sequencing
We selected all 120 high-conﬁdence putative de novo SNVs for
validation. Of these, 37 could not be tested due to unavailability
of appropriate primers or PCR products of sufﬁcient quality for
capillary sequencing. We designed primer pairs using Primer310
and PerlPrimer11 (see online supplementary table S2). PCR was
performed using 25 ng genomic DNA, One Taq DNA
Polymerase (New England Biolabs), 25 mM dNTPs (Fermentas),
5X One Taq standard reaction buffer and 10 pmol of each
forward and reverse primers. Thermocycling conditions were as
recommended by the manufacturer (94C° for 30 s; 30–35 cycles
of 94C° for 30 s, 58–60°C for 40 s and 68C° for 40 s; and 68C°
for 5 min). PCR products were analysed through 0.8% agarose
gel electrophoresis. Following the puriﬁcation of PCR products,
Sanger sequencing was performed using forward primer, reverse
primer or both. CLC Main Workbench software package
(CLCBio Inc) was used to analyse Sanger sequencing data.
Calculation of the reference allele frequency
We used reference allele frequency (RAF) to evaluate the puta-
tive de novo SNVs. RAF is the total number of reads supporting
the reference allele as a fraction of total number of reads sup-
porting both reference and alternative allele.12 For the putative
de novo SNVs that are present in a heterozygous state, RAF
threshold was determined as 0.5–0.7 for the twins and 0.95–1.0
for the parents.
RESULTS
Mapping of the whole-genome sequencing data and
discovery of the sequence variants
We sequenced the whole genomes of the monozygotic twin pair
and their parents using the Illumina HiSeq2000 platform and
generated a total of 538 Gb genomic sequence with a mean
coverage depth of more than 30-fold per individual (see online
supplementary table S3). Using BWA,4 we mapped the
paired-end sequencing reads to the human reference genome
(GRCh37) and discovered genomic variants using the GATK.6
Herein, we discovered genomic variants using the multisam-
ple calling options of UniﬁedGenotyper (a total of 170-fold
coverage). We identiﬁed approximately 3.4 million SNVs and
750 000 small insertions and deletions (indels) per genome (see
online supplementary table S4).
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Identiﬁcation of the putative de novo SNVs
Examination of the genotypes of the twin pair and their parents
synchronously for each of the SNVs identiﬁed an initial set of
putative de novo SNVs. To distinguish true de novo SNVs from
sequencing and variant calling artefacts, we progressively
applied the following set of ﬁlters: (a) novelty vis-á-vis
dbSNP137, (b) having a coverage depth of at least three for the
site encompassing the variant in each individual, (c) presence
outside of the segmental duplications and/or repetitive DNA
and (d) genotyping error (see ‘Methods’). With this ﬁltering
strategy, we identiﬁed a total of 290 high-conﬁdence putative de
novo SNVs. Of these, 159 were shared by the twin pair (group
I); and 83 were speciﬁc for twin I and 48 for twin II (group II)
(see online supplementary tables S5–S7).
Selection of the high-conﬁdence putative de novo SNVs for
validation
Subsequent to the identiﬁcation of the initial call-set, we visually
examined the BAM ﬁles for all of the 290 high-conﬁdence puta-
tive de novo SNVs using IGV.9 We also considered the allelic
depth for each SNV in each individual. This resulted in the ﬁl-
tering of 86/159 shared, 54/83 twin I-speciﬁc and 30/48 twin
II-speciﬁc de novo SNVs (see ‘Methods’ and online
supplementary ﬁgure S1 and tables S8–S11).
We selected the remaining de novo SNV candidates for
Sanger sequencing (73 shared, 29 twin I-speciﬁc and 18 twin
II-speciﬁc) and also classiﬁed them by genomic context, which
revealed a biased distribution towards non-coding regions of the
genome (ﬁgure 1C).13 This is expected because of two reasons:
(a) non-coding regions constitute most of the genome, and (b)
they are subjected to less stringent evolutionary pressure.
We calculated the average RAF and coverage depth values for
all of the putative de novo SNVs (a) shared by the twin pair, (b)
speciﬁc to twin I and (c) speciﬁc to twin II (see ‘Methods’ and
online supplementary table S12). As expected, average RAF is
between 0.95 and 0.97 for the parents. For the twin pair,
average RAF for shared de novo SNVs is 0.59 for twin I and
0.55 for twin II, supporting the heterozygous presence of the
variants. And for the twin-speciﬁc de novo SNV candidates,
RAF values are consistent with mosaic presence (0.68–0.69) in
the twin that carries the variant.
Experimental validation of de novo SNV candidates
Of the 73 shared de novo SNV candidates, 49 could be tested
using capillary sequencing, and 23 conﬁrmed to be de novo
SNV in heterozygous state (see online supplementary table S8).
We considered the timing of mutagenesis as parental or pre-
twinning zygote for these 23 shared de novo SNVs.
Of the 29 twin I-speciﬁc and 18 twin II-speciﬁc high-
conﬁdence putative de novo SNVs (group II), 19 and 15,
respectively, could be analysed by capillary sequencing; and 8/
19 for twin I and 1/15 for twin II were conﬁrmed (see online
supplementary tables S9 and S10).
In order to control the validity of the ﬁltering process that
targeted the putative de novo SNVs classiﬁed as genotyping
error, we selected all 34 for capillary sequencing. Of these, 19
could be tested, and none conﬁrmed as a de novo SNV (see
online supplementary table S13).
We conﬁrmed the exclusive representation of twin-speciﬁc de
novo SNVs by simultaneous Sanger sequencing of the whole
family. The mutant allele for these twin-speciﬁc de novo SNVs
was clearly visible along with the wild-type allele in the capillary
chromatograms (ﬁgure 1D).
We calculated one more time the average RAF and coverage
depth values for the conﬁrmed de novo SNVs as described
above (see online supplementary table S14). Average RAF is
0.96–1.00 for the parents. For the twin pair, it is 0.53 (twin I)
and 0.46 (twin II) for the shared; and 0.65 (twin I) and 0.78
(twin II) for the twin-speciﬁc de novo SNVs. These results are
consistent with the Sanger sequencing chromatograms, which
indicate the mosaic presence of twin-speciﬁc de novo SNVs.
Mosaic representation of a mutation in a parent could be inter-
preted as a de novo mutation in the twins.14–16 We therefore
extended our de novo mutation validation in blood (mesoderm)
to the analysis of DNA samples isolated from the buccal (ecto-
derm) and the urine (endoderm) cells of the parents. We did not
observe the de novo SNVs in either cell type, which suggests that
parental mosaicism does not contribute to the shared de novo
SNVs in the twins (see online supplementary ﬁgure S2).
Calculation of the mutation rate
Mutation rate was calculated based on the number of validated
de novo SNVs and callable bases. Bases with a minimum read
depth of 3 and do not intersect segmental duplications were
considered as callable. We calculated 2 703 445 479 bases for
twin I and 2 702 251 568 bases for twin II. We used the
formula below to calculate the mutation rates3:
m ¼ ðN(1þFNR)=L
At this point, N represents the number of de novo SNVs validated
by capillary sequencing, FNR is the false-negative rate (see online
supplementary table S15) and L is the total number of callable bases.
We calculated a rate of 0.97×10−8 bp per generation for de
novo SNVs shared by the twin pair. For twin-speciﬁc de novo
SNVs, we calculated the rate of 0.34×10−8 bp per generation for
twin I and 0.04×10−8 bp per generation for twin II, respectively.
DISCUSSION
The rate of de novo SNVs in healthy individuals has been inves-
tigated through whole-genome sequencing of mother–father–
offspring trios and yielded rates ranging between 0.82–
1.70×10–8 per base pair.17 Among these overall rates, the early
postzygotic de novo SNVs have not been distinguished from
those which have parental origin. Here we present overall de
novo SNV rate of 1.01 and 1.31×10–8 in a healthy monozy-
gotic twin pair consistent with previous direct estimations. We
also observe that parental mosaicism does not contribute to the
shared de novo SNVs in the twins. Furthermore, we report the
contribution of early postzygotic mutations to the average de
novo SNV burden with a rate of 0.04–0.34×10–8. Our deep
whole-genome sequencing-based approach combined with
effective ﬁltering and validation enabled the direct measurement
of early postzygotic versus prezygotic de novo SNV rate.
The very ﬁrst studies concerned with the estimation of somatic
mutation rate were restricted to coding or non-coding regulatory
regions and mainly focused on disease phenotypes.18 19 The
average somatic mutation rate has been reported to be
7.7×10−10.20 A more recent study that surveyed the whole
genome estimated the somatic mutation rate for common SNPs in
healthy monozygotic twins to be 1.2×10−7 per base pair.12 Conrad
and his colleagues distinguished the germline and non-germline
(somatic and cell line derived) mutations through whole-genome
sequencing of a CEU trio and provided a rate of 2.52×10−7 per
nucleotide for non-germline mutations. This estimate, which is
greater than the estimate presented in this study, is probably inﬂu-
enced by mutagenicity and age of the cell culture.21
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De novo mutations that are not shared by monozygotic twins
could be cell line derived.22 We excluded this possibility by dir-
ectly sequencing whole-blood-derived DNA. We, however, point
out that the rate of postzygotic mutations is likely to be underes-
timated. This is because mutations that occur later in embryo
development will be observed as very low-frequency mosaic
SNVs that will be regarded as sequencing errors by mapping
and variant calling algorithms.23
High levels of allelic, locus and phenotypic heterogeneity
have important implications for gene discovery in complex
human diseases.24 Genomic microarrays and next-generation
sequencing technologies are now enabling researchers to dissect
the molecular basis of complex phenotypes that arise from de
novo mutations.25 This has been demonstrated in common neu-
rodevelopmental diseases such as schizophrenia26 and autistic-
spectrum disorders,27 pointing to a monogenic basis of disease
with the mutation representing a single event of large effect.
However, even after the spectacular success of these modern
genetic studies, a majority of cases remain unsolved. An added
level of complexity, consistent with this ‘de novo model’, could
be the timing of mutational events whereby early postzygotic de
novo mutations could be critically important. This is supported
by the observations that somatic mosaicism has been well docu-
mented in Mendelian phenotypes,14 28 29 including monozy-
gotic twins discordant for a given disorder,30 and by
demonstration of extensive genetic variation in human tissues31
including brain.32 It will be crucial to expand genome sequen-
cing studies to the next level of tissue or even cell type-speciﬁc
interrogation to better delineate causal mutations especially in
sporadic forms of Mendelian disorders.
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